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Abstract 
 It is well established that the process of tumor progression is recognized by the 
immune system, and that cancer cells actively manipulate this system via production of 
inhibitory cytokines, antigenic loss, and alteration of immune-relevant cell surface 
molecules such as costimulatory ligands and Major Histocompatability Complex (MHC) 
II, which is required for CD4+ T-cell recognition.  Regulatory T-cells (Tregs) plan an 
active part in the immune response to cancer.  A growing body of literature suggests that 
Tregs demonstrate improved suppressive capacity when both Treg and effector T-cell 
(Teff) are specific for antigens within the same target cell, but the mechanisms behind 
this observation are as of yet unknown.  In this study we hypothesized that the 
upregulation of MHCII by tumor cells allows for direct recognition by Tregs and 
provides a mechanism for antigen-specific suppression.  Using a novel tumor model in 
which MHCII knockout mice were challenged with an MHCII-inducible, ovalbumin 
(OVA)-expressing B16 melanoma, we were able to demonstrate antigen-specific 
treatment with OVA-specific OTI CD8+ T-cells that was subsequently suppressed by 
OVA-specific OTII Tregs.  Through bioluminescent imaging (BLI), histology, and ex 
vivo flow cytometry, we were able to demonstrate that our OTI cells proliferated, 
matured, trafficked to and accumulated within the tumor, and developed an effector 
phenotype consisting of IFNγ and TNFα cytokine production and efficient lysis of 
antigen-loaded targets.  To expand upon our suppression findings, we developed a panel 
of OVA-expressing B16 tumors with variable expression levels of MHCII and evaluated 
their ability to induce Treg suppression.  Unfortunately, we were unable to demonstrate 
suppression of tumor rejection or alteration in OTI phenotype by our Tregs, and 
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subsequently determined that, through an unknown mechanism, our OVA-expressing 
B16 tumors were unable to present OVA to OTII T-cells, thus nullifying our Treg 
studies.  Although ultimately disappointing, the tumor model, B16 variants, and 
experimental framework generated here will serve as useful tools for the future analysis 
of direct antigen presentation by tumors. 
 
Thesis Advisor:  Dr. Hyam Levitsky 
Second Reader:  Dr. Ivan Borrello
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 Regulatory T-cells (Tregs) play an important role in the control of immune 
responses, and in the setting of tumor immunity, this often results in the suppression of 
what might otherwise be a productive elimination of tumor cells.  Tregs accomplish this 
suppression through a number of different mechanisms that often depend on the tissue, 
effector cell, target cell, and surrounding immune milieu.  While this activity has 
classically been thought of as being antigen non-specific, a growing body of evidence 
suggests that Tregs function at greater capacity when both Treg and effector T-cell (Teff) 
share specificity of antigens within a common target cell.  Tumors are not mere 
bystanders in this process, but are capable of undergoing a number of cellular alterations 
that can manipulate and help to avoid an otherwise productive immune response.  These 
alterations include the production of inhibitory cytokines, antigenic loss/variation, and 
alteration of immune-relevant cell surface molecules such as Major Histocompatability 
Complex (MHC) I and II and costimulatory ligands.  In this series of studies, we 
hypothesized that one such alteration, the upregulation of MHCII, could allow tumor 
cells the ability to directly present antigens to regulatory T-cells, and in doing so would 
provide a mechanism to allow for antigen-specific suppression. 
 In our first series of studies, we designed an in vivo model of immune-mediated 
tumor rejection that could subsequently be suppressed by Tregs.  In order to accurately 
test our hypothesis, our model had to fulfill three requirements.  First, we needed 
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recipient mice incapable of presenting MHCII antigens to our Tregs.  Second, we needed 
a tumor cell line capable of inducible MHCII expression that expressed antigens 
appropriate for both CD8+ and CD4+ recognition.  Finally, we needed appropriate 
antigen-specific CD8+ Teff and CD4+ Treg lines which recognized antigens within our 
tumor cell.  To fulfill these requirements, we successfully created a tumor model within 
MHCII knockout (KO) recipient mice using the MHCII-inducible B16 melanoma line 
that expressed the model antigen ovalbumin (OVA), which bears antigenic epitopes 
recognized by the MHCI-dependent OTI CD8+ T-cell and the MHCII-dependent OTII 
CD4+ T-cell.  We subsequently were able to show both treatment and suppression within 
MHCII KO mice using this model.  As a means of expanding upon this model, we further 
developed and validated a series of OVA-containing B16 tumors with variable expression 
of MHCII that could serve as tools to tease out the intricacies of tumor-Treg direct 
presentation in later experiments.         
 The treatment model we designed utilized the adoptive transfer of naïve OVAI-
specific OTI CD8+ cells that were subsequently capable of eliciting a treatment effect 
upon OVA-expressing B16 tumors.  In order to elicit such an effect, our cells presumably 
had to undergo a number of alterations to convert them from naïve CD8+ cells to 
functional effector cells capable of enacting tumor clearance.  These alterations included 
such processes as proliferation, maturation, trafficking, and execution of effector 
function.  In our second study, we sought to better understand the physiology of our OTI 
CD8+ treatment system over the course of tumor progression.  Using a number of in vivo 
and ex vivo techniques, we were able to accurately characterize the proliferation, 
trafficking and accumulation, cell surface molecule phenotype, and effector functionality 
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of our OTI CD8+ cells during this progression.  With this characterization in hand, we 
hoped to evaluate the changes Tregs have upon this phenotype as a means of insight into 
the mechanisms used by Tregs to enact suppression.     
 Having established and characterized our treatment model, in our third series of 
studies we sought to evaluate the implications of direct antigen presentation by tumors to 
Tregs through examining the ability of our panel of variable MHCII-expressing 
B16.mOVA tumors to elicit Treg suppression.  In examining this suppression, we further 
aimed to characterize the phenotypic and functional alterations imparted upon our OTI 
CD8+ cells by Tregs as a means of better understanding the suppressive mechanisms 
involved.  Unfortunately, we were not unable to demonstrate suppression with our 
variable MHCII-expressing tumor variants, nor were we able to replicate the suppression 
seen with our original B16.mOVA tumor in our initial studies.  We further did not 
demonstrate any alterations to our OTI CD8+ phenotype in the presence Tregs.  In 
analyzing these two failed results, we determine that, through an unknown mechanism, 
our tumor cells were unable to present endogenously produced OVA antigen to our OTII 
T-cells.  Thus, we were unable to make any conclusions regarding the implications of 
direct antigen presentation by tumors to Tregs. 
 While we were unable to accurately test our initial hypothesis due to the failed 
direct presentation of OVA antigen by tumor cells to OTII cells, this study is not without 
its merit.  We succeeded in developing a novel tumor model system along with a series of 
OVA-expressing B16 tumors with variable MHCII expression patterns.  Further, we were 
able to accurately characterize the phenotype and function of our OTI treatment cells 
during the course of tumor progression.  The model system, reagents, and experimental 
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framework generated in this study will serve as valuable tools for future studies aimed at 
elucidating the ability of tumor cells to directly present class II antigens to regulatory T-
cells.   





2.1 Immune Tolerance and Regulatory T-Cells 
 The human body is composed of over 1013 cells (Bianconi et al, 2013) encased 
within the epithelial linings of the skin, gastrointestinal, urinary, reproductive, and 
respiratory tracts.  Colonizing and frequently penetrating these barriers are innumerable 
microbial species.  Many of these are beneficial if not necessary to their host, but a small 
number have the ability to cause infection and bring about significant pathology.  It is the 
responsibility of the immune system to identify and respond to these pathogens in a 
timely and appropriate manner.   
However, detection and clearance of infection does not take place in 
sequestration, but rather in the milieu of the host tissue.  Distinguishing self from non-
self, as well as harmful versus benign, requires an extremely high fidelity system.  
Further, many of the mechanisms used to limit and clear pathogenic invaders can be 
harmful to the host cells themselves, necessitating tight regulation of any appropriately 
triggered immune response.  Insufficiency or over activity of any step in this process can 
result in its own pathology, highlighting the importance of processes involved in immune 
activation, homeostasis, and tolerance.   
 Within the immune system, tolerance implies a lack of response to a given 
antigen.  This can arise in one of three separate but related mechanisms:  central 
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tolerance, peripheral tolerance, and “clonal ignorance” (Van Parijs and Abbas, 1998). 
Central tolerance is established via clonal deletion, alternatively referred to as negative 
selection, of self-reactive T-cells during their maturation within the thymus (Kappler et 
al., 1987).  Lymphocytes that pass this first round of editing make their way into the 
peripherally circulating pool where they are subject to peripheral tolerance, which can be 
brought about in several ways.  These include antigenic seclusion, low T-cell receptor 
(TCR) avidity, anergy, and peripheral deletion (Arnold et al., 1993; Van Parijs and 
Abbas, 1998).  These are passive, cell-intrinsic mechanisms that act in cis to prevent the 
unwanted activation of an individual T-cell bearing a given TCR.  However, these 
mechanisms are not foolproof, and self-reactive T-cells do exist within the periphery and 
can on occasion be activated.  Furthermore, even when responding to a foreign invader, 
reestablishment of homeostasis must follow a productive immune response.  While again 
in this regard there are a number of mechanisms that act intrinsically to a given activated 
cell, such as death by neglect or activation induced apoptotic feedback loops (Van Parijs 
and Abbas, 1998) these mechanisms are not always sufficient.  Therefore, a more ‘active’ 
mechanism of immune tolerance and suppression is necessary.  This active mechanism 
occurs via T-cell dependent dominant control (Sakaguchi et al., 2001) at the hands of the 
regulatory T-cell (Treg). 
   Regulatory T-cells were first described in the early 1970s by Gershon and Kondo 
(Gershon & Kondo, 1970; Gershon & Kondo, 1971), and in the decades to follow have 
been shown to be involved in autoimmunity, tumor immunity, transplant tolerance 
(Kretschmer et al., 2006; Sakaguchi et al., 2001), allergy (Xystrakis et al., 2006), and 
infection (Belkaid, 2007; Rouse et al., 2006) including Mycobacterium tuberculosis 
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(Kursar et al., 2007), and Leishmania major (Anderson et al., 2007b).  They represent 5-
10% of the circulating CD4+ T-cell population (Zou, 2006) and are classically thought of 
as being thymically-derived CD4+ cells that are Foxp3+ CD25+, CD45Rblo, and express 
intermediate levels of ICOS, CTLA-4, GITR, and CD44 (Gavin et al., 2007). 
 Foxp3 is a member of the forkhead/winged-helix family of transcription factors. 
Foxp3 expression is considered to be the hallmark of murine Treg cells and indeed is 
required for their thymic development. Ectopic expression of the FOXP3 gene within 
naïve CD4+ cells can recapitulate much of the same phenotype as shown by naturally 
arising Tregs (Fontenot et al., 2003; Hori et al., 2003).  Mice lacking a functional FOXP3 
gene lack Tregs and develop the ‘Scurfy’ (sf) phenotype characterized by widespread 
autoimmunity, lymphocytic infiltration and hyperproliferation, and early onset death in 
affected mice (Brunkow et al., 2001).  Mutation of this same gene within humans results 
in the IPEX syndrome (Immune dysregulation, Polyendocrinopathy, Enteropathy, X-
linked syndrome), which is a recessive disorder of similar pathology to Scurfy and is 
usually lethal in infancy (Bennett et al., 2001; Wildin et al., 2001). 
 While the IPEX phenotype of humans closely resembles that of the Scurfin 
mouse, Foxp3 expression is not solely confined to regulatory T-cells in humans, and can 
be seen in both CD4+ and CD8+ cells upon activation (Morgan et al., 2005).  Foxp3 
expression is induced in in vitro activated human CD4+ CD25- T-cells.  While this 
expression correlates with hyporesponsiveness to further stimulation and decreased 
cytokine production, it does not impart a dominant regulatory phenotype to these cells 
(Gavin et al., 2006; Wang et al., 2007).  In vitro stimulation of human CD4+ CD25- T-
cells in the presence of TGFß elicits strong Foxp3 expression but does not impart a 
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regulatory phenotype as it does in mice (Tran et al., 2007).  These differences highlight 
not only discrepancies between mice and humans, but also open the door to the 
complexity of what defines the regulatory T-cell population as a whole.  
 
2.2 Induced vs. Natural Regulatory T-Cells 
 A more in depth analysis of regulatory T-cells suggests a diverse population of 
cells with regulatory and suppressive activities.  The classic thymically-derived CD4+ 
Foxp3+ Tregs represent what can be referred to as natural Treg (nTreg).  These nTreg are 
not alone, however, and CD4+ Foxp3- T-cells can be converted in the periphery to 
Foxp3+ cells known as induced, adaptive, or converted Tregs (iTreg) (Curotto De 
Lafaille and Lafaille, 2009).  Location of antigen presentation clearly affects Treg 
development, as nTregs are dependent upon thymic stromal expression of antigen while 
peripheral presentation results in iTreg development (Apostolou et al., 2002).  This 
sometimes leads to the view that nTregs are responsible for tolerance to self while iTregs 
function to harness and control productive immune responses within the periphery.  This 
dichotomy is vastly oversimplified, and iTregs have been shown to constitute a unique 
subdivision within the peripheral Treg pool that functions synergistically with nTregs 
(Haribhai et al., 2009; Zhou and Levitsky, 2007).   
 Further complicating the case of nTreg and iTreg are IL-10 producing T-
regulatory 1 (Tr1) cells (Groux et al., 1997; Roncarolo et al., 2001) and TGFβ producing 
T-helper 3 cells (Th3), which are particularly prominent in the gut (Weiner, 2001).  The 
high prevalence of gut-derived Treg lines highlights the fact that there clearly is a 
relationship between microbial infection/colonization and iTreg development (Curotto De 
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Lafaille and Lafaille, 2009).  The ‘hygiene hypothesis’ proposes a link between the 
increased incidences of allergy in Western countries with decreased childhood infections 
resulting in reduced induction of polyclonal iTregs during infection that are capable of 
controlling future unwanted immune responses such as allergy (Belkaid, 2007; Maizels, 
2005).  DCs purified from small intestinal lamina propria show superior induction of 
iTregs relative to lymphoid organ-derived DC (Sun et al., 2007), and CD103+ DCs in 
mesenteric lymph nodes can induce Tregs from naïve T-cells in a manner that is 
dependent upon TGFß and retinoic acid (RA) (Coombes et al., 2007). 
The differing sites of their generation are also reflected in the TCR repertoires of 
nTreg and iTreg.  iTreg share the same repertoire as the entire naïve CD4+ pool, whereas 
nTreg are much more limited (Curotto De Lafaille and Lafaille, 2009), again likely 
reflecting the antigenic diversity encountered during their development.  Besides TCR 
variability, nTreg and iTreg also express variable patterns of homing receptors (Haribhai 
et al., 2009), again suggesting a potential division of labor between the two populations.  
 Differences between nTregs and iTregs can be seen at the gene level as well. 
Gene profiling studies show that iTregs lack some of the genes associated with nTregs 
(Haribhai et al., 2009; Hill et al., 2007), and that FOXP3 is not necessary for the initiation 
of iTreg development, but is essential to the their suppressive function (Haribhai et al., 
2009).  nTregs, in vivo-generated iTregs, and in vitro-generated iTregs show variability in 
the methylation patterns of an upstream region of the FOXP3 gene TSDR (Treg cell-
specific demethylated region) (Curotto De Lafaille and Lafaille, 2009).  Recent studies 
suggest that there are likely higher-order controls over FOXP3 in the development of 
Treg, and that TCR engagement, IL-2, and TGFß all have effects upon the Treg signature 
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(Hill et al., 2007).  Foxp3 is suggested not to drive de novo Treg development but to 
amplify molecular changes, including promoting its own transcription, initiated by a Treg 
precursor and to solidify these cells towards a permanent Treg lineage (Gavin et al., 
2007).  In all, Tregs surmise an increasingly widening collection of T-cells with the 
capability to suppress varying arms of the immune system in a variety of different ways.  
The mechanisms they use to accomplish this suppression are as equally diverse as the 
populations themselves. 
 
2.3 Mechanisms of Regulatory T-Cell Suppression 
 Regulatory T-cells are capable of suppressing effector cell function via a number 
of different pathways.  The importance of each of these is much debated, and unlike 
absence of functional Foxp3 (Fontenot et al., 2003; Hori et al., 2003), loss of any single 
one of these mechanisms is not enough to completely abrogate overall Treg function 
(Vignali et al., 2008).  Functional loss of many of these pathways is associated with 
different, often organ-specific deficits. Thus it would appear that these pathways act in a 
non-redundant fashion to maintain peripheral tolerance and immune homeostasis.    
Furthermore, identifying pathways necessary for generation and maintenance of the Treg 
pool versus those actively involved in suppressive activity is difficult and likely varies 
amongst the different Treg subsets.  The first reports of Treg function suggested that 
Tregs must be activated via TCR engagement in order to suppress, and that suppression 
occurred via a contact-dependent, cytokine-independent inhibition of IL-2 production by 
effector cells (Thornton and Shevach, 1998).  However, other reports have suggested that 
contact-mediated suppression is necessary for nTregs, whereas iTregs act via inhibitory 
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cytokines such as IL-10 and TGFß (Grossman et al., 2004a).  While the data on the 
mechanisms of Treg-mediated suppressive function are highly varied and often 
conflicting, they are not necessarily mutually exclusive and in a number of setting may be 
due to differences in experimental setups, in vivo versus in vitro model systems, and 
human versus murine systems.  Overall, these often conflicting data speak to the 
complexity of Treg-mediated immune suppression and tolerance.   
 The first mechanism regulatory T-cells use to inhibit effector function involves 
the production of inhibitory cytokines, most notably IL-10 and TGFβ, which are 
produced by Tregs upon TCR engagement (Nakamura et al., 2001).  IL-10 is produced by 
a number of immune cells including those of the innate system as well as T-helper 1 
(Th1) and Treg cells (Anderson et al., 2007b).  The importance of Treg production of IL-
10 is unclear.  Several allergy & asthma models suggest that IL-10 production by nTregs 
and iTregs is important for disease control (Hawrylowicz and O’Garra, 2005).  Further, 
IL-10 has been shown to be necessary for the function of Tregs in preventing colitis in 
adoptive transfer studies using SCID mice (Asseman et al., 1999), and IL-10 deficient 
mice develop autoimmune colitis but interestingly do not develop autoimmunity within 
other organs (Kühn et al., 1993).  Conversely, IL-10 production by Th1 cells, and not 
Tregs, appears to be the primary source of IL-10 mediated suppression in chronic 
cutaneous leishmaniasis (Anderson et al., 2007), and IL-10 production by Tregs was not 
correlated with suppressed clearance of M. tuberculosis (Kursar et al., 2007).  
 TGFβ was one of the first recognized mechanisms of Treg-mediated suppression, 
and is also probably the most widely debated.  As mentioned previously, TGFβ appears 
to be heavily involved in the generation of iTregs, and iTregs are enriched in genes 
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involved in the TGFß signaling pathway relative to nTregs (Haribhai et al., 2009).  In 
vitro stimulation of human CD4+ CD25- T-cells in the presence of TGFβ elicits strong 
Foxp3 expression but does not impart a regulatory phenotype as it does in mice (Tran et 
al., 2007).  Naïve murine CD4+ cells cultured in tumor cell-conditioned media develop 
an iTreg phenotype with suppressive capability.  This conditioning is abrogated when 
anti-TGFβ antibody is included within the media (Liu et al., 2007).  In vitro functional 
assays show mixed results.  Most appear to agree that suppression is contact-dependent, 
but data addressing the importance of TGFβ is conflicting.  Some studies have suggested 
that suppression can occur in the absence of TGFβ production by Tregs or TGFβ-
responsiveness by Teff cells (Piccirillo et al., 2002), whereas other studies have 
suggested that Tregs utilize self-produced, membrane-bound TGFβ to exert their 
suppressive effects (Nakamura et al., 2001).  These latter studies offer that perhaps the 
complicated biology of TGFβ production, and the multiple forms the molecule can be 
found in, likely complicates its analysis.  In vivo models have shown that TGFß signaling 
is required for Treg-mediated control of pancreatic islet-reactive CD8+ cells in a type-I 
diabetes model (Green et al., 2003), and that administration of anti-TGFß antibody 
prevents suppression of autoimmune colitis in an adoptive transfer mouse model (Read et 
al., 2000).  Finally, treatment of tumor-bearing mice with anti TGFß antibody results in 
increased tumor clearance and decreased conversion of iTregs in some models (Liu et al., 
2007). 
 A third, recently identified suppressor cytokine produced by Tregs is IL-35.  
Tregs are thus far the only cells known to produce IL-35, and its ectopic expression 
confers a regulatory phenotype to naïve CD4+ cells.  Furthermore, recombinant IL-35 
	   13	  
suppresses proliferation in vitro, IL-35 KO mice were unable to suppress proliferation, 
and these same mice were unable to control homeostatic proliferation of adoptively 
transferred cells and resultant autoimmune inflammatory bowel disease in vivo (Collison 
et al., 2007).   
 The second mechanism utilized by Treg cells to mediate suppression involves the 
direct killing of effector cells via cytolytic pathways, most notably the granzyme/perforin 
systems akin to those used by CD8+ T-cells and NK cells.  In humans, iTregs express 
high levels of granzyme B, but not granzyme A, and can mediate perforin-dependent 
cytolysis of allogeneic target cells in an MHC/TCR-independent fashion (Grossman et 
al., 2004b).  Human nTregs, on the other hand, express high levels of granzyme A, with 
little granzyme B (Grossman et al., 2004a).  Both populations are capable of mediating 
perforin-dependent cytolysis of autologous cells including T-cells and dendritic cells in a 
Fas/FasL independent manner (Grossman et al., 2004a).  In mice, stimulation of iTregs 
results in the upregulation of granzyme B, but not granzyme A or perforin.  Granzyme B 
KO mice show reduced in vitro iTreg suppression whereas perforin KO mice do not 
(Gondek et al., 2005).  In another study, granzyme B deficient mice were shown to clear 
both allogeneic and syngeneic tumor challenges better than WT mice.  Granzyme B was 
shown to be expressed at high levels in tumor-infiltrating Tregs but not in naïve Tregs, 
and adoptive transfer of WT, but not granzyme B or perforin KO Tregs led to decreased 
tumor clearance.  Tumor-infiltrating Tregs are able to induce CD8+ and NK cell death in 
a granzyme B- and perforin-dependent manner (Cao et al., 2007).  In some of these same 
mouse studies, iTregs were shown to cause dose-dependent apoptosis of Teff in a 
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polyclonal TCR-stimulated coculture.  This effect was abrogated in the presence of anti-
GITR stimulation, as was the upregulation of granzyme B (Gondek et al., 2005).   
Finally, besides the granzyme/perforin system, one study has demonstrated an antigen-
specific CD4+ CD25+ cell line derived from a BalbC mouse that is able to kill B-cells 
bearing the appropriate antigen via the Fas/FasL pathway.  This same cell line was 
unresponsive to cognate antigen stimulation, required exogenous IL-2, and mediated 
bystander suppression, consistent with a Treg phenotype (Janssens et al., 2003).    
 A third method that Tregs can utilize to suppress effector cells is through 
metabolic disruption of target cells.  One mechanism therein involves the killing of Teff 
by Treg via cytokine-deprivation induced apoptosis (Pandiyan et al., 2007), the best 
studied of which involves IL-2.  IL-2 is required for generation, peripheral maintenance, 
and acquisition of suppressor function by Tregs (Thornton et al., 2004).  IL-2 is not 
necessary for the induction of Foxp3+ expression in developing T-cells, but is needed for 
the maintained expression of growth & metabolism genes, suggesting a role in the 
peripheral homeostasis and competitive fitness of Tregs (Fontenot et al., 2005a).  Tregs 
do not produce IL-2, however, and must compete with Teff, which secrete it.  Owing to 
this necessity, Tregs typically express CD25, also known as the high-affinity IL-2Rα, 
which when combined with CD122 (IL-2Rβ) and CD132 (IL-2Rγ) produces a 
heterotrimeric IL-2 receptor with a 100-fold increased affinity for IL-2 relative to the 
heterodimeric receptor expressed by conventional T-cells.  This provides Tregs a 
significant competitive advantage over Teff and serves as a potential mechanism for 
suppression (von Boehmer, 2005; de la Rosa et al., 2004).  Further supporting this 
concept, addition of anti-CD25 antibody blocks in vitro Treg suppression, as does anti-
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IL-2 antibody.  Both of these can be reversed with the addition of exogenous recombinant 
IL-2 (de la Rosa et al., 2004).  Somewhat contrastingly, however, is the result that in vitro 
suppression can occur with cells from IL-2 KO and IL-2Rα KO mice (Fontenot et al., 
2005a), providing further proof that Tregs utilize multiple mechanisms for suppression.   
 Another means of metabolic disruption utilized by Treg involves the manipulation 
of adenosine metabolism.  Extracellular nucleotides and ATP are often released by 
damaged and dying cells and serve as natural proinflammatory mediators.  Tregs 
selectively express both CD39 and CD73, which collectively metabolize these molecules 
into AMP and adenosine (Borsellino et al., 2007; Deaglio et al., 2007; Koie et al., 2006). 
AMP inhibits Th1 and Th2 cytokine expression and cell proliferation (Kobie et al., 2006) 
via interactions with the adenosine ASA receptor on Teff cells.  CD39 KO mice show 
reduced in vitro suppressive capability and fail to block skin allograft rejection in vivo 
(Deaglio et al., 2007).  Foxp3 has been shown to promote CD39 expression, and TCR 
stimulation increases CD39 catalytic activity.  Interestingly, while virtually all murine 
Tregs express CD39, only a subset of human Tregs do.  These CD39+ human Tregs are 
very sparse in the relapsing/remitting form of multiple sclerosis (Borsellino et al., 2007). 
 A separate but related form of adenosine-mediated suppression has been reported 
through cAMP signaling.  cAMP is a common second messenger within innumerable cell 
signaling cascades.  Within Teff cells, high levels of cAMP serve to inhibit IL-2 
production, cell growth, and proliferation.  Treg cells have a very high level of 
intracellular cAMP.  Recent studies have shown that Tregs & Teff are able to form gap 
junctions through which this cAMP is able to be transferred.  cAMP antagonists and gap 
junction inhibitors blocked this suppression (Bopp et al., 2007). 
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 The mechanisms of cytokine inhibition, direct target cell killing, and metabolic 
disruption demonstrate the wide range of mechanisms Tregs can utilize to suppress Teff 
cell function.  Tregs not only communicate with Teff, however, but many other cell 
types, most notably antigen presenting cells (APCs).  These interactions provide another 
level of suppressive mechanisms whereby Tregs can eventually impact Teff function.     
 
2.4 Interactions of Regulatory T-Cells and Dendritic Cells  
 Besides their direct interactions with target effector cells, Tregs also affect 
dendritic cells and other host antigen presenting cells (APCs). Through a variety of 
mechanisms, Treg have the ability to decrease the immune stimulatory capacity of these 
APCs, and in doing so suppress effector cell function.  These same interactions affect the 
Treg cell as well, and quite often the reduction in Teff stimulatory capacity brought on by 
Tregs also increases the ability of the APC to stimulate Treg development.   
 The first mechanism through which Tregs can elicit suppressive function through 
DCs involves decreasing the costimulatory potential of these APCs.  Upon acquiring 
antigen within their environment, peripheral DCs migrate to secondary lymphoid 
structures where they mature and present antigen in the context of MHC:TCR 
interactions, in the classic “signal 1.”  Production of an effector response requires this 
signal along with a stimulatory “signal 2,” which is provided in the form of costimulatory 
molecules on the DC such as CD80 and CD86.  T-cells bear ligands to these molecules in 
the form of CD28 and CTLA-4.  Ligation of effector cell CD28 by DC CD80/86 results 
in activation of effector cells, whereas ligation by CTLA-4 results in downregulation of 
these costimulatory molecules (Oderup et al., 2006).   
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 Tregs rapidly downregulate the expression of CD80 and CD86 by DC in in vitro 
cocultures in a contact-dependant mechanism (Cederbom et al., 2000), but do not 
decrease DC survival.  Treatment with anti-CTLA-4 antibody abrogates this 
downregulation, and CD80 and CD86 expression are restored after removal of Tregs 
(Oderup et al., 2006).  This ability to downregulate costimulatory molecules is highly 
context dependent, however. Immature BMDCs cocultured with Tregs show reduced 
expression of CD80, CD86, MHCII, CD40, and CD11c, and decreased stimulation of 
CD8 effector cells.  However, coculture of Tregs with DCs previously matured with LPS, 
CpG, or anti-CD40 does not affect expression levels or stimulatory potential (Serra et al., 
2003).  In a related fashion, WT T-helper cells can assist in overcoming the suppressive 
effects of Tregs upon diabetogenic CD8 cells, whereas CD40L (CD154) KO T helper 
cells cannot, owing again to the maturation state of the DC in question (Serra et al., 
2003).   
 A large proportion of Tregs constitutively expresses CTLA-4, and treatment with 
anti-CTLA-4 reverses protection from autoimmune gastritis by adoptively transferred 
Tregs (Read et al., 2000).  Secretion of TGFβ by Tregs post-TCR engagement is 
increased by CTLA-4 costimulation (Nakamura et al., 2001).  Anti-CTLA-4, but not anti-
TGFβ or anti-IL-10 treatment abrogated anti-diabetogenic effects of adoptively 
transferred Treg (Serra et al., 2003).  Further, pulmonary DCs show increased MHCII, 
CD80, and CD86 expression along with an increased ability to promote T-cell 
proliferation in the absence of Tregs in a mouse asthma model (Lewkowich et al., 2005).  
Human Tregs reduce DC stimulatory potential, lead to increased IL-10 production, and 
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decrease DC costimulatory molecules.  Anti-TGFβ administration partially reversed these 
effects (Misra et al., 2004). 
 A second system used by Tregs to modulate suppressive function through DCs 
involves tryptophan catabolism through the enzyme indoleamine 2,3-dioxygenase (IDO), 
which is expressed by DCs. IDO/tryptophan catabolism has been shown to be involved in 
autoimmunity, tumor clearance, asthma, and pregnancy (Mellor and Munn, 2004).  IDO 
leads to decreased tryptophan availability and the production of pro-apoptotic 
metabolites, which have T-cell suppressive effects.  When stimulated by TCR 
engagement, Tregs are able to stimulate DC expression of IDO in two ways.  The first 
involves a CTLA-4-dependent mechanism and requires CD80/86 expression along with 
cytokine production by DCs.  The second mechanism is CTLA-4 independent, but 
cytokine-dependent and occurs in the presence of LPS.  This second pathway occurs via 
the production of IFNγ by Tregs, which occurs in the presence of LPS and can stimulate 
IDO (Fallarino et al., 2003). 
 A third mechanism used by Tregs to steer DCs towards a suppressive state 
involves Lymphocyte Activation Gene 3 (LAG-3/CD223).  LAG-3 is structurally similar 
to CD4 and interacts with MHCII on APCs with much higher affinity.  It is expressed on 
activated CD4 & CD8 T-cells as well as Treg cells (Workman and Vignali, 2005).  High 
levels of LAG-3 mRNA are seen in both nTregs & iTregs, but it is undetectable on the 
cell surface of nTregs immediately ex vivo (Huang et al., 2004), and is selectively 
upregulated by Tregs following activation.  Ectopic expression of LAG-3 in naïve CD4+ 
(Huang et al., 2004) and even activated T-cells reduces their proliferation and confers a 
suppressive phenotype (Workman and Vignali, 2005).  LAG-3 mediates both in vivo and 
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in vitro suppression.  LAG-3 deficient Tregs show reduced suppression potential in vitro, 
which is also seen with administration of anti-LAG-3 antibody (Huang et al., 2004).  
LAG-3 deficient mice, or WT mice treated with anti-LAG-3 antibody, produce twice as 
many CD4 & CD8 as WT hosts, and LAG-3 deficient T-cells undergo increased 
homeostatic proliferation in lymphopenic recipients relative to WT cells (Workman and 
Vignali, 2005).   
 The mechanism involved in LAG-3 suppression appears to be two-fold, as the 
interaction of LAG-3 with MHCII induces changes both in DCs as well as in Tregs. 
LAG-3 engagement of MHCII on DCs inhibits DC maturation and immunostimulation 
via an ITAM-mediated signaling pathway that is both antigen- and contact-dependent.  
LAG-3 signaling is not required for this inhibition of DC maturation, as MHCII cross-
linking produces similar results as LAG-3 engagement (Liang et al., 2008).  In contrast, 
binding to MHCII and signaling through the cytoplasmic domain of LAG-3 is required 
for its effects upon the regulatory activity of Tregs (Workman and Vignali, 2005).  
 Yet another mechanism involved in the control of DC stimulatory capacity by 
Tregs involves extended contact by Treg with DCs.  Two photon laser-scanning 
microscopy (TPLSM) has revealed that both Tregs and naïve T-cells indistinguishably 
interact directly with DCs in draining lymph nodes (DLN), but no direct Treg-Tnaive 
interactions were reported.  Interaction of Tregs with DCs preceded the inhibition of 
Tnaive by DCs, with increasing numbers of Tregs leading to decreased Tnaive:DC 
swarms & clusters, and presumably reduced priming of Teffs.  Both T-cell populations 
displayed similar lymph node homing to the paracortical T-cell zone in the absence of 
antigen, and to the T-cell:B-cell boundary in DLNs in the presence of antigen (Tang et 
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al., 2006).  Further studies have shown that naïve T-cell motility is decreased and T-
cell:DC interactions are longer in the absence of Treg (Tadokoro et al., 2006).  One 
possible mediator of these effects is Neuropilin-1 (Nrp-1).  Nrp-1 is expressed by most 
Tregs but not Tnaive and promotes prolonged interactions and more immune synapses 
with immature DCs, thus potentially giving Tregs an advantage in low antigen 
environments.  Blocking antibody to Nrp-1 abrogates this extended Treg:DC interaction, 
and ectopic expression of Nrp-1 in Tnaive lengthens DC contact duration (Sarris et al., 
2008). 
 Tregs have suppressive effects not only on DCs, but their progenitors, as well as 
other APC subsets.  For instance, human Tregs can exert suppressive effects on 
monocytes/macrophages (Taams et al., 2005).  Coculture of human Tregs with 
monocytes drives development of alternatively activated macrophages (AAM), which 
have a suppressive phenotype.   Tregs make monocytes/macrophages less responsive to 
LPS, an effect attributable to IL-4, IL-10, and IL-13 (Tiemessen et al., 2007).   
 As mentioned, while Tregs can influence the stimulatory capacity of DCs, DCs 
themselves are crucial to the generation and function of Tregs.  The maturation/activation 
state, DC subtype, DC costimulatory molecule expression, and surrounding cytokine 
milieu all have profound implications upon the generation of Tregs from Tnaive cells by 
DCs.  Many of these changes in DCs are coordinated, such that the relative importance of 
each has yet to be fully elucidated.  Further, given the wide range of DC subtypes, data 
from one model does not always correlate with others.  Still some general themes are 
present.     
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 DC maturation clearly affects Treg conversion from Tnaive.  Pretreatment of DCs 
with LPS or anti-CD40 has been shown to decrease conversion of Tnaive into Tregs.  
This effect was found to be synergistic, and administration of anti-CD154 (CD40L) 
antibody conversely increased Treg conversion (Wang et al., 2008).  Similar results were 
obtained when the Toll Like Receptor (TLR) poly(I:C) was used as a maturation signal 
(Yamazaki et al., 2008).  These findings likely relate in part to alterations in 
costimulatory signals that result from DC maturation, as knockout of CD40, CD80, and 
CD86 within DCs has also been shown to increase conversion of Tregs relative to WT 
DCs.  Further, signaling through other costimulatory/suppressor pathways such as CTLA-
4, PD-L1, and GITR have also been shown to affect Treg conversion by DCs (Wang et 
al., 2008).  
 Besides maturation status, different DC populations appear to have greater innate 
propensity for Treg conversion than others.  The ability of CD103+ DCs in mesenteric 
lymph nodes to induce Tregs in the presence of TGFß and retinoic acid (RA) has already 
been mentioned (Coombes et al., 2007).  Further, in vivo antigen delivery to splenic 
CD8+ DC but not CD8- DC has been shown to preferentially convert Tnaive to Tregs.  
These same studies also showed a significant role for TGFβ, as CD8+ DCs were able to 
produce endogenous TGFβ and TGFβ binding protein, which were not produced by 
CD8- DCs, and addition of TGFβ blocking antibodies abrogated the enhanced Treg 
conversion seen in CD8+ DCs.  Interestingly, CD8- DCs were shown to express the 
TGFβ receptor, and addition of exogenous TGFβ to CD8- DCs allowed for improved 
Treg conversion (Yamazaki et al., 2008).  Similarly, CD8+ DCs have shown increased in 
vitro conversion in the presence of TGFβ relative to CD8- DC (Wang et al., 2008).  In 
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related work, it has been shown that DC deficiency of alpha-V-beta-8 (αVβ8) integrin, 
which is involved in conversion of TGFß into its active state, results in reduced Treg 
conversion in vitro in a TGFß-dependent manner.  Mice with DCs lacking this integrin 
develop autoimmune colitis with reduced colonic Tregs (Travis et al., 2007).  
 These studies indicate not only baseline differences in Treg conversion potential 
among differing DC populations, but also highlight some of the functional differences 
between these populations that likely account for their differing Treg converting 
potential, amongst which cytokine profiles are of high importance.  Besides the 
implications of TGFβ, DC production of IL-6 and IL-10 have also shown importance.  
IL-6 is secreted by matured DCs, and IL-6 knockout DCs show an increased Treg 
conversion relative to WT (Wang et al., 2008).  Tregs have been shown to induce APCs 
to secrete IL-10.  In turn, IL-10 knockout APCs result in reduced suppressive capability 
of Tregs, as does addition of anti-IL-10 (Kryczek et al., 2006).  Cytokines in the 
surrounding milieu also affect DC-Treg interaction.  Both the Th1 and Th2 cytokines 
IFNγ and IL-4, respectively, have been shown to inhibit in vitro conversion of Tregs, an 
effect that was reversed with addition of appropriate blocking antibodies (Wang et al., 
2008).  
 In all, these studies highlight the importance of the DC-Treg interaction and the 
many mechanisms by which the two cell populations bidirectionally affect one another’s 
function.  The bulk of these mechanisms are focused on secondary and tertiary signals 
within this immune crosstalk.  The importance of the MHC-TCR interaction, the so-
called “signal 1,” has yet to be addressed.  This signal is itself at the heart of the adaptive 
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immune response, and is of significant importance when examining the specificity of 
Treg function.    
 
2.5 Specificity of Regulatory T-Cell Function 
  The question of Treg specificity is one of significant debate.  Classically, Tregs 
have been thought to undergo antigen-specific generation and activation, but once 
activated, to function non-specifically.  This dogma originates from early work by 
Thornton & Shevach (Thornton and Shevach, 2000) who used a series of in vitro 
coculture experiments to characterize the antigenic requirements of Tregs.  They found 
that Tregs required TCR stimulation, either through cognate antigen-MHC interaction or 
anti-CD3, to become activated, but once activated, mediated suppression in a cytokine-
independent, contact-dependent, APC-independent, antigen-non-specific fashion.  
Activated Tregs could suppress Teffs from different TCR specificities, even when those 
T-cells were of different MHC background or were anti-CD3 stimulated.  Similarly, 
evidence for Treg specificity in vivo in models of autoimmunity, transplant, cancer, and 
infection clearly demonstrates that Tregs bear antigen specificity as it pertains to their 
generation and activation, but is less clear when examining functional specificity.   
 Many groups have now been able to isolate tumor-associated antigen (TAA) 
specific Tregs from human samples.  Nishikawa et al (Nishikawa et al., 2005a) found that 
NY-ESO-1-specific CD4+ Th1 cells could be induced from PBMCs of both normal 
donors as well as patients with NY-ESO-1 positive melanoma.  However, except in 
patients that were seropositive for NY-ESO-1, these populations could only be detected 
following depletion of CD4+ CD25+ Tregs, suggesting suppression of Th1 cells in the 
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assay.  Further separation of these populations into naïve (CD45RA) and 
effector/memory(CD45RO) cells revealed that NY-ESO-1-specific Th1 induced from 
normal donors and seronegative patients came from naïve CD4+ cells, whereas those 
from seropositive patients came from both populations.  These Th1 from memory 
populations were found to be more resistant to Treg suppression.   
 Wang et al (Wang et al., 2004) isolated a Treg clone from a pool of TILS from a 
melanoma patient with specificity for the cancer-testis antigen LAGE1.  The clone was 
CD4+ CD25+ GITR+ CTLA4+ Foxp3+ and when ligand-activated could suppress anti-
CD3 stimulated polyclonal Teff response in a contact-dependent manner.  Vence et al 
(Vence et al., 2007) recently isolated a panel of TAA-specific Tregs from the peripheral 
blood of melanoma patients, but not from healthy donors.  They found specificities to a 
variety of tumor antigens including gp100, TRP1, NY-ESO-1, & survivin.  These Tregs 
proliferated in culture when provided with appropriate antigenic peptide, secreted IL-10, 
expressed high levels of Foxp3, and were able to suppress autologous T-cells in a 
contact-dependent manner.     
 In another study, Van der Burg et al (van der Burg et al., 2007) identified 
increased frequencies of Tregs within the tumor and corresponding DLNs of cervical 
cancer patients and isolated a panel of CD4+ Tregs with specificity for the HPV 
oncoproteins E6 & E7 from these tissues.  These Tregs did not display a singular cell 
marker & cytokine secretory profile, but rather were variable in these regards.  However, 
all clones were able to suppress the proliferation and cytokine secretion of responder T-
cells when placed into in vitro coculture, including responder T-cells with specificities 
for alloantigen, HIV-1 antigens, and HA antigens. 
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  Jandus et al (Jandus et al., 2009) recently identified a population of DQ6/Melan-
A25-36  multimer+ CD4+ cells within a series of melanoma patients that were involved in a 
peptide vaccine trial using Melan-A26-35 (A27L) peptide vaccine aimed at boosting antigen-
specific CD8+ responses.  They found these multimer+ cells in a high percentage of 
melanoma patients’ peripheral blood, but only sparingly in healthy controls.  In several 
cases where tumor-infiltrated lymph nodes were available, they found increased 
multimer-positive cells relative to the peripheral blood.  Within these multimer+ cells, a 
high percentage (19-74%) were found to be Foxp3+. These multimer+ cells failed to 
proliferate in vitro prior to vaccination, even after CD25-depletion or addition of CpG, 
CD40L, IL-2, IL-6, IL-15, or IL-7.    Over the course of peptide vaccination, the overall 
numbers of multimer+ cells stayed fairly consistent, however the percentage of 
multimer+ Foxp3+ cells decreased dramatically (0-21%).  In post-vaccine samples where 
Foxp3+ cells were <10%, proliferative capacity was restored.  Further, not only did these 
cells now proliferate, they also secreted Th1 cytokines.  To determine the source of these 
pre- versus post-vaccine multimer+ cells, the authors sequenced the TCR Vβ region 
along with the CDR3 of several different patient samples.  They found restricted Vβ 
usage post-vaccine with no overlap of CDR3 sequences pre- and post-vaccine, indicating 
the de novo expansion of antigen-specific, multimer+ cells. 
 Recently, Bonertz et al (Bonertz et al., 2009) described a system in which they 
were able to identify a number of TAA-specific Teffector/memory cells as well as Treg 
cells within the peripheral blood of 170 colorectal cancer patients.  DCs were pulsed with 
a panel of synthetic long peptides representing 11 known tumor antigens (EGFR, Muc-1 
signal sequence, Muc-1 tandem repeat, Her-2/neu, p53, telomerase, survivin, heparanase 
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1, heparanase 2, & CEA) or non-TAA controls and then incubated with patient T-cells to 
identify Teff via IFNγ ELISPOT.  They also repeated this same procedure using T-cells 
that had been depleted of CD4+ CD25+ T-cells (Tregs) and similarly evaluated for IFNγ 
ELISPOT.  TAA-specific Tregs were identified by incubating these same peptide-pulsed 
DCs with MACS-enriched CD4+ CD25+ T-cells, and then subsequently evaluating this 
Treg pool for the ability to suppress the proliferation of anti-CD3 stimulated polyclonal 
Teff.  They were able to identify a highly individualistic pattern of TAA-specific Teff 
and Treg cells within the peripheral blood of these patients that did not exist in control 
patients.  Depletion of Treg cells increased the IFNγ signature only for a certain set of 
these TAAs, but not others.  Interestingly, they found that these TAAs were the same 
ones that also produced TAA-specific Tregs.   
 Finally, recent work in a model of mucosal allergy response has shown an 
expansion of CD4+ CD25+ CD127- Foxp3+ Tregs with specificity to fungal antigens 
from Aspergillus fumigatus and Candida albicans.  In addition to the expanded number 
of Tregs, patients who suffer from the allergic disease allergic bronchopulmonary 
aspergillosis (ABPA) demonstrated an increased frequency of fungus-specific Th2 cells, 
suggesting a failed suppression of these cells by Tregs in symptomatic individuals 
(Bacher et al., 2013). 
 These human studies have definitively shown the presence of antigen-specific 
Tregs, but have as of yet been unable to demonstrate functional specificity, and if 
anything have demonstrated antigen non-specific function.  A number of mouse models 
have similarly shown the presence of antigen-specific Tregs.  In one such study, 
vaccination with a panel of SEREX-identified self-antigens derived from a chemically-
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induced mouse sarcoma induced CD4+ CD25+ Foxp3+ Tregs that were capable of 
peptide-dependent in vitro suppression that was contact-dependent, cytokine-
independent, and abrogated with anti-GITR antibody.  This suppressive capability waned 
over 8 weeks post-vaccination but was regained upon in vitro cognate peptide stimulation 
(Nishikawa et al., 2005b).  This study, however, like the human studies, failed to assess 
the ability of Tregs to function in an antigen-specific manner.   The best studies 
examining this concept have come from mouse models of transplant tolerance and 
autoimmunity.   
 Hori et al (Hori et al., 2002) examined the developmental and functional 
requirements for CD4+ CD25+ Tregs in mice bearing an anti-myelin basic protein 
(MBP) transgenic TCR.  When this TCR is crossed onto the RAG-/- background, mice 
spontaneously develop Experimental Autoimmune Encephalitis (EAE), a disease similar 
to multiple sclerosis.  Mice on a RAG+/+ background do not develop EAE.  Transfer of 
total CD4+ cells from a RAG+ MBP mouse into a RAG-/- recipient does not lead to 
EAE, but transfer from a RAG- MBP mouse, or transfer of CD25-depleted CD4+ from a 
RAG+ MBP mouse does lead to EAE.  They found that RAG- MBP mice lack CD4+ 
CD25+ Treg, while RAG+ MBP mice do not.  Transfer of CD25+ CD4+ cells from 
either a RAG+ WT mouse or a RAG+ MBP mouse protected RAG- recipients from EAE 
induced by adoptive transfer of RAG- MBP CD4+ cells.  Interestingly, transfer of CD4+ 
CD25+ MBP-depleted cells from RAG+ MBP donors did not prevent recipient EAE.  
Analysis of TCRα & TCRβ usage revealed that non-transgenic CD25+ CD4+ cells from 
RAG+ MBP+ animals displayed oligoclonal TCR usage, suggesting perhaps that their 
failure to protect from EAE was due to a reduced TCR repertoire.  
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 In a second model, Tarbell et al (Tarbell et al., 2004) utilized DCs from NOD 
mice to ex vivo expand BDC2.5 TCR transgenic T-cells, which see a single pancreatic 
islet autoantigen, into CD4+ CD25+ Tregs.  These expanded Tregs demonstrated more 
potent suppression in vitro than their non-expanded counterparts.  In vivo, as few as 5000 
expanded antigen-specific Tregs were able to suppress insulitis (Type-1 DM) that results 
from the transfer of polyclonal Teff cells into NOD.Scid mice, whereas 10E5 polyclonal 
Tregs from NOD mice could not.  Furthermore, these Tregs could suppress insulitis even 
when administered 14 days following transfer of diabetogenic T-cells.    
 Samy et al (Samy et al., 2005) analyzed the role of polyclonal Tregs in 
Autoimmune Ovarian Disease (AOD), which occurs in day 3 thymectomized (d3tx) 
mice.  They found that the ovarian DLN was the site of the T-cell activation that leads to 
AOD, and that polyclonal Tregs could suppress this activation in the draining ovarian 
lymph node.  They also found similar suppression of the organ-specific draining lymph 
nodes in mouse models of dacroadenitis and autoimmune prostatitis.  While polyclonal 
Tregs capable of suppressing AOD where found throughout the body, they were enriched 
within the draining ovarian lymph node.  Depletion of adoptively transferred Tregs 
resulted in reversal of protection and severe AOD.  Finally, they found that polyclonal 
Tregs from female mice were superior to Tregs from male mice at protecting from AOD 
when Treg contact with ovarian antigen was delayed by removal of the ovary prior to 
adoptive transfer and then later transplant of an ovary back into the recipient.  This 
female > male response was not present, however, when the ovarian antigens were 
present at the time of Treg adoptive transfer.        
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 Yu et al (Yu et al., 2005) examined the ability of proteolipid protein-1 (PLP-1) 
antigen-specific Tregs from TCR transgenic 5B6 mice to suppress EAE induced by a 
variety of antigen-specific Teff cells.  They found that they could expand PLP-1 Tregs 
from 5B6 mice using in vivo delivery of an Ig-PLP-1 fusion protein in an adjuvant-free 
setting.  These Tregs, when adoptively transferred, were able to suppress EAE in RAG-/- 
recipients brought about by adoptive transfer of pathogenic 5B6 Teff cells.  This effect 
was reversed upon administration of anti-IL-10 antibody.  These 5B6 Tregs were also 
able to suppress EAE when transferred into WT mice that had been vaccinated against 
PLP-1 peptide or CNS homogenate along with adjuvant.  When injected into (C57B6 x 
SJL/J) F1 mice (which are MHCII I-Ab x I-As) 5B6 Treg (which see I-As) were able to 
protect mice from EAE when vaccinated with PLP-1 peptide (I-As restricted), but not 
when vaccinated against myelin oligodendrocyte glycoprotein (MOG) (I-Ab restricted) or 
myelin basic protein (MBP) (I-As restricted).  However, when the 5B6 Treg were pre-
activated with PLP1 peptide in vitro, they were able to suppress EAE in mice vaccinated 
with MOG peptide.  Also, administration of Ig-PLP-1, Ig-PLP-2, and Ig-MBP3, but not 
control Ig post induction of EAE with CNS homogenate vaccination all reversed EAE in 
SJL/J mice.  Depletion of Tregs with anti-CD25 prior to EAE induction reversed this 
protection from EAE.  Finally, 5B6 Tregs were able to ameliorate EAE in SJL/J mice 
vaccinated with CNS homogenate and PLP-2 peptide, but not MBP peptide (both 
peptides are I-As restricted), suggesting intra-molecular (PLP-2), but not inter-molecular 
(MBP) suppressive functions.   
 Sánchez-Fueyo et al (Sánchez-Fueyo et al., 2006) developed a transplant model of 
alloantigen specificity utilizing a transgenic mouse (ABM) with a TCR highly specific 
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for the class II molecule I-Abm12, which is expressed on a variant strain of the B6 mouse 
known as B6.C-H2bm12/KhEg (bm12).  The I-Abm12 differs from the parental B6 I-Ab by 
only 3 amino acids, and yet this difference results in bm12 skin allograft rejection by WT 
B6 mice.  The authors identified a Treg population within the AMB TCR-transgenic T-
cell pool.  These ABM Tregs were anergic to stimulation with bm12 splenocytes and 
were capable of suppressing ABM Teff proliferation in vitro, whereas WT B6 Tregs were 
not.  Further, the ABM Tregs were capable of mediating bystander suppression of Teffs 
bearing a different TCR.  In vivo ABM Tregs were able to prevent bm12 skin graft 
rejection by adoptively transferred AMB Teff at a 1:1 ratio in a nude B6 model.  WT B6 
Treg were able to provide some protection, but only when used in much higher Treg:Teff 
(3:1) ratios.  ABM Tregs were also able to prevent rejection of bm12 skin grafts by WT 
B6 polyclonal Teff in these same B6 nude recipients.  AMB Treg were not able to protect 
BalbC skin grafts, even when used in high Treg:Teff ratios.  However, ABM Treg, when 
transferred at a high Treg:Teff (4:1) ratio, were able to protect (Balbc x bm12) F1 skin 
grafts from rejection by WT B6 polyclonal Teff, demonstrating ‘linked suppression.’ 
 Collectively, these mouse studies demonstrate antigen-specific activation of Tregs 
with improved functional capacity when antigen specificity is maintained.  Further, 
through concepts such as linked suppression, the necessity for the Treg’s antigen to be 
present on the protected cell for suppression to take place, strongly suggests at least an 
element of functional antigenic specificity.  It does not, however, definitively show that 
Tregs function in an antigen-specific manner in vivo.   
 To answer this question definitively, Zhou & Levitsky (Zhou & Levitsky, 
unpublished data) devised an elegant series of experiments utilizing a mixed tumor model 
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within the BalbC A20 mouse lymphoma system. In that model, mice were challenged 
subcutaneously with a 1:1 mixture of A20 tumor bearing the model antigen influenza 
hemagluttinin (HA) and the bioluminescent luciferase (luci) enzyme (A20.HA.luci) along 
with a second A20 tumor bearing the model antigen chicken egg ovalbumin (OVA) 
(A20.OVA).  Tumor-bearing mice were then treated with in vitro polarized Th1 cells 
from transgenic 6.5 αβ TCR mice, which recognize HA peptide 100-120 presented by I-
Ed (Kirberg et al., 1994), with the addition of increasing amounts of one of two sets of in 
vitro generated Tregs.  These Tregs were either derived from the same 6.5 TCR mouse as 
the Th1 cells and thus bore the same antigenic specificity, or were from the transgenic 
DO11 αβ TCR mice, which recognize OVA peptide 323-339 presented by I-Ad (Murphy 
et al., 1990) and therefore bore a different antigenic specificity.  Then, through 
bioluminescent imaging they were able to directly monitor growth of the A20.HA.luci 
tumor, and via caliper measurements were able to measure total tumor mass.  As shown 
in Figure 2.1, they were able to demonstrate the antigen-specific suppression of 6.5 Th1 
cells by the 6.5 Treg with no suppression by the DO11 Treg.  The 6.5 Tregs were then 
validated to be non-suppressive to a DO11 Th1 response in the reverse ‘criss-cross’ 
experiment as shown.  They further were able to explant these tumors at the end of the 
treatment course and through in vitro proliferation assays using 6.5 and DO11 responder 
cells verified that the HA and OVA antigens were appropriately present or absent based 
upon the tumor curves. These experiments very clearly demonstrate that Tregs are 
capable of antigen-specific suppression in the setting of a heterogeneous mixed-tumor 
model, but left open the question as to the mechanism through which this functional 
specificity was achieved.    
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Figure 2.1 Tregs demonstrate antigen-specific suppression of Th1-mediated tumor 
rejection in vivo. 
Recipient mice were injected with a 1:1 mix of either A20.HA.luci and A20.OVA (A) or 
A20.OVA.luci and A20.HA (B).  Mice were then treated with Teffs and Tregs as 
indicated and tumor size monitored with bioluminescence and caliper measurements.  
Shown here is bioluminescent imaging data measuring luci-bearing tumor size.  (A) 6.5 
Treg, but not DO11 Treg, are able to suppress the rejection of A20.HA.luci tumor cells 
by 6.5 Th1 cells.  (B) These same 6.5 Tregs do not suppress the rejection of 
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2.6 Regulatory T-Cells and Cancer 
 It has long been recognized that the immune system plays an important role in the 
development and progression of cancer.  The idea that the immune system sees and 
suppresses a continuous onslaught of cancerous precursors was first suggested by Ehrlich 
in 1909 (Ehrlich, 1909).  This idea was further expanded upon and the formal “cancer 
immunosurveillance” model proposed by Burnett and Thomas in the late 1950s (Burnett, 
1957; Thomas, 1959).  Since that time, a large volume of work has gone into clarifying 
the exact roles that the immune system plays during the process of tumorigenesis, 
immune editing, and tumor immune escape (reviewed in Dunn et al., 2002; Dunn et al., 
2004).     
 Tregs were first proposed to have a negative effect on tumor immunotherapy back 
in 1975 (Fujimoto et al., 1975).  A large body of data supporting the idea that Tregs have 
a negative impact upon cancer progression comes from mouse models wherein a number 
of studies have shown that the depletion of Tregs or reduction in their suppressive 
capability improves immune-mediated tumor clearance (reviewed in Zou, 2006).  This 
has been accomplished in several ways.  Administration of antibody against CD25, the 
high-affinity IL2 receptor subunit expressed on Tregs and Teffs, has been shown to 
effectively deplete Tregs and lead to reduced tumor growth (Onizuka et al., 1999; 
Shimizu et al., 1999).  Tregs have also been shown to be preferentially depleted with 
administration of cyclophosphamide.  While also a primary chemotherapeutic agent, this 
drug has been shown to deplete Tregs at much lower doses than are required for its direct 
anti-tumor activity, and administration of low-dose cyclophosphamide has been shown to 
promote immune-mediated rejection in a number of models  (Rollinghoff et al., 1977; 
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Glaser, 1979; Turk et al., 2004), including a cyclophosphamide-resistant leukemia model 
(Awwad & North, 1989). 
 Blocking of Treg function has also been shown to promote improved tumor 
outcomes.  Antibody targeted against glucocorticoid-induced tumor-necrosis factor 
receptor related protein (GITR), a molecule expressed by Tregs and involved in their 
suppressive function, has been found to reduce the suppressive capacity of Tregs in vitro 
(Shimizu et al., 2002) and was subsequently shown to result in protection from melanoma 
challenge (Turk et al., 2004) and in rejection of established sarcoma (Ko et al., 2005).  
Finally, administration of blocking antibodies to cytotoxic T-lymphocyte associated 
antigen 4 (CTLA-4), another marker expressed by Tregs and involved in their 
suppressive function, resulted in rejection of established melanoma tumors with 
protection against subsequent challenge (Leach et al., 1996).  
 Along with the aforementioned studies that suggest the removal of Tregs or 
dampening of their function results in improved tumor outcomes, studies have also 
investigated the ability of adoptively transferred Tregs to suppress otherwise potent anti-
tumor immune responses.  Multiple studies in mouse melanoma models have shown that 
the co-transfer of CD4+ CD25+ T-cells, i.e. Tregs, but not CD4+ CD25-, i.e. T naïve, can 
abolish the anti-tumor effect of tumor-antigen specific cytotoxic CD8+ T-cells, thus 
suggesting an active role of Tregs in the suppression of immune-mediated tumor rejection 
(Turk et al., 2004; Antony et al., 2005; Chen et al., 2005).  
 In human studies, evidence supporting the idea that Tregs negatively affect tumor 
immune clearance and prognosis begins with correlative data from cancer patients.  
Increased frequencies of Tregs in patients with lung and ovarian cancer were first 
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described by Woo and colleagues (Woo et al., 2001) and have since been seen in 
peripheral blood of patients with a wide range of tumors including breast, ovarian, lung, 
leukemia, esophageal, hepatocellular, gastric, melanoma, colorectal, lymphoma, and 
pancreatic (reviewed in Zou, 2006).  Many of these same studies were able to 
demonstrate in vitro suppressive capability of patient Tregs to tumor-associated antigens.   
 Beyond their often increased frequency within peripheral blood, Treg numbers 
have also been shown to be altered within tumor, peritumoral tissue, and draining 
lymphatic tissue.  In malignant melanoma samples, Tregs have been shown to selectively 
accumulate within tumor tissue as opposed to surrounding tissue or peripheral blood 
(Ahmadzadeh et al., 2008). In ovarian cancer, increased numbers of tumor-infiltrating 
Tregs have been correlated with a decreased survival.  These same Tregs, as well as 
Tregs from tumor ascites, were shown to inhibit Her-2/neu TAA-specific CD8+ 
cytotoxicity both in vitro and in vivo (Curiel et al., 2004).  Increased numbers of Tregs 
within lymphoid infiltrates surrounding the tumor, but not within the tumor body, are 
associated with poor prognosis in breast cancer (Gobert et al., 2009), and Tregs from 
similar lymphoid infiltrates have been associated with an active, proliferating ICOShi 
Ki67+ phenotype that co-localized with mature DC-LAMP+ and pDC+ cells which are 
both involved in Treg proliferation and survival (Menetrier-Caux et al., 2009).    
 More recently, strategies based upon Treg depletion via CD25+ similar to those 
employed in mouse models have made an impact within human studies of ovary, breast, 
lung (Barnett et al., 2005), renal cell (Dannull et al., 2005), and melanoma (Attia et al., 
2005).  Also, administration of low-dose cyclophosphamide in cancer patients has also 
shown the ability to improve immune responses (Berd & Mastrangelo, 1988). Further, 
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administration of anti-CTLA-4 antibodies have recently been shown to produce tumor 
regression in patients with both metastatic melanoma and ovarian cancer (Phan et al., 
2003; Hodi et al., 2003), and have now been FDA approved for treatment of metastatic 
melanoma, providing further translational evidence that Tregs in fact play an important 
role in the evasion of immune-mediated tumor clearance.  Overall it is now clear that 
active suppression by Tregs is one of the main methods by which tumors evade immune 
clearance (Dunn et al., 2002; Dunn et al., 2004; Zhou, 2006).  
 
2.7 Tumor Immune Manipulation   
 It is now clear that functional Tregs can be found within a variety of different 
tumors and are often associated with an overall poor prognosis.  The role that the tumors 
themselves play in this process is an evolving one, but evidence increasingly suggests 
that tumors are not bystanders in this process, but rather are actively involved in the 
recruitment, conversion, and functional manipulation of Tregs and Teffs within the tumor 
microenvironment.  
 Tregs located within tumors are the result of both trafficking of previously 
generated thymically-derived nTregs as well as conversion from circulating Tnaive cells 
into iTreg, and in fact iTreg and nTreg have been shown to contribute independently to 
tumor-specific immune tolerance (Zhou and Levitsky, 2007).  As many tumor antigens 
are self antigens (Khong & Restifo, 2002), a substantial proportion of the circulating 
nTreg pool likely bears specificity for antigens with the tumor microenvironment.  Tregs 
have been shown to traffic based upon a number of different signals.  One such signaling 
system involves the chemokine CCL22, also known as macrophage-derived chemokine 
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(MDC), which binds to the CCR4 receptor on T-cells.  DCs and macrophages have both 
been shown to produce CCL22 which rapidly binds to CCR4 on activated T-cells, 
including Tregs, with much greater affinity than naïve T-cells (Wu et al., 2001).  
Recently, Curiel and colleagues (Curiel et al., 2004) demonstrated that CCL22 is 
effectively produced by both tumor resident macrophages as well as tumor cells 
themselves.  Further, they found that administration of anti-CCL22 antibody reduced 
tumor-infiltrating Tregs, implicating that CCL22 signaling plays a major role in Treg 
recruitment into tumors.     
 Besides recruitment of pre-existing nTregs, tumors are highly capable of the 
conversion of iTregs from Tnaive cells.  Antigen-specific T-cell anergy has been shown 
to occur early in the course of tumor progression (Stavely-O’Carroll et al., 1998) and to 
be dependent upon host APC processing of antigen (cross-tolerance) rather than direct 
tumor-T-cell interaction (Cuenca et al., 2003; Sotomayor et al., 2001).  The tumor 
microenvironment produces a number of signals, including VEGF, IL-10, and TGFβ, 
leading to suppression of DC maturation and immature/dysfunctional DCs (Gabrilovich, 
2004; Zou, 2005).  These DCs in turn further secrete TGFβ and IL-10, and are capable of 
inducing conversion and proliferation of Tregs in the tumor (Jonuleit et al., 2000; 
Ghiringelli et al., 2005; Seo et al., 2001; Chen et al., 2003; Fantini et al., 2004).   
 While tumors create a microenvironment that promotes Treg influx and 
conversion, they also manipulate T-cell function through a number of different 
mechanisms.  A growing number of immune cell-surface proteins with important roles in 
the regulation of cell-mediated immunity have been found on tumor cells.  Notable within 
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these are the negative coregulatory molecules PD-L1 and galectin-9, as well as the 
antigen-presenting molecules MHCI and MHCII.    
 Programmed death ligand-1 (PD-L1), also known as B7-H1, binds to the 
programmed death-1 (PD-1) molecule, which is expressed by a number of immune cell 
subsets including T, B, and myeloid derived cells.  PD-1 expression is considered a 
marker of immune exhaustion, and T-cells expressing this molecule are typically 
dysfunctional in their proliferative and effector capacities (Blackburn et al., 2009; 
Wherry et al., 2007; Day et al., 2006).  High levels of PD-1 expression on these same 
cells is associated with an immunosuppressive environment that is favorable to tumor 
growth in a number of models (Ahmadzadeh et al., 2009; Sfanos et al., 2009).  
 PD-1 binds to one of two receptors; PD-L1 and PD-L2.  PD-L2 is exclusively 
expressed by APCs, whereas PD-L1 expression has a much broader tissue distribution 
including liver, lung, spleen, and marrow (Blank & Mackensen, 2007; Latchman et al., 
2001; Freeman et al., 2000).  PD-L1 expression has also been found on a number of 
different tumors (Loos et al., 2008; Zhang et al., 2009), and its expression within tumor 
cells is increased following exposure to IFNγ, an important Th1 cytokine (Zhang et al., 
2009; Zhou et al., 2010).  PD-L1 expression by tumor cells has been associated with a 
poor prognosis in a number cancers, including melanoma, pancreatic, lung, stomach, 
colon, breast, renal, cervical, and leukemia (Blank et al., 2007; Loos et al., 2008; Gao et 
al., 2009; Thompson et al., 2004; Geng et al., 2008; Karim et al., 2009).  
 Ligation of PD-1 by PD-L1 can lead to effector cell exhaustion, suppression of 
cytokine production, and apoptosis (Day et al., 2006; Ahmadzadeh et al., 2009; Isogawa 
et al., 2005; Dong et al., 2002), and thus the expression of PD-L1 by tumors potentially 
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allows a direct suppressive mechanism between tumor and Teff.  Interestingly, co-
infiltration of tumors by Tregs and PD-1+ Teffs has been described in high-risk breast 
cancer patients (Ghebeh et al., 2007) as well as in the tumor-laden livers of AML-bearing 
mice (Zhou et al., 2009a).  This suggests that perhaps PD-1/PD-L1 may also play a role 
in the suppressive capacity of Tregs.  Recent studies by Zhou and colleagues (Zhou et al., 
2010) have in fact shown that the ability of Tregs to suppress Teff in vitro is dramatically 
reduced when the PD-1/PD-L1 pathway is altered via either knockout or blocking 
antibodies.  They were further able to show that blocking this same pathway in vivo 
enhances the efficacy of adoptive cell therapy; an effect that was made even more robust 
when specific Treg depletion was incorporated.  Similarly, combination blockage of PD-
1 and CTLA-4 has recently been shown by multiple groups to impair Treg function and 
improve tumor outcomes (Duraiswamy et al., 2013; Curran et al., 2010).  Multiple other 
studies have also shown that blocking the PD-1/PD-L1 axis improves adoptive 
immunotherapy (Strone et al., 2003; Okudaira et al., 2009; Thompson et al., 2005).   
Thus it would appear that the PD-1/PD-L1 pathway is an important one for tumor 
immunity, and manipulation of this pathway by tumors can serve as a potential means for 
tumor immune manipulation and escape via alterations of both Teff and Treg functions. 
      A second negative regulatory pathway tumors can make use of involves the 
inhibitory effects of galectins upon the immune system.  Galectins are glycan-binding 
proteins with affinity for N-acetyllactosamine sequences on cell surface glycoconjugates 
(Camby et al., 2006).  Glycan binding can mediate intracellular signaling which results in 
downstream effects upon multiple cellular processes including cell survival and apoptosis 
(Taams et al., 2006).  Galectins have been found in tumor and tumor-associated stroma in 
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multiple tumor types including melanoma, glioma, breast, and gastric tumors and their 
expression levels have shown correlation with aggressiveness of tumor growth and 
metastasis (Liu & Rabinovich, 2005).  Galectin-1 has been shown to be secreted by 
melanoma cells and have immunosuppressive effects upon Th1 responses (Rubenstein et 
al., 2004).   
 Another particularly interesting galectin is galectin-9.  Galectin 9 has been shown 
to serve as a ligand for T-cell immunoglobulin and mucin domain 3 (TIM-3), a molecule 
expressed by lymphocytes, DCs, and monocytes (Zhu et al., 2005; Anderson et al, 
2007a).  Binding of galectin-9 to TIM-3 results in Th1 cell death (Zhu et al., 2005), and 
TIM-3 blockade has been shown to increase the frequency of IFNγ-secreting T-cells 
(Sabatos et al., 2003).  Combination of TIM-3 blockade with either PD-1 or CTLA-4 
blockade has also been investigated and found to have increased anti-tumor affect 
compared to single agent blockade (Ngiow et al., 2011).  Interestingly, recent work by 
Sakuishi and colleagues (Sakuishi et al., 2013) has demonstrated that intratumoral Tregs 
show a high degree of TIM-3 positivity, and intratumoral TIM-3+ Tregs had greater 
suppressive capability than their TIM-3 negative counterparts.  They further found that 
combined blockade using TIM-3 and PD-1 resulted in improved tumor clearance as well 
as multiple alterations in Treg phenotype including downregulation of key genes 
involved in Treg suppression including perforin, IL-10, PD-1, and LAG-3.  Finally, they 
found a synergistic effect on tumor clearance when TIM-3 blockade was couple to Treg-
specific depletion using Foxp3-DTR mice.  In all, their data suggest once again that the 
TIM3 pathway is another potent negative inhibitory pathway with implications upon 
tumor, Tregs, and Teffs.       
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 B and T lymphocyte attenuator (BTLA), a CD28 family member, is another 
inhibitory molecule involved in negative regulation and is expressed by multiple immune 
effector cells (Watanabe et al., 2003).  It binds to the herpes virus entry mediator 
(HVEM) molecule, which is expressed by a wide range of immune cells (Murphy & 
Murphy, 2010), but can also be found in tumors including melanoma cells (Derre et al., 
2010).  Blockade of the BTLA/HVEM pathway has been shown to augment TIL 
expansion and function (Fourcade et al., 2012), and serves as yet another example of a 
negative costimulatory pathway that tumor cells can utilize to alter immune response.   
 Besides the recruitment of Tregs and the utilization of negative costimulatory 
pathways, tumor cells also make use of multiple alterations in antigen presentation 
molecules.  The most classic example of this finding occurs with the loss of MHCI 
expression. MHCI presents antigens to CD8+ T-cells, making them prone for CTL 
recognition.  Loss, downregulation, or alteration of MHCI coding sequences are all 
mechanisms by which tumors can evade CD8+ T-cell recognition.  (Rivoltini et al., 2002; 
Hicklin et al., 1999; Bicknell et al., 1994; Natali et al., 1989).  MHCI loss is considered to 
be the most common strategy used by tumors to avoid T-cell-mediated rejection (Drake 
et al., 2006; Marincola et al., 2006), with some studies showing MHCI loss in 50% of 
human tumor samples (Rees & Mian, 1999).  MHCI loss comes with a cost, making cells 
susceptible to NK-mediated killing due to lack of MHCI negative signaling to NK-cell 
killer inhibitory receptors (KIRs).  Besides the absence of MHCI negative signaling, NK 
cells also require activating signaling via molecules such as MICA and MICB, which are 
expressed on a number of tumors.  Loss of these molecules by tumors, therefore, 
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potentially allows MHCI-negative cells to avoid killing by NK cells (Rees & Mian 1999; 
Lanier 2005; Groh et al., 2002). 
 In contrast to the loss of expression seen for MHCI, many tumor cells have been 
found to upregulate expression of MHCII genes.  MHCII is an αβ-heterodimeric 
transmembrane glycoprotein capable of presenting antigenic peptides to cognate T-cell 
receptors (TCRs) of CD4+ T-cells, and in humans is composed primarily of the HLA-
DR, -DQ, and –DP molecules (Benacerraf, 1981; Janeway et al., 1988).  MHCII 
expression is tissue specific, with constitutive expression in many antigen presenting cells 
and inducible expression in many cell types including tumors (Goodwin et al., 2001).  
Both human and mouse melanomas provide an excellent example of this phenomenon. 
Melanocytes are naturally devoid of MHCII molecules, but melanomas on the other hand 
often express such molecules, especially HLA-DR (Aoudjit et al., 2004; Holzmann et al., 
1987; Ruiter et al., 1991; Bernsen et al., 2003). This expression can be either inducible or 
constitutive, with inducible expression frequently elicited by exposure to inflammatory 
cytokines, most notably IFNγ (Deffrennes et al., 2001).   Increasing frequency of MHCII 
expression is seen through the transformation of benign nevi to dysplastic nevi to primary 
melanoma to malignant melanoma (Ruiter et al., 1984), and melanomas constitutively 
expressing HLA-DR demonstrate increased metastasis and poor prognosis (Holzmann et 
al., 1987; Ruiter et al., 1991; Zaloudik et al., 1988) with similar findings also found for 
HLA-DQ and HLA-DP (Ostmeier et al., 2001).   
 MHCII expression is dependent upon the transcription factor class II 
transactivator (CIITA), which is the master switch for MHCII expression (Deffrennes et 
al., 2001; Goodwin et al., 2001). CIITA is essential for transcriptional activation of all 
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MHCII genes and has a helper function in MHCI gene expression (Holling et al., 2006; 
LeibundGut-Landmann et al., 2004).  Constitutive expression of CIITA results from 
activation of the upstream promoter III element, which is classically used by B-
lymphocytes.  IFNγ-inducible expression, on the other hand, is from promoter IV, which 
is known to be an IFNγ-responsive sequence (Deffrennes et al., 2001; van der Stoep et 
al., 2007; Goodwin et al., 2001).  Exactly how CIITA becomes activated in cancers is not 
fully understood.  It is now evident that CIITA expression is highly influenced by 
epigenetic modifications (Holling et al., 2006), which are well known to be a hallmark of 
cancer (Esteller, 2003).  Further, there has been recent demonstration of mitogen-
activated protein kinase (MAPK) pathways as regulators of CIITA transcription in 
melanoma, with particular identification of an AP-1 responsive site in the CIITA 
promoter III region (Martins et al., 2007). 
 The expression of MHCII in tumors is somewhat paradoxical, since it allows 
direct presentation to CD4 cells by tumor-expressed MHC:peptide complexes (Zarour et 
al., 2002; Zeng et al., 2001), which one might think would make tumors more prone to 
immune-mediated clearance.  This is in fact not the case, however, as evidenced by the 
aforementioned correlation between melanoma progression and increasing MHCII 
expression frequency.  Explanations for this phenomenon are varied and inconclusive.  
Classically, it has been hypothesized that expression of MHCII with a lack of 
costimulatory molecules on tumor cells results in a “signal 1” without “signal 2” with 
resultant induction of T-cell anergy (Rosenberg 2001; Rivoiltini et al., 2002; Rabinovich 
et al., 2007).  More recently, improved understanding of negative costimulatory pathways 
such as PD-1/PD-L1 and their utilization by tumor cells has provided another possible 
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explanation that reinforces and goes beyond the simple lack of costimulation, and given 
their shared IFNγ-inducible features is particularly intriguing (Zhang et al., 2009; Zhou et 
al., 2010). 
 Somewhat akin to the actions of the PD-1/PD-L1 pathway is the interaction of 
MHCII with lymphocyte activation gene 3 (LAG-3).  LAG-3 is a negative regulator of 
activated T-cells with close relationship to the CD4 molecule itself (Huard et al., 1994; 
Hannier et al., 1998).  Both LAG-3 and CD4 bind to MHCII, but LAG-3 binds with much 
higher affinity (Workman et al., 2002; Huard et al., 1995).  LAG-3 has previously been 
shown to regulate activated T-cell expansion (Workman et al., 2004). LAG-3 has been 
further shown to negatively regulate T-cell homeostasis via Treg dependent and 
independent mechanisms (Workman & Vignali, 2005).  Recently it has been shown that 
LAG-3 and PD-1 work synergistically and their combined blockade results in improved 
tumor clearance (Woo et al., 2012).  Thus, through interactions with LAG-3, MHCII may 
be able to not only serve as a supplier of “signal 1,” but may also allow negative 
costimulatory signaling.  
 
2.8 Experimental Motivation 
 A growing body of evidence suggests the potential for functional specificity in 
regulatory T-cells, and the data of Zhou and Levitsky (Figure 2.1; unpublished) 
demonstrating the antigen-specific suppression of immune-mediated rejection in the A20 
lymphoma model strongly supports this idea.  Their findings further raise a number of 
questions regarding the mechanisms by which Tregs enact their suppressive effects.  
Their model utilized a heterogeneous tumor in which all relevant antigens were present in 
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the tumor microenvironment and available to tissue- and draining lymph node-resident 
APCs.  The fact that they saw antigen-specific suppression would seem to suggest that 
these APCs were somehow being bypassed and were not involved in the suppressive 
mechanism used.  Direct presentation by the tumor to the Tregs would, therefore, serve as 
a reasonable explanation for the specificity they demonstrated.  One caveat to that 
interpretation, however, is the fact that the A20 tumor line used is itself a functional APC 
bearing high levels of MHCII and costimulatory molecules (Sotomayor et al., 2001).  
Thus, arguing that direct tumor antigen presentation is responsible as opposed to 
presentation by a third party APC is a bit like splitting hairs, with application only to 
lymphoid malignancies.   
 The idea becomes strengthened and implications broadened when taking into 
account the large volume of data demonstrating the upregulation of MHCII on solid 
tumors, most notably melanomas.  While a number of explanations for this upregulation 
have been postulated it certainly stands to be considered that the upregulation of MHCII 
by tumors during the course of their progression may in fact be beneficial to tumor cells 
through direct recognition by CD4+ T-cells.  This seems particularly plausible given the 
tendency for MHCII expression to increase in the setting of inflammatory cytokines such 
as IFNγ (Deffrennes et al., 2001).  Such inflammatory cytokines likely represent 
preceding tumor recognition and an already ongoing immune response.  Induction of 
MHCII in this setting could allow for direct presentation to Tregs in an attempt by the 
tumor to elicit suppression; a sort of immunologic ‘Hail Mary.’  In support of this idea, 
Wang and colleagues (Wang et al., 2005) have isolated and characterized a Treg clone 
(TIL164) from a melanoma TIL pool, which recognizes a previously undescribed gene 
	   46	  
ARCTI (Ag recognized by Treg cells 1).  This clone was able to suppress proliferation 
and IL-2 secretion of melanoma-reactive T-cells.  Interestingly, they found that tumor 
cells themselves, but not B-cells loaded with tumor lysate, were able to activate TIL164.  
This is potentially explained with findings from Tsuji and colleagues (Tsuji et al., 2012) 
who recently identified a novel HSP90-dependent antigen presentation pathway that 
exists within MHCII+ melanoma cells and allows for direct presentation of endogenous 
tumor antigen to CD4+ cells.   
 Taken as a whole, it seems reasonable to hypothesize that the upregulation of 
MHCII by tumor cells, potentially coupled with novel antigen processing pathways, 
could allow for direct presentation of tumor-derived antigens to Tregs with resultant 
antigen-specific suppression of immune-mediated tumor rejection.  The following 
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Chapter 3 
 




 In order to test our hypothesis, we first had to establish a model of an antigen-
specific immune-mediated tumor rejection that could subsequently be suppressed by 
Tregs.  While a number of such models have been previously described (Chen et al., 
2005; Antony et al., 2005; Turk et al., 2004) and even used in our laboratory, the goal of 
our studies necessitated development of a new model.  To begin with, we desired to have 
an in vivo mouse model wherein tumor cells could potentially be the only MHCII+ cell 
capable of presenting antigen to Tregs.  While this could potentially be accomplished 
with bone marrow chimeras, the simplest solution was the use of an MHCII knockout 
(KO) mouse.  Of the many commonly used mouse strains, the C57BL/6 mouse expresses 
only one MHCII allele (I-Ab), and an MHCII knockout mouse for that strain has 
previously been described (Madsen et al., 1999), making the C57BL/6 strain an ideal host 
for our experiments. 
 Second, our hypothesis was dependent on the upregulation of MHCII by tumor 
cells, and thus required a tumor line that did not express MHCII at baseline but could 
upregulate MHCII when exposed to inflammatory cytokines such as IFNγ.  The B16-F10 
tumor line is a C57BL/6 background melanoma that has previously been described to 
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demonstrate IFNγ-inducible expression of MHCII (Xie et al., 2010; Quezada et al., 2010) 
and was a commonly used line within our own laboratory.  Further, B16-F10 expresses a 
number of well-known tumor antigens and has been extensively studied in adoptive cell 
therapy (ACT) models (Overwijk et al., 1998; Muranski et al., 2008; Overwijk & Restifo, 
2001), making it well suited for our studies. 
 Finally, in order to establish a model of antigen-specific immune-mediated tumor 
rejection with suppression by Tregs, we had to have definable antigens within our tumor 
that could be targeted by both effector and regulatory T-cells.  Given that our target 
tumor was to be MHCII negative at baseline, a treatment based upon CD8+ effector cells 
was sought.  Several such models have been utilized in the B16-F10 tumor, including 
targeting of the self-antigen gp100 using CD8+ cells from the TCR transgenic Pmel 
mouse (Overwijk et al., 1998) and targeting of the model antigen ovalbumin (OVA) 
using CD8+ cells from the TCR transgenic OTI mouse (Hogquist et al., 1994; 
Dobrzanski et al., 1999; 2000; 2001).  This latter method was of particular interest for 
several reasons.  First, our laboratory had extensive experience with the OVA antigen 
including prior work with OVA in the B16-F10 system.  Further, besides MHCI 
recognition of antigen from the OVA protein by the OTI TCR transgenic mouse, MHCII 
recognition of antigen from the OVA protein by the OTII TCR transgenic mouse has also 
been well described (Barnden et al., 1998), making the OVA antigen and its recognition 
by the MHCI-dependent OTI and MHCII-dependent OTII TCR transgenic mice an ideal 
target. 
 In this first study, we set out to design a model wherein C57BL/6 WT and MHCII 
knockout mice would be challenged with B16 tumor cells bearing the OVA antigen and 
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treated with OVA-specific OTI CD8+ cells with subsequent suppression of this treatment 
using OVA-specific OTII Treg cells.  After evaluating several different iterations of this 
concept, we successfully identified a subcutaneous tumor challenge model using the 
B16.mOVA tumor line that showed an appropriate treatment response to adoptive 
transfer of OTI CD8+ cells.  We were also able to demonstrate an apparent suppression 
of this response with addition of OTII Tregs in the MHCII knockout mouse, suggesting a 
role for direct antigen presentation of tumors to Tregs.  Further, given the suppression 
demonstrated using our MHCII-inducible tumor, we developed and characterized 
MHCII-constitutive and non-inducible variants of the B16.mOVA tumor line as tools to 
allow future experiments to explore further the suppression seen in this study.  
 
3.2 Materials and Methods 
 
3.2.1 Mice 
 Mice six to eight weeks old were used for all experiments, with matching of 
donor/recipient gender whenever possible.  All mice were housed and bred in the Johns 
Hopkins University Cancer Research Building I mouse facility using standard 
procedures, and all experiments involving the use of mice were performed in accordance 
with protocols approved by the Animal Care and Use Committee of the Johns Hopkins 
University School of Medicine.   
 C57BL/6 WT (C57BL/6NCr) and C57BL/6 45.1+/+ (B6-LY5.2/Cr) mice 
homozygous for the CD45.1/Ly5.2 congenic marker were purchased from the NCI 
(Frederick, MD).  C57BL/6 Thy1.1+/+ (B6.PL-Thy1a/CyJ) mice homozygous for the 
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Thy1.1/CD90.1 congenic marker, C57BL/6 I-Ab-/- (B6.129S2-H2dlAB1-Ea/J) mice bearing 
a homozygous deletion within the MHCII gene locus (Madsen et al., 1999), C57BL/6 
RAG1-/- (B6.129S7-Rag1tm1Mom/J) mice bearing a homozygous deletion of the Rag1 
gene, and C57BL/6 OTII+/+ (B6.Cg-Tg(TcraTcrb)425Cbn/J) mice bearing homozygous 
insertion of the OTII αβ TCR specific for chicken ovalbumin peptide 323-339 (OVAII - 
ISQAVHAAHAEINEAGR) presented by the MHCII molecule I-Ab (Barnden et al., 
1998) were purchased from Jackson Laboratory (Bar Harbor, ME).  C57BL/6 RAG1-/- 
OTI+/+ (B6.129S7-Rag1tm1MomTg(TcraTcrb)1100Mjb) mice bearing homozygous 
knockout of the Rag1 gene along with homozygous insertion of the OTI αβ TCR specific 
for chicken ovalbumin peptide 257-264 (OVAI - SIINFEKL) presented by the MHCI 
molecule H-2Kb (Hogquist et al., 1994) and C57BL/6 RAG1-/- OTII+/+ (B6.129S7-
Rag1tm1MomTg(TcraTcrb)425Cbn) mice bearing homozygous knockout of the Rag1 gene 
along with homozygous insertion of the OTII αβ TCR specific for OVAII were 
purchased from Taconic (Germantown, NY).  C57BL/6 Foxp3-GFP+/+ and +/y mice 
were a generous gift from Dr. Alexander Rudensky (Fontenot et al., 2005b).  
 C57BL/6 OTII+/+ Thy1.1+/+ mice were created by crossing C57BL/6 OTII+/+ 
with C57BL/6 Thy1.1+/+ to create OTII+/- Thy1.1+/- F1 progeny.  These F1 progeny 
were then intercrossed and F2 progeny typed according to the presence of Thy1.1, 
absence of Thy1.2, and increase in CD4:CD8 ratio as seen in CD4 transgenic mice to 
suggest OTII+/? Thy1.1+/+ status.  Since this CD4:CD8 skewing cannot differentiate 
between OTII+/- and OTII+/+, F2 offspring were then testcrossed to C57BL/6 WT mice 
and progeny again typed for CD4, CD8, Thy1.1, and Thy1.2.  F2 parents were considered 
to be OTII+/+ only if all pups showed CD4:CD8 skewing with a minimum of 8 pups 
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typed.  Once successfully generated, male and female OTII+/+ Thy.1.1+/+ mice were 
maintained as an independent colony.   
 C57BL/6 OTII+/- Thy1.1+/- Foxp3+/y mice were generated by crossing C57BL/6 
OTII+/+ Thy1.1+/+ male mice with a C57BL/6 Foxp3-GFP+/+ female.  Resultant female 
progeny were OTII+/- Thy1.1+/- Foxp3-GFP+/- and were not utilized due to decreased 
frequency of Foxp3 expression resulting from random X-inactivation in Foxp3-GFP 
heterozygotes.  Male progeny on the other hand were Foxp3-GFP hemizygotes (+/y) and 
thus all Foxp3+ cells expressed the transgenic Foxp3-GFP and were subsequently used as 
Treg donors.   
 C57BL/6 RAG1+/- OTI+/- CD45.1+/- mice were generated by crossing C57BL/6 
RAG1-/- OTI+/+ mice with C57BL/6 45.1+/+ mice to create heterozygote F1 progeny 
that were used as donors in experiments. 
  
3.2.2 Tumor Cell Lines and Culture 
 All tumor cell lines were grown in ‘CTL’ media comprised of RPMI 1640 
supplemented with 10% fetal bovine serum (FBS), penicillin-streptomycin (100 IU/ml & 
100 ug/ml), L-glutamine (2 mM), HEPES buffer (5 mM), and 2-mercaptoethanol (100 
uM) at 37°C in a humidified 5% CO2 incubator.  Addition of G418 (1000 ug/ml) was 
used for selection/maintenance of mOVA expression, and hygromycin (200 ug/ml) was 
used for selection/maintenance of C2TA expression.  For in vitro induction of MHCI & 
MHCII, cells were cultured in 100 U/ml IFNγ (Peprotech; Rocky Hill, NJ) for three days.   
 The B16-F10 cell line is a melanoma derived from the C57BL/6 background.  It 
has undetectable baseline MHCI and MHCII expression, both of which can be induced by 
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exposure to IFNγ.  The B16-F10-D cell line is a variant of this same B16-F10 tumor that 
similarly has undetectable baseline MHCI and MHCII, but through unknown 
mechanisms has lost the ability upregulate MHCII in the presence of IFNγ.  Both of these 
tumor lines were contained within longstanding laboratory stocks.  B16.mOVA is a 
derivative of the B16-F10 line, which has been engineered to express a membrane-bound 
version of chicken ovalbumin (OVA) via stable transfection with pcDNA3.1(+)/mOVA 
under G418 selection as previously described (Preynat-Seauve et al., 2007) and was a gift 
from Dr. Bertrand Huard along with the parental pcDNA3.1(+)/mOVA construct.   
  B16-F10-D.mOVA was created by stably transfecting the parental B16-F10-D 
line with the same pcDNA3.1(+)/mOVA construct used to create the B16.mOVA line.  
Briefly, 2E6 B16-F10-D cells were transfected with 2 ug of pcDNA3.1(+)/mOVA 
plasmid DNA using Amaxa nucleofection solution V under program P-020 (Lonza; 
Allendale, NJ) and plated into non-selective CTL media.  48 hours post transfection 
G418 selection media was added and cells allowed to grow for approximately two weeks.  
Following this selection window, cells were seeded into flat-bottom, 96-well culture 
plates (Corning; Tewksbury, MA) at limiting dilution and cultures continued for another 
two weeks until single cell-clones could be identified in 1/3 or less of dilution wells.  
These single-cell clones were harvested and evaluated for OVA content via B3Z assay.  
OVA-positive clones were then challenged subcutaneously into C57BL/6 WT and I-Ab 
KO mouse recipients to verify tumor growth.  A single OVA-expressing clone capable of 
growing in both WT and I-Ab KO mice was utilized for all subsequent experiments. 
 B16.mOVA.C2TA was created by stably transfecting the parental B16.mOVA 
line with the plasmid construct pcDNA3.1/Hygro/CIITA.  This construct contained a full-
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length human CIITA gene, previously cloned from pcDNA1-amp-tagCIITA, which was 
kindly provided by Dr. Suzanne Ostrand-Rosenberg (Tai et al., 1999), within a 
hygromycin selectable vector.  B16mOVA cells were nucleofected with this construct 
and stably selected with G418 and hygromycin.  Following initial selection, bulk stable 
transfectants were single-cell sorted on a BD FACSAria (BD Biosciences; San Jose, 
CA) for high levels of I-Ab expression and single-cell plated into 96-well flat-bottom 
plates (Corning; Tewksbury, MA).  Single-cell clones were subsequently analyzed for 
OVA content with B3Z assay, CIITA expression via I-Ab expression in flow cytometry, 
and challenged into C57BL/6 WT and I-Ab KO mouse recipients to verify tumor growth 
as above. A single OVA-expressing, I-Ab positive clone capable of growing in both WT 
and I-Ab KO mice was utilized for all subsequent experiments.     
 
3.2.3 B3Z Assay 
 The B3Z cell line is a CD8+ T-cell hybridoma expressing a TCR specific for 
OVA peptide 257-264 (OVAI – SIINFEKL) presented by the MHCI molecule H-2Kb.  
The cells further carry a beta-galactosidase (lacZ) construct under the control of the IL-2 
promoter (Shastri & Gonzalez, 1993).  Upon TCR engagement and activation, these cells 
express beta-galactosidase, which is capable of producing a quantifiable colorimetric 
readout using Chlorphenolred-β-D-galactopyranoside (CPRG) (Millipore; Billerica, MA) 
in B3Z lysates.  B3Z hybridoma cells were seeded at 5E4 cells/well in 200 ul CTL media 
in a 96-well round-bottom plate (Corning; Tewksbury, MA) along with varying ratios of 
tumor (starting at 1:1 and diluting down) and incubated for 18 hours in a humidified 37°C 
5% CO2 incubator.  Addition of 5 ug/ml OVAI peptide (Genscript; Piscataway, NJ) was 
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used as a positive control.  After 18 hours, 150 ul media was removed and replaced with 
50 ul PBS and 100 ul CPRG lysis solution containing 0.5 mM CPRG and 0.5% NP40 
detergent in PBS.  Cells were incubated in this solution for 5 or 24 hours in a humidified 
37°C 5% CO2 incubator, and then light absorbance at 595 nm was determined on a 
Powerwave X340 spectrophotometer (Bio-Tek Instruments; Winooski, VT). 
 
3.2.4 OTI Tc1 Culture 
 Generation of OTI Tc1 cells was based upon a method modified from Dobrzanski 
and colleagues (Dobrzanski et al., 1999).  C57BL/6 RAG1+/- OTI+/- 45.1+/- splenocytes 
were harvested into single cell suspension by crushing through a 100 um cell strainer (BD 
Biosciences; San Jose, CA) followed by subsequent red blood cell (RBC) lysis using 
ammonium-chloride-potassium lysis buffer (ACK) (Gibco; Carlsbad, CA).  RBC-free 
splenocytes were then peptide loaded by incubating 10E6 cells/ml in warmed CTL media 
containing 2 ug/ml OVA I peptide (Genscript; Piscataway, NJ) in culture flasks for 2 
hours in a humidified 37°C 5% CO2 incubator.  Cells were then washed twice and 
counted.  Peptide-loaded splenocytes were then seeded at 1E6 cells/ml in 30 ml ‘Tc1 
media’ consisting of CTL containing 20 U/ml human IL-2 (NCI Clinical Repository; 
Rockville, MD), 2 ng/ml IL-12 (Peprotech; Rocky Hill, NJ), and 2 ug/ml anti-IL-4 
antibody (NCI Clinical Repository; Rockville, MD) and cultured upright in a T162 flask 
(Corning; Tewksbury, MA) for two days in a humidified 37°C 5% CO2 incubator.  On 
day two, 30 ml of warmed Tc1 media was added and flasks laid flat for another day of 
culture.  On day 3, an additional 40 ml of warmed Tc1 media was again added and the 
cells cultured for another day.  Cells were harvested on day 4 and subjected to dead cell 
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removal using two rounds of ficoll-paque (GE Life Sciences; Piscataway, NJ) separation.  
Following dead cell removal, cells were stored at 4°C in CTL media until ready for use.  
Cell purity was analyzed by FACS analysis for CD8 and CD45.1 and was consistently 
greater than 95% CD8+. Prior to adoptive transfer, cells were washed 3 times in ice-cold 
PBS, counted, and diluted as needed. 
 
3.2.5 OTI Tc0 Isolation 
 C57BL/6 OTI+ splenocytes were harvested into single cell suspension by 
crushing through a 100 um cell strainer (BD Biosciences; San Jose, CA) followed by 
subsequent red blood cell (RBC) lysis using ammonium-chloride-potassium lysis buffer 
(ACK) (Gibco; Carlsbad, CA).  RBC-free splenocytes were then enumerated and washed 
with ice-cold PBS.  CD8+ cells were then purified using negative selection with MACS 
CD8a+ T-cell Isolation Kit I or II according to manufacturer instruction using MACS LS 
separation columns (Miltenyi; Auburn, CA).  Following purification, cells were stored at 
4°C in CTL media until ready for use.  Cell purity was analyzed by FACS analysis for 
CD8, CD4, and Thy1.2 and was consistently greater than 95% CD8+ Thy1.2+ CD4-. 
Prior to adoptive transfer, cells were washed 3 times in ice-cold PBS, counted, and 
diluted as needed. 
       
3.2.6 Regulatory T-Cell Culture 
 Regulatory T-cells were generated using two different culture methods which 
each produced equivalent in vitro suppressive ability (data not shown).  In the first 
method, C57BL/6 RAG-/-OTII+/+ splenocytes were harvested into single cell suspension 
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by crushing through a 100 um cell strainer (BD Biosciences; San Jose, CA) followed by 
subsequent red blood cell (RBC) lysis using ammonium-chloride-potassium lysis buffer 
(ACK) (Gibco; Carlsbad, CA).  RBC-free splenocytes were then enumerated and washed 
with ice-cold PBS.  CD4+ cells were then purified using positive selection with MACS 
CD4 (L3T4) Microbeads according to manufacturer instruction using MACS LS 
separation columns (Miltenyi; Auburn, CA). Following purification, cells were stored at 
4°C in CTL media in preparation for culture and cell purity was analyzed by FACS 
analysis for CD4 and Thy1.2 and was typically around 75% CD4+ Thy1.2+.  10 cm 
tissue culture plates (Corning; Tewksbury, MA) were coated for 2 hours at room 
temperature with 10 ml PBS containing 2 ug/ml of non-azide, low-endotoxin anti-CD28 
(clone 37.51) and anti-CD3 (clone 145-2C11) antibodies (BD Biosciences; San Jose, CA) 
and subsequently washed twice with 10 ml PBS.  Purified CD4+ cells were then seeded 
into antibody-coated plates at 1E6 CD4+ cells/ml in 10 ml ‘Treg media’ consisting of 
CTL containing 5 ng/ml hTGFβ (R&D Systems; Minneapolis, MN), 500 U/ml hIL-2 
(NCI Clinical Repository; Rockville, MD), and 100 nM Retinoic Acid (Sigma; St. Louis, 
MO).  Cells were then cultured for 2 days in a humidified 37°C 5% CO2 incubator.  On 
day 2, 30 ml additional pre-warmed Treg media was added and the culture continued for 
a total of 6 or 7 days.  Cells were harvested, washed in ice-cold PBS, counted, and stored 
at 4°C in CTL media until ready for use.  Cells were analyzed for purity using FACS 
analysis for Foxp3, CD4, and CD25.  Purity usually exceeded 75% Foxp3+ CD4+ 
CD25+. Prior to adoptive transfer, cells were washed 3 times in ice-cold PBS, counted, 
and diluted as needed.   
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 In the second method of Treg culture, C57BL/6 OTII+/- Thy1.1+/- Foxp3-
GFP+/y splenocytes were harvested into single cell suspension and subjected to RBC 
lysis as above.  RBC-free splenocytes were then enumerated and seeded at 1E6 
splenocytes/ml in 50 ml Treg media into at T162 flask (Corning; Tewksbury, MA).  2 
ug/ml OVAII peptide (Genscript; Piscataway, NJ) was added to each flask and the cells 
cultured upright for 4 days.  On day 4, an additional 50 ml of pre-warmed Treg media 
was added, and the flasks were laid down for an additional day of culture.  On day 5, an 
additional 20 ml of pre-warmed CTL media containing 500 U/ml hIL-2 was added and 
the cells cultured a final day.  On day 6 cells were harvested, washed with ice-cold PBS, 
and FACS sorted for CD4+ Foxp3-GFP+ on a BD FACSAria (BD Biosciences; San 
Jose, CA) to a final purity of >98%.  Following sorting, cells were stored in CTL at 4°C 
until ready for use.  Prior to adoptive transfer, cells were washed 3 times in ice-cold PBS, 
counted, and diluted as needed. 
 
3.2.7 IV Tumor Challenge Model 
 A fresh vial of tumor cells was thawed for each challenge experiment and grown 
for approximately 7 days with harvest at approximately 70% confluency to ensure 
exponential growth.  For challenge, cells were harvested from adherent culture flasks 
using 0.25% trypsin-EDTA (Gibco; Carlsbad, CA) and washed in ice-cold CTL media.  
Cells were washed 3 times in ice-cold PBS, counted, and diluted to 5E5 cells/ml in ice-
cold PBS.  Mice were then challenged with 1E5 tumor cells via tail vein injection of 200 
ul tumor suspension on day 0.  On day 7 mice were adoptively transferred via tail vein 
injection with OTI Tc0 or Tc1 cells with or without OTII Tregs.  For evaluation of lung 
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metastases, mice were sacrificed on day 21.  Lungs were harvested and washed in PBS 
followed by fixation in Fekete’s Solution (70% ETOH/ 3.7% Paraformaldehyde/0.75 M 
Glacial Acetic Acid) (Sigma; St. Louis, MO) for at least 24 hours.  Left lung surface 
metastases were then enumerated using a Leica EZ4 dissecting microscope (Leica 
Microsystems; Wetzlar, Germany).  For survival studies, mice were evaluated daily 
beginning at day 21 and sacrificed at the first sign of suffering.  All mice were autopsied 
to confirm presence of lung metastatic burden as a reasonable cause of death/illness.   
 
3.2.8 Subcutaneous Tumor Challenge Model 
 A fresh vial of tumor cells was thawed for each challenge experiment and grown 
for approximately 7 days with harvest at approximately 70% confluency to ensure 
exponential growth.  For challenge, cells were harvested from adherent culture flasks 
using 0.25% trypsin-EDTA (Gibco; Carlsbad, CA) and washed in ice-cold CTL media.  
Cells were washed 3 times in ice-cold PBS, counted, and diluted to 1E6 cells/ml in ice-
cold PBS.  Mice were then challenged subcutaneously with 1E5 tumor cells in the 
previously shaved right flank on day 0.  On day 6, mice were transferred to fresh clean 
caging and provided with water containing trimethoprim/sulfamethoxazole (Sulfatrim; 
dosed for 95 mg/kg/24hr; obtained from the Johns Hopkins Hospital pharmacy) in 
preparation for irradiation. On day 7, mice were irradiated at 500 Rads whole body 
irradiation and then adoptively transferred via tail vein injection with OTI Tc0 or Tc1 
with or without OTII Tregs.  Tumor size was then determined with cross-sectional caliper 
measurement once or twice weekly.  Mice were sacrificed at the first sign of suffering or 
for timed explant sampling as indicated.   
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3.2.9 Antibodies and Flow Cytometry 
 I-Ab-FITC (clone AF6-120.1), I-Ek-FITC (clone 14-4-4S), H-2Kb-FITC (clone 
AF6-88.5), H-2Dd-FITC (clone 34-2-12), CD25-PE (clone PC61), CD4-APC (clone 
RM4-5), CD8-PE (clone 53-6.7), Thy1.1-PerCP (clone OX-7), and Thy1.2-FITC (clone 
30-H12) were purchased from BD Biosciences (San Jose, CA).  PD-L1-
BrilliantViolet421 (clone 10F.9G2) was purchased from BioLegend (San Diego, CA). 
Foxp3-FITC (clone FJK-16s) was purchased from eBioscience (San Diego, CA).  All 
antibodies were titrated for optimal staining intensity vs. background signal for 1E6 
cells/reaction.  All isotype control antibodies were from the same manufacturer and used 
at the same concentration as their associated test antibody.     
 For all extracellular antibody staining, 1E6 cells were washed with FACS buffer 
containing 1X Hanks Balanced Salt Solution (HBSS), 10 mM HEPES buffer, 2% FBS, 
and 0.1% sodium azide and stained with appropriate antibody for 15 minutes at room 
temperature in the dark followed by two washings with FACS buffer.  No more than 5 
antibodies were stained at a single time.  Cellular fixation/permeabilization was 
performed using the Foxp3 Staining Buffer Set (eBioscience; San Diego, CA) according 
to manufacturer instructions with fixation performed for 45 minutes at 4°C in the dark.   
Subsequent intracellular staining was performed for 30 minutes at 4°C in the dark with 
washes using the staining buffer set.  For multi-step staining sequences, the following 
sequence was always followed: extracellular antibody, fixation/permeabiliation, 
intracellular stain.  Following staining, cells were stored in FACS buffer at 4°C in the 
dark and were analyzed within 24 hours of staining.   
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 Flow cytometry was performed on the BD FACSCaliber, FACSAria, or 
LSRII with data acquisition using CellQuest Pro or FACSDiva (BD Biosciences; 
San Jose, CA).  Data analysis was further performed with FACSDiva as well as FlowJo 
(Tree Star Inc.; Ashland, OR). 
 
3.2.10 Histology 
Mice were sacrificed and tumors harvested into ice-cold CTL media.  Tissues 
were then blotted to remove excess CTL and transferred to Intermediate Tissue-Tek 
CryoMolds (Sakura Finetek; Torrance, CA) containing a small layer of Optimal Cutting 
Temperature (OCT) media (Sakura Finetek; Torrance, CA) and subsequently covered 
with OCT media.  Tissue chambers were then flash-frozen in a beaker of liquid nitrogen-
cooled isopentane (Sigma; St. Louis, MO).  Once fully frozen, samples were transferred 
on dry ice to an -80°C freezer for storage prior to cryosectioning.  Tissue was 
subsequently cryosectioned at 5 um sections onto “Plus” slides, fixed in ice-cold acetone 
for 10 minutes, and air dried for 30 minutes by the Johns Hopkins Histology Core.  
Following sectioning and fixation, slides were stored in a -80°C freezer until stained.   
 Primary antibodies used for staining included:  I-Ab-biotin (clone AF6-120.1; Ms 
IgG2a), H-2Kb-FITC (clone AF6-88.5; Ms IgG2a) (BD Biosciences; San Jose, CA), and 
Rat anti-CD274 (PD-L1) (clone MIH6; Rat IgG2a) (Abcam; Cambridge, MA).  All 
isotype controls were used at the same concentration and were from the same supplier as 
the test antibody.  Fluorescein/Oregon Green Rabbit IgG Antibody (Invitrogen; 
Camarillo, CA) was used as a secondary antibody to increase primary antibody-FITC 
signal. Goat anti-Rabbit AlexaFluor488, Goat anti-Rat AlexaFluor647 (Invitrogen; 
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Camarillo, CA), and Stretavidin-Cy3 (Sigma; St. Louis, MO) were used for tertiary 
staining.      
For staining, slides were allowed to warm to room temperature for 5 minutes in a 
laminar flow hood and then tissue demarcated with an ImmunEdge Pen (Vector Labs; 
Burlingame, CA) prior to rehydration with PBS for 10 minutes at room temperature.  All 
subsequent staining and blocking steps were performed in a light-protected, humidified 
chamber with three PBS washes between steps.   Samples were first treated with 1-2 
drops Molecular Probes Endogenous Biotin Blocking Kit (Invitrogen; Camarillo, CA) 
solutions A and B for 30 minutes each at room temperature.  They were then covered 
with 100 ul isotype-control blocking antibodies at 10 ug/ml in Blocking Buffer (2% IgG-
free BSA and 5% normal mouse serum (Jackson Immunoresearch; West Grove, PA) in 
PBS) for 1 hour at room temperature.  This blocking solution was then shaken off without 
PBS wash and replaced with primary antibodies at 10 ug/ml in Blocking Buffer and 
incubated overnight at 4°C.  Slides were then incubated with 100 ul of 2 ug/ml secondary 
antibody in PBS/2%BSA for 1 hour at room temperature, washed, and incubated with 
100 ul of tertiary antibodies diluted 1:100 in PBS/2%BSA for 1 hour at room 
temperature.  Nuclei were then counterstained with Hoechst 33342 (Invitrogen; 
Camarillo, CA) diluted 1:50,000 in PBS for 15 minutes at room temperature.  Following 
PBS wash, slides were fixed and mounted using a single drop of Aqua Poly/Mount 
(Polysciences; Warrington, PA) and cover slips placed and immobilized with nail polish.  
Slides were then stored face-up in light-protected slide boxes at 4°C until imaging.   
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Imaging was performed using a Nikon E800 fluorescent microscope using 
standard DAPI, FITC, Cy3, and Cy5 filter sets.  Image acquisition and analysis was 




3.3.1 Treatment and Suppression in the IV Challenge Model 
 The first tumor model evaluated was a B16 pulmonary metastasis model.  
B57BL/6 WT mice were challenged on day 0 with 1E5 B16.mOVA and treated on day 7 
with increasing amounts of Tc1-polarized OTI CD8+ cells.  Mice were subsequently 
sacrificed on day 21 to evaluate tumor burden within the lungs.  As shown in Figure 3.1, 
OTI Tc1 demonstrated a dramatic and dose-dependent treatment effect upon lung 
metastasis at the day 21 time point, with treatments of 3E6 or greater OTI Tc1 resulting 
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Figure 3.1 OTI Tc1 decrease B16.mOVA lung metastases in a dose-dependent 
fashion in WT mice. 
C57BL/6 WT mice IV challenged with 1E5 B16.mOVA on day 0 and treated on day 7 
with indicated doses of OTI Tc1 cells were sacrificed on day 21 and lungs harvested for 
evaluation.  (A) Left lung surface metastases were enumerated as a means of evaluating 
overall tumor burden.  Data from each mouse in a single study is presented, with bars 
indicating Mean and Standard Deviation in each group of 5 mice.  (B) Representative 
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 Based upon the impressive response seen at day 21, we next investigated the 
duration of this treatment effect by following mice in a survival study.  WT mice were 
challenged and treated as in the previous study, but instead of sacrificing at day 21 were 
followed daily with sacrifice and autopsy performed at the first signs of suffering.  As 
shown in Figure 3.2, despite the apparent magnitude of response seen at the single day 21 
time point, treatment benefit was not long lived, with mean survival being 28 days for 
untreated mice and a maximum of 49 days for the 5E6 treated group; a mere three weeks 
survival benefit.  Several explanations for this lack of treatment durability were 
considered, including loss of OVA from tumor cells and effector cell exhaustion.  The 
first of these, OVA antigen loss, was evaluated by seeding tumor explants into in vitro 
proliferation assays using naïve OTI responder splenocytes.  These studies indicated that 
antigen loss had not occurred, as explant samples by and large maintained the ability to 
stimulate naïve OTI splenocytes (data not shown).  Effector cell exhaustion was not 
evaluated.    
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Figure 3.2 Survival of WT mice in the B16.mOVA lung metastasis model. 
C57BL/6 WT mice IV challenged with 1E5 B16.mOVA on day 0 and treated on day 7 
with indicated doses of OTI Tc1 cells were followed and sacrificed with confirmatory 
autopsy at the first sign of illness. Kaplan-Meier survival curves are shown, with median 
survival for the groups being as follows: PBS – 28 days; 1E6 – 36; 2E6 – 42; 3E6 – 42; 
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 Despite the fact that the treatment effect seen for Tc1 was not permanent, the 
response seen at day 21 was striking enough to warrant evaluating the effect that addition 
of Tregs would have to the observed treatment response.  As before, WT mice were IV 
challenged with B16.mOVA on day 0 and subsequently treated on day 7.  Based upon the 
results from our prior studies, a dose of 2.5E6 Tc1 was given since this dose fell at the 
edge of complete treatment vs. tumor breakthrough and was thought to be an appropriate 
dose to evaluate Treg suppression.  OTI Tc1 treatment was performed with or without the 
simultaneous administration of 10E6 OTII Tregs.  This dose of Tregs represented a 4:1 
Treg:Tc1 ratio, which our experience in other models had shown to be an appropriate 
high-end starting ratio.  As shown in Figure 3.3, the addition of OTII Tregs had no effect 
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Figure 3.3 OTII Tregs do not suppress OTI Tc1 in the lung metastasis model. 
C57BL/6 WT mice IV challenged with 1E5 B16.mOVA on day 0 and treated on day 7 
with indicated doses of OTI Tc1 and/or 10E6 OTII Tregs were sacrificed on day 21 and 
lungs harvested for evaluation.  Left lung surface metastases were enumerated as a means 
of evaluating overall tumor burden.  Data from each mouse in a single study is presented, 
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 The failure of OTII Tregs to suppress the OTI Tc1 could be explained by a 
number of possibilities.  First, the ratio used here was 4 Treg to 1 Teff, which in prior 
studies using primarily CD4 Teffs had been shown to be sufficient in cases where 
suppression was achievable.  However, this was our first experience with attempting to 
suppress a CD8+ response in this fashion, and given the differences in tumor model, 
treatment modality, antigen, and TCR donor mice, the assumption of this dosing ratio 
being adequate may not have been accurate.  That being said, the fact that no suppression 
was seen at all made this seem less likely, as inadequate numbers should have at least 
shown some effect.  Further, given the technical difficulty of generating Tregs, the 
number used here was at the upper limit of achievable in vitro production, and thus 
increasing the Treg dose was not a feasible option for further evaluation.  
 Besides a possible inadequate dosing of Tregs, we also considered the possibility 
that the OTI Tc1 cells may have been terminally polarized in a manner that would be 
beyond the suppressive capabilities of our Tregs.  In our early phase studies to evaluate 
these cells as a treatment modality, we had found them to be highly potent at eliciting 
antigen-dependent target cytotoxicity, with high-level expression of IFNγ and granzyme 
(data not shown).  Perhaps the effector function of our Tc1 was too overwhelming to be 
suppressed by our Tregs, and another less polarized treatment modality would be more 
appropriate. 
 Potentially compounding this effect was the route we had chosen for our tumor 
challenge.  The IV tumor challenge model used here successfully seeded melanoma cells 
primarily within the capillary beds of the lung.  As our treatment cells and Tregs were 
adoptively transferred in the same IV fashion, they would have had nearly immediate 
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access to the tumor upon transfer.  This immediate access of Teff to target may have 
bypassed certain suppressive mechanisms, or simply cut short the timing needed for 
Tregs to interact appropriately with tumor, Teff, and/or host APC machinery in order to 
enact suppression.  An alternative route of challenge that would allow more limited tumor 
access and require greater T-cell trafficking might allow our Tregs more time and 
perhaps a broader range of mechanisms to enact suppression.   
 
3.3.2 Treatment and Suppression in the Subcutaneous Challenge Model 
 To address several of the considerations raised in the IV challenge model, we next 
sought to evaluate treatment using a subcutaneous tumor challenge model.  The hope here 
being that by transferring the tumor burden from the immediately hematogenously-
accessible site afforded with the IV challenge to a site not immediately accessibly to an 
IV-injected effector cell, we would broaden the mechanistic scope and timing available 
for suppression.  Further, we also sought to evaluate an alternative treatment option, since 
there were concerns that our Tc1 cells may not have been amenable to Treg suppression.  
We thus chose to evaluate the use of naïve OTI CD8+ cells which we subsequently 
referred to as ‘Tc0’ cells, with the multiple steps required for naïve cells to proliferate, 
traffic, and develop effector phenotype providing ample opportunities for Treg 
suppression.   
 To this end, C57BL/6 WT and MCHII knockout (KO) mice (I-Ab-/-) were 
challenged subcutaneously with 1E5 B16.mOVA tumor cells on day 0 and subsequently 
treated with 500 Rads non-myeloablative whole-body irradiation followed by adoptive 
transfer of 2.5E6 OTI Tc1 or Tc0 cells to compare the two formats.  A third group of WT 
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mice was challenge with the parental B16-F10 tumor line and similarly treated to serve as 
a control for treatment antigen-dependence.  Mice were subsequently followed with 
weekly measurement of tumor size.  As shown in Figure 3.4, Tc1 and Tc0 were able to 
provide significant treatment effect in both WT and MHCII KO mice challenged with 
B16.mOVA, but as expected failed to provide such an effect in WT mice challenge with 
non-OVA bearing parental B16-F10.  Tc0 were equivalent if not slightly superior to Tc1 
in their treatment effect at equal dosing, and thus a subsequent experiment, shown in 
Figure 3.4(D) was performed to titrate the treatment dosing of OTI Tc0.  This titration 
experiment suggested that the 2.5E6 dosing was in fact appropriate for OTI Tc0.     
 Based upon these results, we decided to next evaluate the addition of OTII Tregs 
to the subcutaneous challenge model with treatment by OTI Tc0.  C57BL/6 WT and 
MHCII KO mice were similarly challenged, treated, and followed as before, with 
addition of 7.5E6 OTII Treg given along with Tc0 treatment, representing a 3:1 Treg:Tc0 
ratio.  As shown in Figure 3.5, addition of OTII Tregs resulted in what appeared to be 
suppression of OTI Tc1 in MHCII KO mice but not in WT mice. 
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Figure 3.4 OTI Tc1 and Tc0 treat subcutaneous B16.mOVA in an antigen-
dependent fashion in both WT and MHCII KO mice. 
C57BL/6 WT and MHCII KO mice were subcutaneously challenged with 1E5 
B16.mOVA or parental B16-F10 on day 0 and treated on day 7 with 500 Rads non-
myeloablative whole body irradiation followed by indicated doses of OTI Tc1 or Tc0 
cells.  Tumor size was then monitored weekly using caliper measurements of tumor 
cross-sectional area.  Mean +/- Standard Deviation for each group of 5 mice is shown. 
(A) Treatment of B16mOVA in WT mice.  (B) Treatment of B16mOVA in MHCII KO 
mice.  (C) Treatment of B16-F10 in WT mice.  (D) Tc0 treatment titration in B16mOVA-
bearing WT mice. 
 
	   72	  
 
Figure 3.5 OTII Treg suppress OTI Tc0 in MHCII KO but not WT recipients. 
(A) C57BL/6 WT and (B) MHCII KO mice were subcutaneously challenged with 1E5 
B16.mOVA on day 0 and treated on day 7 with 500 Rads non-myeloablative whole body 
irradiation followed by 2.5E6 OTI Tc0 cells with or without co-administration of 7.5E6 
OTII Tregs.  Tumor size was then monitored weekly using caliper measurements of 
tumor cross-sectional area.  Mean +/- Standard Deviation for combined data from three 
independent experiments is shown, with numbers in parentheses indicating the total 
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 The findings in Figure 3.5 were encouraging but also somewhat difficult to 
interpret, and were consistent within three independent experiments (as shown pooled in 
the figure).  While there was some overlap between the curves, there appeared to be a real 
suppressive effect of OTII Tregs upon Tc0 in the MHCII KO mice, which was not 
observed in the WT mice.  Upon closer examination, it was evident that the difference 
between the two groups of mice was not in the Treg curves, which were quite similar, but 
in the Tc0 only curves.  MHCII mice treated with Tc0 showed a prolonged treatment 
effect compared to WT mice when comparing the 28 and 35 day time points.  This 
allowed for separation of the Treg group from the Tc0 only group in the MHCII KO mice 
but not in the WT mice.  One possible explanation for this finding was that the WT 
recipient mice bear CD4 cells, particularly Tregs, which are not present in the MHCII KO 
mice.  Our treatment strategy had utilized whole-body irradiation to help eliminate 
endogenous immune cells in the recipients, but we had selected a non-myeloablative dose 
and thus recovery of these cells would eventually occur.  Recovery of endogenous 
polyclonal Tregs in the WT mice could potentially allow for suppression of our Tc0 cells.  
In contrast, MHCII KO mice do not bear CD4 cells, so no endogenous Treg population 
would be present to suppress our Tc0 upon bone marrow recovery.  A better 
understanding of the immune response in our model was needed in order to truly evaluate 
this possibility, which would be the focus of future studies.  
 
3.3.3 Development and Characterization of B16 Variants 
 Although difficult to interpret, the findings in Figure 3.5 were certainly 
encouraging, as there did appear to be suppression in the MHCII KO mice.  This 
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suppression was not complete, however, and displayed a lag relative to untreated mice. 
However, if suppression was dependent upon tumor MHCII expression as we had 
hypothesized, then a model where MHCII was expressed only after inflammation, as was 
thought to be the case for our B16.mOVA tumor, would be expected to display a lag such 
as the one seen in our results.  Presumably, if the tumor were to constitutively express 
MHCII this lag would not occur.  In order to evaluate this concept further, we needed to 
broaden our tumor repertoire with the construction of B16.mOVA tumors with variable 
expression patterns of MHCII.  Specifically, to couple with our MHCII-inducible line, we 
desired to create OVA-expressing B16 melanoma lines wherein MHCII was 
constitutively expressed and a second where MHCII could not be expressed. 
 To accomplish this goal, two new cell lines had to be created and validated.  First, 
we took our B16.mOVA line and stably transfected it with the human CIITA gene, which 
is the master regulator of MHCII expression, to create the MHCII-constitutive line 
B16.mOVA.CIITA.  In parallel, we took the B16-F10-D line, a B16-F10 derivative that 
has lost the ability to upregulate MHCII, and stably transfected it with the mOVA gene 
construct to create the MHCII-non-inducible line B16-F10-D.mOVA.  After selection, 
limiting dilution cloning, and validation of in vivo growth for both lines (data not shown) 
we set out to verify antigen content and MHC expression profiles of our B16.mOVA 
variants in vitro and in vivo. 
 To begin with, we first assessed the in vitro expression of MHCI and MHCII in 
the presence and absence of exposure to IFNγ.  Tumor cells were cultured for 72 hours 
with and without 100 U/ml IFNγ and then evaluated for cell surface MHCI and MHCII 
expression via flow cytometry.  As shown in Figure 3.6, we were successful in creating 
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B16 melanoma lines with non-inducible, inducible, and constitutive expression of MHCII 
in vitro.  Inducible expression of MHCI was also seen in all three lines, with the 
B16.mOVA.CIITA line showing detectable baseline MHCI expression unlike the other 
two lines. 
 Based upon the MHCI and MHCII expression seen in our tumor variants, we also 
investigated the expression pattern of PD-L1, a negative costimulatory molecule known 
to be expressed on some tumors with upregulation in the presence of IFNγ.  B16 variants 
were cultured as before with and without IFNγ and analyzed for cell surface PD-L1 
expression via flow cytometry.  As shown in Figure 3.7, PD-L1 expression was present at 
low levels in the absence of IFNγ and demonstrated marked upregulation in the presence 
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Figure 3.6 In vitro MHCI and MHCII expression of B16.mOVA variants in the 
presence and absence of IFNγ . 
B16-F10-D.mOVA, B16.mOVA, and B16.mOVA.CIITA tumor lines were cultured for 
72 hours with and without 100 U/ml IFNγ and then evaluated for cell-surface expression 
of MHCI (H-2Kb) and MHCII (I-Ab) via flow cytometry. 
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Figure 3.7 In vitro PD-L1 expression of B16.mOVA variants in the presence and 
absence of IFNγ . 
B16-F10-D.mOVA, B16.mOVA, and B16.mOVA.CIITA tumor lines were cultured for 
72 hours with and without 100 U/ml IFNγ and then evaluated for cell-surface expression 
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 We next verified the OVA antigen content of our lines using in vitro recognition 
with the OVA-specific hybridoma B3Z.  B16.mOVA variants and non-OVA containing 
parental lines were cultured as before with and without IFNγ and then placed into 
overnight coculture with B3Z cells.  Cultures were then lysed and incubated with the 
colorimetric CPRG substrate to assess for the presence of β-galactosidase (β-gal), which 
in the B3Z line is under the control of the IL-2 promoter and is expressed only upon 
antigen-specific stimulation.  As seen in Figure 3.8, OVA-containing B16 variants 
exposed to IFNγ were capable of stimulating B3Z cells as seen with readout at both 5 and 
24 hours.  In contrast, non OVA-expressing parental variants exposed to IFNγ did not 
stimulate B3Z cells.  Interestingly, B16.mOVA variants not exposed to IFNγ were unable 
to stimulate B3Z cells, which in conjunction with the data from Figure 3.6 suggests that 
the baseline MHCI expression of these cells was too low to adequately present OVA to 
the B3Z hybridoma.   
 With the in vitro OVA content and expression of MHCI, MHCII, and PD-L1 
determined, we next sought to verify that these same changes occurred in vivo.  To 
accomplish this, C57BL/6 WT and MHCII KO mice were challenged with 1E5 
B16.mOVA tumor variants on day 0 and treated on day 7 with 500 Rads non-
myeloablative whole body irradiation followed by adoptive transfer of 2.5E6 OTI Tc0 or 
PBS as performed previously.  Mice were then sacrificed one week after treatment and 
tumor masses harvested and processed for histologic evaluation of MHCI, MHCII, and 
PD-L1 expression.  As can be seen in Figure 3.9, exposure of B16.mOVA variants to 
OTI Tc0 in vivo resulted in MHCI, MHCII, and PD-L1 expression patterns that closely 
resembled those seen with in vitro exposure to IFNγ. 
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Figure 3.8 OVA-containing B16 variants stimulate the OVA-specific B3Z 
hybridoma in vitro. 
OVA-containing B16 tumor lines B16-F10-D.mOVA, B16.mOVA, and 
B16.mOVA.CIITA, along with non OVA-containing parental lines B16-F10 and B16-
F10-D, were cultured for 72 hours with and without 100 U/ml IFNγ and then cocultured 
overnight with the B3Z hybridoma.  Cultures were lysed and β-gal activity detected by 
incubation for 5 or 24 hours with the colorimetric substrate CPRG followed by 
measurement of light absorption at 595 nm.  Mean +/- Standard Deviation for 3 replicate 
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Figure 3.9 In vivo expression of MHCI, MHCII, and PD-L1 in B16.mOVA variants 
upon exposure to OTI Tc0. 
C57BL/6 WT and MHCII KO mice were challenged with 1E5 B16.mOVA tumor 
variants on day 0 and treated on day 7 with 500 Rads non-myeloablative whole body 
irradiation followed by adoptive transfer of 2.5E6 OTI Tc0 or PBS.  Mice were sacrificed 
one week after treatment (day 14) and tumor masses harvested and processed for 
histologic evaluation of (A) MHCI (H-2Kb), (B) MHCII (I-Ab), and (C) PD-L1 
expression.  Shown here are representative images from I-Ab-/- recipients.  3 mice were 
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 Specifically, all three tumors upregulated MHCI and PD-L1 upon OTI Tc0 
treatment, and both B16.mOVA and B16.mOVA.CIITA, but not B16-F10-D.mOVA, 
demonstrated expression of MHCII, with B16.mOVA.CIITA also demonstrating MHCII 
expression in untreated tumors as expected.  As displayed in Figure 3.10, combination of 
these markers clearly demonstrated the restriction of MHCII expression to the tumor 
mass in MHCII KO mice, with overlying host epidermis demonstrating MHCI expression 
but not MHCII expression. Collectively, these data demonstrate the B16.mOVA variants 
created here express OVA, are recognized by OTI Tc0, and demonstrate the desired 
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Figure 3.10 MHCII clearly demarcates the tumor in OTI Tc0 treated MHCII KO 
mice. 
C57BL/6 WT and MHCII KO mice were challenged with 1E5 B16.mOVA tumor 
variants on day 0 and treated on day 7 with 500 Rads non-myeloablative whole body 
irradiation followed by adoptive transfer of 2.5E6 OTI Tc0 or PBS.  Mice were sacrificed 
one week after treatment and tumor masses harvested and processed for histologic 
evaluation.  Displayed here are a Merge (A) of DAPI nuclear stain (C), MHCI (H-2Kb) 
(D), and MHCII (I-Ab) (E), as well as an H&E stain (B) demonstrating necrotic tumor 
mass with overlying epidermis.  Representative images from I-Ab-/- recipients are shown.  
3 mice were used per group. 
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3.4 Discussion 
   
 The B16-F10 tumor line was generated in the 1970s by Fidler and colleagues 
(Fidler et al., 1976; Fidler & Bucana, 1977) and since has been widely disseminated.  As 
such, it has experienced a great deal of drift and tumors from different sources are known 
to demonstrate a wide degree of variability in growth kinetics, metastatic potential, and 
treatment capability (Overwijk & Restifo, 2001).  In this first study, we therefore first 
sought to establish an appropriate treatment model with our B16.mOVA tumor line. 
Particular emphasis was placed upon defining a minimum treatment dose for tumor 
response, as prior experience within our laboratory had demonstrated that Treg 
suppression requires a careful balance of tumor burden, effector cell number, and Treg 
cell number, with Tregs failing to demonstrate suppression when Teff are in extreme 
excess. 
 Our initial attempts utilized a lung metastasis model with treatment by OTI Tc1 
previously described by Dobrzanski and colleagues (Dobrzanski et al., 1999; 2000; 
2001).  We were able to successfully generate in vitro polarized OTI cells that produced 
IFNγ and granzyme and lysed OVA-bearing target cells in vitro (data not shown).  When 
utilized for in vivo treatment, these cells were able to show tumor killing (Figure 3.1), but 
when compared to the dosing used in the experiments by Dobrzanski and colleagues, we 
needed much higher doses of Tc1 cells to accomplish tumor treatment.  Furthermore, 
their studies were able to demonstrate long-term tumor-free survival with treatment by 
OTI Tc1, whereas in our study this treatment effect was short lived (Figure 3.2), 
providing a maximum increased survival of only three weeks.  The cause for these 
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differences is unknown at this time.  Differences in our tumor could account for these 
differences.  As noted above, the B16-F10 line as a whole has become highly variable 
since its generation over 30 years ago.  Further, our derivative line B16.mOVA was fairly 
recently derived (Preynat-Seauve et al., 2007) and the OVA construct, its cellular 
location, and its antigenic processing could all have varied between the two models.  
While we were able to verify that tumor explants in our mice had not lost OVA 
expression (data not shown), we did not further characterize these explants.  We also 
considered it a strong possibility that our Tc1 cells were either exhausted or even perhaps 
dying within recipient mice.  In fact, multiple recent studies have indicated that in vitro 
acquisition of effector phenotype results in inferior antitumor response in vivo, owing 
largely to impaired proliferative and survival capacities of effector cells (Gattinoni et al., 
2005b; 2006; Klebanoff et al., 2005).  At the time, our studies were not designed to 
evaluate this possibility, however, and thus that question remains unanswered.   
 Although not ideal, the treatment benefit afforded by our Tc1 cells in the lung 
metastasis model was thought to be large enough to allow detection of a Treg suppressive 
effect, and thus Tregs were evaluated in this model.  We initially aimed to use as few 
treatment cells as possible with as many Tregs as possible to give the best chance of 
seeing suppression.  Unfortunately, as shown in Figure 3.3, even at a 4:1 Treg:Tc1 ratio 
we were unable to see suppression in our model.  As previously discussed, we considered 
a number of causes for this failure, including inadequate Treg numbers, inappropriate 
Teffector phenotype, and poor tumor location.  Amongst these options, Treg numbers 
could not be increased, as we were at the technical limit of in vitro production in our 
system.   
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 Regarding the phenotype of our effector cells, our Tc1 polarization had been 
based upon the aforementioned studies by Dobrzanski and colleagues, which had been 
successful at treating B16-OVA lung metastases, but had not evaluated the interactions of 
Tregs with these cells.  It seemed entirely possible that these Tc1 cells may have been so 
heavily polarized that they were ‘insuppressible.’  Given this concern, along with 
concerns regarding the long-term treatment failure the Tc1 cells demonstrated, we 
decided to evaluate a different effector cell method.  A study by Chen and colleagues 
(Chen et al., 2005) had demonstrated the ability of naïve HA-specific CD8 cells to 
proliferate, traffic, polarize, and kill antigen-bearing tumor cells in vivo.  They further 
demonstrated the ability of antigen-specific Tregs to suppress this CD8-mediated effect.  
The concept of using naïve CD8 cells as effectors was appealing, as we envisioned that 
their use could potentially solve both the long-term treatment failure as well as the failure 
of suppression seen in our Tc1 model.  As such we attempted to treat our B16.mOVA 
line with naïve OTI CD8+, which we termed ‘Tc0.’   
 In parallel with this switch, we also changed the route of tumor challenge used in 
our studies.  Besides inadequate Treg numbers and inappropriate effector cell phenotype, 
we also thought that the location of our tumor might make it difficult for suppression to 
take place, although we could find no studies that had investigated the idea previously.  
By using IV tumor challenge we were seeding lung capillaries with tumor. These same 
capillary beds would be the first ones encountered by our treatment cells, and they would 
do so prior to exposure to any lymphoid organs such as spleen or lymph nodes.  It seemed 
reasonable to think that this direct access of highly polarized effector cells to tumor 
would potentially bypass a number of regulatory mechanisms used for suppression.  This 
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shortcoming would presumably be less of an issue for Tc0 cells, since as naïve cells they 
would need host lymphatic tissue to become polarized.  Use of a subcutaneous model 
would further allow multiple time point measurement and generation of growth curves as 
opposed to the single data points generated in the lung metastasis model.   
 In switching to the subcutaneous treatment model, we also incorporated the use of 
non-myeloablative whole body irradiation of our mice prior to the administration of 
treatment cells.  This was done largely on the basis of multiple studies (Gattinoni et al., 
2005a; Dudley et al., 2008), including our own preliminary data in this model (not 
shown), which demonstrated an enhanced treatment efficacy when irradiation was 
incorporated to adoptive cell therapies.  A number of explanations for this effect have 
been proposed, including decreased host immune cell competition, increased availability 
of cytokines, and liberation of tumor antigens, but none have been fully proven to be the 
cause for the treatment benefit seen.  Despite the lack of full mechanistic understanding, 
the treatment benefit of irradiation is well established and was successfully utilized here.   
 Thus, we converted our model to one where tumor cells were challenged 
subcutaneously and treated with OTI Tc0 cells.  As demonstrated in Figure 3.4, this 
model allowed for antigen-specific treatment of B16.mOVA in both WT and MHCII KO 
mice in a manner that was comparable if not superior to Tc1 cells.  Addition of Tregs to 
this model, as shown in Figure 3.5, resulted in what appeared to be suppression in the 
MHCII KO hosts but not WT hosts.  Upon further examining this data, we were stuck 
with two general observations. 
 The first of these was that, while the Treg curves between the WT and MHCII KO 
groups were similar, the treatment effect seen in WT mice was less robust than that in 
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MHCII KO mice.  This decreased treatment intensity reduced the window available for 
Treg suppression making interpretation within the WT recipients more difficult.  While a 
number of explanations could be provided for this observation, the obvious one that 
occurred to us was the presence of endogenous Tregs in WT mice but not in MHCII KO 
mice.  While we had utilized lymphocyte-depleting radiation prior to our adoptive 
transfer, this depletion is not perfect, and further the host bone marrow was still intact 
and would resume immune cell production.  Recovery of endogenous polyclonal Tregs in 
WT mice could potentially allow for suppression of our Tc0 cells.  In contrast, MHCII 
KO mice do not possess CD4 cells, and therefore recovery of their bone marrow would 
not produce endogenous Tregs that could suppress our OTI.  To investigate this theory 
further, we first needed a better characterization of the OTI cells in our model, which 
subsequent studies would later seek to achieve.    
 The second observation we were struck by in Figure 3.5 was the lag in 
suppression that occurred in the MHCII KO mice.  In our hypothesis, the recognition of 
tumor cells by effector cells would result in exposure to inflammatory cytokines that 
could induce upregulation of MHCII on the tumors, thereby allowing them to directly 
present antigens to Tregs.  This would presumably result in a lag of suppression during 
the interval where tumors were being seen and killed by effector cells but had not yet 
upregulated MHCII.  Thus, our findings with an MHCII-inducible tumor fit very well 
with the model we had proposed.  To further extend and support this idea, we 
hypothesized that the constitutive expression of MHCII by our tumor would result in a 
reduction, or perhaps elimination, in this suppressive lag, and conversely a decrease or 
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complete inability to up-regulate MHCII would result in a decreased to absent 
suppressive potential. 
  To answer this question, we had to create B16 tumor variants with constitutive 
and non-inducible MHCII expression.  To accomplish the first of these, we inserted the 
CIITA gene into our B16.mOVA line to create B16.mOVA.CIITA.  CIITA is essential 
for transcriptional activation of all MHCII genes and has a helper function in MHCI gene 
expression (Holling et al., 2006), and we envisioned its forced expression within our 
tumor cell would result in constitutive MHCII expression.  To accomplish the second of 
these, we utilized a B16 variant, B16-F10-D, which had been shown years earlier by the 
lab to not up-regulate MHCII in the presence of IFNγ (data not shown).  To this cell we 
added the same mOVA antigen expressed by our MHCII-inducible B16-F10 line to 
create B16-F10-D.mOVA.  Once created, we successfully showed that all three of our 
B16 variants expressed OVA (Figure 3.8) and demonstrated the desired pattern of MHCI 
and MHCII expression in the presence and absence of IFNγ in vitro (Figure 3.6).  We 
further were able to demonstrate that these in vitro findings were recapitulated upon 
effector cell exposure (and presumably IFNγ exposure) in vivo (Figures 3.9 and 3.10).  
Finally, along with the expression patterns of MHCI and MHCII, we were able to 
demonstrate that our B16 variants upregulated the expression of the negative co-
stimulatory molecule PD-L1 in the presence of IFNγ both in vitro (Figure 3.7) and in vivo 
(Figure 3.9).  This expression of PD-L1 by tumors and upregulation by IFNγ has been 
well documented (Zhang et al., 2009; Zhou et al., 2010) and shown to have important 
implications upon tumor outcome and Treg function within tumors (Ghebeh et al., 2007; 
Zhou et al., 2009a; Zhou et al., 2010).   
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 In conclusion, in this first study we were able to develop a novel subcutaneous 
B16 tumor challenge system in which OVA-expressing B16 cells were treated by a 
combination of non-myeloablative whole body irradiation and adoptive transfer of OTI 
Tc0 cells in both WT and MHCII KO recipients.  Although not perfect, we were further 
able to demonstrate a suppressive effect of OTII Tregs upon this treatment in our MHCII 
KO recipients.  To allow for further elucidation of this effect, we successfully generated 
and validated both in vitro and in vivo two new OVA-expressing B16 tumor lines with 
constitutive and non-inducible MHCII expression to go along with our initial MHCII-
inducible B16.mOVA line.  Future studies will aim to better understand the treatment 
model generated here by evaluating the phenotype of our Tc0 cells over the course of 
tumor progression, evaluate the effect of Tregs upon this Tc0 phenotype, and finally to 
determine the effects that variable tumor MHCII expression has upon the suppressive 
capabilities of Tregs in this model. 
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Chapter 4 
 




  In our first study, we were able to establish a model of antigen-specific immune-
mediated tumor rejection of B16.mOVA by OTI CD8+ that could subsequently be 
suppressed by OTII Tregs in MHCII KO mice.  To better understand the physiology of 
this model, we next set out to characterize the phenotype of our OTI Tc0 (naïve) CD8+ 
cells as they elicited the treatment effect seen.  Through accurately defining our CD8+ 
populations and effector cell phenotype, we hoped to eventually evaluate the changes 
Tregs have upon this phenotype as a means of insight into the mechanisms used by Tregs 
to enact suppression.     
 CD8+ T-cells exist as a series of distinct functional subpopulations comprised of 
antigen-inexperienced naïve (TN) cells and antigen-experienced effector (TE), effector 
memory (TEM), and central memory (TCM) cells. After encountering antigen, T-cells 
undergo proliferation and differentiation based upon a number of signals from the 
surrounding immune environment including TCRs, cytokines, and costimulatory 
molecules (Sallusto et al, 2004; Wherry et al., 2003). The largest pool of cells generated 
are TE cells, the majority of which are short lived and die as their effector function 
eliminates antigen.  A smaller pool of TCM and TEM cells is also generated which can 
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respond to repeated exposure to antigen by proliferating and differentiating into TE cells.  
These TE cells are once again typically short lived but can also revert back to memory 
cells (Wherry et al., 2003; Fearon et al., 2001).  
 Each of these subpopulations differs in its phenotype, including tissue trafficking, 
accumulation, function, and long-term persistence potential (Sallusto et al., 2004), all of 
which influence their ability to enact long-standing immunity.  Once example of 
phenotypic variability within CD8+ cells involves cell surface expression of the adhesion 
molecule CD62L.  TCM cells are classically considered to be CD62L+, allowing them to 
migrate into secondary lymphatic tissue such as lymph nodes where they are capable of 
rapidly proliferating when exposed to antigen.  In contrast, TEM cells lack CD62L 
expression, enabling them to migrate away from lymph nodes into peripheral tissues 
where they can enact effector function (Butcher & Pickler, 1996).  TE cells, also known 
as cytotoxic T-cells (Tc or CTL), also lack CD62L and can be further divided into type 1 
(Tc1) and type 2 (Tc2), both of which are capable of killing through the 
granzyme/perforin pathway.  Tc1 cells produce IL-2, IFNγ, and TNFα, whereas Tc2 cells 
typically produce IL-4, IL-5, and IL-10 (Carter & Dutton, 1995; 1996; Cerwenka et al., 
1998).  Both Tc1 and Tc2 have been shown to mediate durable antigen-specific reduction 
of tumor growth and increased mouse survival in a B16-OVA lung metastasis model.  
Tc1, however, were shown to be 5-fold more effective at clearance than Tc2, with Tc1 
demonstrating superior persistence in the tumor over time (Dobranzski et al., 1999). 
Based upon this data, we had selected to use OTI Tc1 in our initial treatment model, but 
found that our cells, unlike those of Dobrzanski and colleagues, were unable to enact 
long-term immune protection.    
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 Clues to this failure come from a number of recent studies that have evaluated the 
importance of CD8 phenotype and lineage in protective immunity (Berger et al., 2008; 
Wherry et al., 2003). It has been suggested that in vitro acquisition of an effector 
phenotype is a large reason for the poor survival often seen in adoptively transferred 
CD8+ cells (Gattinoni et al., 2005b; 2006; Dudley et al., 2001; Yee et al., 2002; 
Klebanoff et al., 2005), and transfer of alternative populations of CD8+ cells has been 
under investigation.  Studies within both mouse and human melanomas have shown a 
superior long-term effect with adoptive transfer of antigen-specific TCM cells over TEM/TE 
cells (Klebanoff et al., 2005; Chapuis et al., 2012).  TE derived from TCM have been 
shown to have greater capacity than TEM to persist in vivo, have greater proliferative 
potential, and are more efficient at mediating long-term protective immunity (Wherry et 
al., 2003; Berger et al., 2008).  Use of TN populations has also been shown to provide 
long-term antigen-specific immunity (Chen et al., 2005), likely owing to the ability of 
these cells to form all major CD8 populations upon antigenic stimulation in vivo.   
 In our second study, we set out to define the phenotype acquired by our OTI+ 
CD8+ cells following the adoptive transfer of TN cells into B16.mOVA tumor-bearing 
mice.  We were able to successfully show that our CD8+ cells expanded, trafficked to, 
and accumulated within the tumor mass.  We further demonstrated based upon surface 
molecule expression that our cells developed into all major CD8+ subpopulations, with 
secondary lymphoid tissues containing greater percentages of TN and TCM cells whereas 
peripheral tumor tissue demonstrated primarily TEM/TE cells.  These tumor resident 
TEM/TE cells further demonstrated a high frequency of exhaustion marker expression, 
which may account for the lack of permanent tumor rejection seen in our model.  Finally, 
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we were able to demonstrate that our CD8+ cells secreted IFNγ and TNFα cytokines 
consistent with a Tc1 phenotype and were able to effectively lyse antigen-bearing targets 
throughout the course of tumor progression.   
 
4.2 Materials and Methods 
 
4.2.1 Mice 
 Mice six to eight weeks old were used for all experiments, with matching of 
donor/recipient gender whenever possible.  All mice were housed and bred in the Johns 
Hopkins University Cancer Research Building I mouse facility using standard 
procedures, and all experiments involving the use of mice were performed in accordance 
with protocols approved by the Animal Care and Use Committee of the Johns Hopkins 
University School of Medicine.   
 C57BL/6 WT (C57BL/6NCr) and C57BL/6 45.1+/+ (B6-LY5.2/Cr) mice 
homozygous for the CD45.1/Ly5.2 congenic marker were purchased from the NCI 
(Frederick, MD).  C57BL/6 I-Ab-/- (B6.129S2-H2dlAB1-Ea/J) mice bearing a homozygous 
deletion within the MHCII gene locus (Madsen et al., 1999) were purchased from 
Jackson Laboratory (Bar Harbor, ME).  C57BL/6 RAG1-/- OTI+/+ (B6.129S7-
Rag1tm1MomTg(TcraTcrb)1100Mjb) mice bearing homozygous knockout of the Rag1 gene 
along with homozygous insertion of the OTI αβ TCR specific for chicken ovalbumin 
peptide 257-264 (OVAI - SIINFEKL) presented by the MHCI molecule H-2Kb (Hogquist 
et al., 1994) were purchased from Taconic (Germantown, NY).  C57BL/6 Luci+/+ mice 
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expressing firefly luciferase under the control of the β-actin promoter (Cao et al., 2004) 
were a generous gift from Dr. Leo Luznik.   
 C57BL/6 RAG1+/- OTI+/- CD45.1+/- and RAG1+/- OTI+/- Luci+/- mice were 
generated by crossing C57BL/6 RAG1-/- OTI+/+ mice with C57BL/6 45.1+/+ and 
C57BL/6 Luci+/+, respectively, to create heterozygote F1 progeny which were used as 
donors in experiments. 
 
4.2.2 Tumor Cell Lines and Culture 
 All tumor cell lines were grown in ‘CTL’ media comprised of RPMI 1640 
supplemented with 10% fetal bovine serum (FBS), penicillin-streptomycin (100 IU/ml & 
100 ug/ml), L-glutamine (2 mM), HEPES buffer (5 mM), and 2-mercaptoethanol (100 
uM) at 37°C in a humidified 5% CO2 incubator.  Addition of G418 (1000 ug/ml) was 
used for selection/maintenance of mOVA expression. 
 The B16-F10 cell line is a melanoma derived from the C57BL/6 background and 
was contained within longstanding laboratory stocks.  It has virtually undetectable 
baseline MHCI and MHCII expression, both of which can be induced by exposure to 
IFNγ.  B16.mOVA is a derivative of the B16-F10 line, which has been engineered to 
express a membrane-bound version of chicken ovalbumin (OVA) via stable transfection 
with pcDNA3.1(+)/mOVA under neomycin/G418 selection as previously described 
(Preynat-Seauve et al., 2007) and was a gift from Dr. Bertrand Huard.  
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4.2.3 OTI Tc0 Isolation 
 C57BL/6 OTI+ splenocytes were harvested into single cell suspension by 
crushing through a 100 um cell strainer (BD Biosciences; San Jose, CA) followed by 
subsequent red blood cell (RBC) lysis using ammonium-chloride-potassium lysis buffer 
(ACK) (Gibco; Carlsbad, CA).  RBC-free splenocytes were then enumerated and washed 
with ice-cold PBS.  CD8+ cells were then purified using negative selection with MACS 
CD8a+ T-cell Isolation Kit I or II according to manufacturer instruction using MACS LS 
separation columns (Miltenyi; Auburn, CA).  Following purification, cells were stored at 
4°C in CTL media until ready for use.  Cell purity was analyzed by FACS analysis for 
CD8, CD4, and Thy1.2 and was consistently greater than 95% CD8+ Thy1.2+ CD4-. 
Prior to adoptive transfer, cells were washed 3 times in ice-cold PBS, counted, and 
diluted as needed. 
 
4.2.4 Subcutaneous Tumor Challenge and Treatment 
 A fresh vial of tumor cells was thawed for each challenge experiment and grown 
for approximately 7 days with harvest at approximately 70% confluency to ensure 
exponential growth.  For challenge, cells were harvested from adherent culture flasks 
using 0.25% trypsin-EDTA (Gibco; Carlsbad, CA) and washed in ice-cold CTL media.  
Cells were washed 3 times in ice-cold PBS, counted, and diluted to 1E6 cells/ml in ice-
cold PBS.  Mice were then challenged subcutaneously with 1E5 tumor cells in the 
previously shaved right flank on day 0.  On day 6, mice were transferred to fresh clean 
caging and provided with water containing trimethoprim/sulfamethoxazole (Sulfatrim; 
dosed for 95 mg/kg/24hr; obtained from the Johns Hopkins Hospital pharmacy) in 
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preparation for irradiation. On day 7, mice were irradiated at 500 Rads whole body 
irradiation and then adoptively transferred via tail vein injection with OTI Tc0.  Tumor 
size was then determined with cross-sectional caliper measurement once or twice weekly.  
Mice were sacrificed at the first sign of suffering or for timed explant sampling as 
indicated. 
 
4.2.5 In Vivo Bioluminescent Imaging 
 D-Luciferin (Perkin-Elmer; Waltham, MA) was prepared fresh at 15 mg/ml in 
PBS, sterile filtered using a 0.22 um syringe filter, and stored on ice in the dark prior to 
injection.  Mice were given 200 ul intraperitoneal (i.p.) injection of D-Luciferin to 
provide an approximate dose of 150 mg/kg.  They were then anesthetized using 
isoflurane in preparation for imaging.  Imaging was performed 10 minutes after injection 
of D-Luciferin in order to optimize light signal per the manufacturer’s protocol.  Mice 
were imaged using the IVIS Spectrum (Perkin-Elmer; Waltham, MA) in vivo imaging 
system under real-time isoflurane anesthesia.   
 To ensure signal accuracy, the longest exposure without pixel saturation was 
utilized.  No more than 5 mice were imaged at a single time to minimize signal bleed.  To 
maximize signal sensitivity, the smallest imaging field that could fit all samples was 
utilized.  For groups demonstrating wide mouse-to-mouse variability, mice bearing large 
signal intensity were imaged and removed to allow reimaging and uncovering of lower-
intensity signals. Image data was acquired and analyzed using Living Image software 
(Perkin-Elmer; Waltham, MA).  Regions of Interest (ROIs) were generated based upon a 
2% maximum pixel signal threshold within each image, and data expressed as Radiance 
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(photons/s/cm^2) in order to control for variability in exposure times used.  Mice were 
imaged once or twice weekly, and never more than every other day to avoid anesthesia-
induced failure to thrive.   
 
4.2.6 In Vivo CTL Kill Assay 
 C57BL/6 CD45.1+/+ donor mice were sacrificed and spleens harvested for use as 
target cells.  RBC-free, single cell suspensions were then prepared as described 
previously.  Splenocytes were then counted, seeded at 10E6 cells/ml in warmed CTL 
media with or without 1 ug/ml OVAI peptide (Genscript; Piscataway, NJ) into culture 
flasks, and incubated 2 hours at 37°C in a humidified 5% CO2 incubator for peptide 
loading.  Cells were transferred to 50 ml conical tubes and washed with warmed PBS.  
Cell pellets were then thoroughly resuspended in 1 uM (OVAI targets) or 0.1 uM 
(unlabeled targets) Carboxyfluorescein Succinimidyl Ester (CFSE)(Invitrogen; Carlsbad, 
CA) and incubated for 20 minutes in a light-protected 37°C water bath.  CFSE labeling 
was then quenched with ice-fold FBS for 5 minutes on ice and cells washed twice with 
ice-cold PBS and counted.  Peptide loaded (CFSE high) and non-loaded (CFSE low) cells 
were then mixed 1:1 for a total cell count of 50E6 cells/ml and stored on ice in the dark 
prior to injection.  Recipient mice were i.v. injected with 200 ul target mix via tail vein.  
Extra cells were stored overnight at 4°C in CTL for use as FACS controls.  Recipients 
were sacrificed and harvested approximately 18 hours later for analysis of target cell 
killing via flow cytometry. % Lysis was defined as being equal to (1-(target/non-
target))x100. 
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4.2.7 Ex Vivo Lymphocyte Isolation and Stimulation 
 Tumor-bearing mice were sacrificed and spleens, lymph nodes, and tumors 
harvested into ice-cold CTL media.  RBC-free, single cell suspensions of spleens and 
LNs were prepared as outlined previously.  Given the large volume of necrotic debris, 
tumor tissue samples required more elaborate processing.  Single cell tumor suspensions 
were prepared by crushing tissue through a 100 um cell strainer (BD Biosciences; San 
Jose, CA).  Cells were then washed with ice-cold RPMI and spun at 1000 RPM, leaving 
smaller dead cell fragments in the supernatant.  This step was repeated until the 
supernatant was grossly clear of pigmented debris.   Red blood cell (RBC) lysis was then 
performed using ammonium-chloride-potassium lysis buffer (ACK) (Gibco; Carlsbad, 
CA).  Dead cell removal was then further performed using one or two rounds of ficoll-
paque (GE Life Sciences; Piscataway, NJ) separation.  Cells were counted and stored in 
ice-cold CTL media until ready for FACS staining or in vitro stimulation. 
 For in vitro stimulation, 1E6 explant cells were seeded in 1 ml CTL media in a 
24-well flat bottom plate (Corning; Tewksbury, MA).  2 ug/ml OVAI peptide (Genscript; 
Piscataway, NJ) was then seeded into test wells along with 1 ul/ml GolgiPlug 
(brefeldin A) (BD Biosciences; San Jose, CA).  Negative controls received GolgiPlug 
without OVAI peptide, and positive controls were treated with 2 ul/ml Leukocyte 
Activation Cocktail containing PMA/ionomycin and GolgiPlug (BD Biosciences; San 
Jose, CA).  Cells were then incubated overnight (~16 hours) at 37°C in a humidified 5% 
CO2 incubator.  The following morning, cells were harvested and analyzed via flow 
cytometry.  
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4.2.8 Antibodies and Flow Cytometry 
 CD4-APC (clone RM4-5), CD8-PE and CD8-A700 (clone 53-6.7), Thy1.2-FITC 
(clone 30-H12), TNF-APC (clone MP6-XT22), CD44-V500 (clone IM7), Ki67-PerCP-
Cy5.5 (clone B56), and IFNγ-PE (clone XMG1.2) were purchased from BD Biosciences 
(San Jose, CA).  Galectin-9-PE (clone 108A2), CD127-APC (clone A7R34), PD-1-
BrilliantViolet421 (clone 29F.1A12), IL-17a-PacificBlue (clone TC11-18H10.1), 
and TIM-3-PE (clone RMT3-23) were purchased from BioLegend (San Diego, CA).  
Thy1.1-APC-eFluor780 (clone HIS51), CD62L-PerCP-Cy5.5 (clone MEL-14), KLRG-
1-PE-Cy7 (clone 2F1), IL-2-PE-Cy7 (clone JES6-SH4), and LAG-3-PE (clone C9B7W) 
were purchased from eBioscience (San Diego, CA). CD4-PE-TexasRed (clone RM4-5) 
was purchased from Invitrogen (Camarillo, CA).  All antibodies were titrated for optimal 
staining intensity vs. background signal for 1E6 cells/reaction.  All isotype control 
antibodies were from the same manufacturer and used at the same concentration as their 
associated test antibody.     
 Qdot625-“tetramer” specific for OTI CD8+ cells was prepared in house.  
Monomer of H-2Kb coupled with the chicken ovalbumin peptide 257-264 SIINFEKL 
were prepared by the NIH Tetramer Core Facility (Atlanta, GA) and stored at -80°C until 
ready for tetramerization.  For tetramerization, a 25 ul aliquot of approximately 2 ug/ml 
monomer stock was thawed on ice and diluted to a total volume of 100 ul with sterile 1X 
PBS.  20 ul of Qdot625-Streptavidin (Invitrogen; Camarillo, CA) was then added to the 
monomer, mixed thoroughly, and allowed to incubate on ice in the dark for 20 minutes.  
This step was repeated a total of 4 times to yield a final solution of 200 ul tetramer at 
0.225 ug/ml concentration.  Formed tetramer was titrated using RAG-/- OTI+/+ 
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splenocytes and stored at 4°C until use.  All formed tetramers were used within one 
month of preparation.  It should be noted that this is in fact not a true tetramer, as each 
Qdot has between 5 and 10 streptavidin molecules bound to it, each of which can bind 
up to 4 monomers.  Thus, the end molecule is a large multimer and not a true tetramer. 
 For all extracellular antibody staining, 1E6 cells were washed with FACS buffer 
containing 1X Hanks Balanced Salt Solution (HBSS), 10 mM HEPES buffer, 2% FBS, 
and 0.1% sodium azide and stained with appropriate antibody for 15 minutes at room 
temperature in the dark followed by two washings with FACS buffer.  No more than 5 
antibodies were stained at a single time.  Cells were similarly washed for tetramer 
staining but were incubated for 30 minutes.  Viability staining using LIVE/DEAD 
Yellow and Aqua Fixable Dead Cell Stain Kit (Invitrogen; Camarillo, CA) was 
performed according to the manufacturer’s instructions at a 1:2000 dilution with a 30 
minute room temperature incubation and washing steps using PBS.  Cellular 
fixation/permeabilization was performed using the Foxp3 Staining Buffer Set 
(eBioscience; San Diego, CA) according to manufacturer instructions with fixation 
performed for 45 minutes at 4°C in the dark.   Subsequent intracellular staining was 
performed for 30 minutes at 4°C in the dark with washes using the staining buffer set.  
For multi-step staining sequences, the following sequence was always followed:  
Tetramer, extracellular antibody, Live/Dead stain, fixation/permeabiliation, intracellular 
stain.  Following staining, cells were stored in FACS buffer at 4°C in the dark and were 
analyzed within 24 hours of staining.   
 Flow cytometry was performed on the BD FACSCaliber, FACSAria, or 
LSRII with data acquisition using CellQuest Pro or FACSDiva (BD Biosciences; 
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San Jose, CA).  Data analysis was further performed with FACSDiva as well as FlowJo 
(Tree Star Inc.; Ashland, OR). 
 
4.2.9 Histology 
 Mice were sacrificed and tumors, spleens, and lymph nodes (LN) harvested into 
ice-cold CTL media.  Tissues were then blotted to remove excess CTL and transferred to 
Intermediate Tissue-Tek CryoMolds (Sakura Finetek; Torrance, CA) containing a small 
layer of Optimal Cutting Temperature (OCT) media (Sakura Finetek; Torrance, CA) and 
subsequently covered with OCT media.  Tissue chambers were then flash-frozen in a 
beaker of liquid nitrogen-cooled isopentane (Sigma; St. Louis, MO).  Once fully frozen, 
samples were transferred on dry ice to a -80°C freezer for storage prior to cryosectioning.  
Tissue was subsequently cryosectioned at 5 um sections onto “Plus” slides, fixed in ice-
cold acetone for 10 minutes, and air dried for 30 minutes by the Johns Hopkins Histology 
Core.  Following sectioning and fixation, slides were stored in a -80°C freezer until 
stained.   
 Primary antibodies used for staining included:  I-Ab-biotin (clone AF6-120.1; Ms 
IgG2a) and CD45.1-FITC (clone A20; Ms IgG2a)(BD Biosciences; San Jose, CA).  All 
isotype controls were used at the same concentration and were from the same supplier as 
the test antibody.  Fluorescein/Oregon Green Rabbit IgG Antibody (Invitrogen; 
Camarillo, CA) was used as a secondary antibody to increase primary antibody-FITC 
signal. Goat anti-Rabbit AlexaFluor488 (Invitrogen; Camarillo, CA) and Stretavidin-
Cy3 (Sigma; St. Louis, MO) were used for tertiary staining.      
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 For staining, slides were allowed to warm to room temperature for 5 minutes in a 
laminar flow hood and then tissue demarcated with an ImmunEdge Pen (Vector Labs; 
Burlingame, CA) prior to rehydration with PBS for 10 minutes at room temperature.  All 
subsequent staining and blocking steps were performed in a light-protected, humidified 
chamber with three PBS washes between steps.   Samples were first treated with 1-2 
drops Molecular Probes Endogenous Biotin Blocking Kit (Invitrogen; Camarillo, CA) 
solutions A and B for 30 minutes each at room temperature.  They were then covered 
with 100 ul isotype-control blocking antibodies at 10 ug/ml in Blocking Buffer (2% IgG-
free BSA and 5% normal mouse serum (Jackson Immunoresearch; West Grove, PA) in 
PBS) for 1 hour at room temperature.  This blocking solution was then shaken off without 
PBS wash and replaced with primary antibodies at 10 ug/ml in Blocking Buffer and 
incubated overnight at 4°C.  Slides were then incubated with 100 ul of 2 ug/ml secondary 
antibody in PBS/2%BSA for 1 hour at room temperature, washed, and incubated with 
100 ul of tertiary antibodies diluted 1:100 in PBS/2%BSA for 1 hour at room 
temperature.  Nuclei were then counterstained with Hoechst 33342 (Invitrogen; 
Camarillo, CA) diluted 1:50,000 in PBS for 15 minutes at room temperature.  Following 
PBS wash, slides were fixed and mounted using a single drop of Aqua Poly/Mount 
(Polysciences; Warrington, PA) and cover slips placed and immobilized with nail polish.  
Slides were then stored face-up in light-protected slide boxes at 4°C until imaging.  
 Imaging was performed using a Nikon E800 fluorescent microscope using 
standard DAPI, FITC, Cy3, and Cy5 filter sets.  Image acquisition and analysis was 
performed using Nikon Elements Software (Nikon Metrology; Brighton, MI). 
 




4.3.1 OTI CD8 Expand and Accumulate within the Tumor 
 To evaluate the function of our OTI CD8+ cells in vivo, we first sought to 
examine their ability to traffic to and accumulate within the tumor.  In order to 
accomplish this, we initially utilized a bioluminescent imaging (BLI) approach to allow 
for analysis of OTI accumulation within tumors over multiple sequential time points.  
Recipient MHCII KO mice were challenged with 1E5 B16.mOVA tumor on day 0 and 
treated on day 7 with 500 Rads non-myeloablative whole body irradiation followed by 
adoptive transfer of 2.5E6 Tc0 cells from OTI+/- Luci+/- donor mice.  Mice were then 
subjected to bioluminescent imaging every other day to detect the location of OTI cells 
via the activity of the luciferase enzyme.  As shown in Figure 4.1, OTI cells quickly 
trafficked to and preferentially accumulated within the tumor mass.  With our imaging 
modality, cells could be detected in what appeared to be draining lymph nodes as early as 
day 10 (three days post transfer), with OTI clearly evident within the tumor as early as 
day 12.  Accumulation continued through day 14 and appeared to level off after that 
point.  Whether this was due to a slowing of trafficking and accumulation, or perhaps just 
the detection limit of our system could not be determined.  In either case, OTI cells 
clearly persisted even when tumor treatment effect began to wane.  
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Figure 4.1 OTI CD8+ quickly traffic to and accumulate within B16.mOVA tumors. 
C57BL/6 MHCII KO mice were challenged with 1E5 B16.mOVA tumor on day 0 and 
treated on day 7 with 500 Rads non-myeloablative whole body irradiation followed by 
adoptive transfer of 2.5E6 Tc0 cells from OTI+/- Luci+/- donor mice or PBS control.  
Mice were then imaged every other day to detect the location of OTI cells, with 
corresponding caliper measurements of tumor size performed with each round of 
imaging.  Mean +/- Standard Deviation for groups of 3 mice are shown. PBS mice were 
sacrificed following day 24.  (A) BLI of mice over the course of tumor progression.  (B) 
Tumor growth over time as determined by caliper measurements.  (C) Representative 
BLI images of a single mouse over time with experiment day indicated in the upper left 
corner for each image. 
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  To further expand upon and validate our bioluminescent imaging data, we next 
performed histologic analysis of tumors to verify that our OTI cells were in fact 
penetrating and accumulating within the tumor.  To accomplish this, mice were similarly 
challenged and treated as before, only with use of Tc0 from OTI+/- CD45.1+/- as 
opposed to OTI+/- Luci+/- donors. Mice were sacrificed one week after treatment and 
tumor masses harvested and processed for histologic evaluation of MHCII and the 
congenic marker CD45.1 expressed only by OTI cells.  As can be seen in Figure 4.2, OTI 
CD8+ cells were found in large abundance both immediately surrounding as well as deep 
within the tumor tissue, confirming our BLI data.  Also noteworthy within this 
evaluation, although not depicted here, was the fact that MHCII expression correlated 
very well with the presence of OTI cells.  Regions of tumor with the highest OTI content 
demonstrated intense MHCII staining, and conversely areas devoid of OTI cells had 
minimal to no MHCII signal.  This finding was well in line with our hypothesis of 
inflammation-induced MHCII upregulation in our B16.mOVA tumor.     
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Figure 4.2 OTI CD8+ are readily detectable within tumors. 
C57BL/6 WT and MHCII KO mice were challenged with 1E5 B16.mOVA tumor on day 
0 and treated on day 7 with 500 Rads non-myeloablative whole body irradiation followed 
by adoptive transfer of 2.5E6 OTI+/- CD45.1+/- Tc0 or PBS.  Mice were sacrificed one 
week after treatment and tumor masses harvested and processed for histologic evaluation.  
Displayed here are a Merge (A) of DAPI nuclear stain (C), CD45.1 (D), and MHCII (I-
Ab) (E), as well as an H&E stain (B) demonstrating necrotic tumor mass with overlying 
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 As a final method to investigate the proliferation and expansion of our OTI cells, 
we explanted spleens, draining lymph nodes (DLN), and tumors over the course of 
treatment to assess for total numbers of OTI+ and OTI- CD8+ cells via flow cytometry.  
Mice were challenged and treated as before, with sacrificing and tissue harvesting 
performed weekly throughout tumor treatment.  Samples were processed to create single 
cell suspensions and subsequently analyzed via flow cytometry for the expression of CD8 
and OTI-specific tetramer.  In a second experiment, samples were similarly generated and 
evaluated for the expression of the proliferation marker Ki67 within CD8+ cells.  
Unfortunately, due to technical limitations of the staining procedure, we were unable to 
differentiate between OTI+ and OTI- CD8+ when performing Ki67 analysis.  As shown 
in Figure 4.3(A&B), total OTI+ and OTI- CD8+ cells within spleens and LNs expanded 
early in the course of tumor treatment with the largest increase occurring between the 
second and third weeks post treatment.  OTI+ CD8+ subsequently plateaued with 
continued increase in total CD8+ cells indicating ongoing expansion of host-derived 
CD8+.  Due to the large volume of necrotic debris within tumor samples and low relative 
quantity of tumor infiltrating lymphocytes (TILs), accurate total numbers of TILs could 
not be determined.  
 Tumor infiltrating CD8+ cells were, however, able to be identified and analyzed 
on a percentile basis for analysis of Ki67 staining along with CD8+ cells from spleen and 
DLNs as shown in Figure 4.3(C&D).  Ki67 staining from spleens and DLNs revealed a 
high level of CD8+ proliferation early in the course of treatment with a dramatic decrease 
occurring again between the second and third weeks post treatment.  This proliferation of 
CD8+ cells was seen both for OTI-treated mice as well as untreated mice, likely 
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indicating a large component of homeostatic proliferation following irradiation.  Within 
TIL samples, Ki67 staining was overall lower, but interestingly did not demonstrate the 
same dramatic drop between weeks two and three post treatment, perhaps suggesting a 
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Figure 4.3 Proliferation and accumulation of OTI+ and OTI- CD8+ T-cells in 
tumor-bearing mice. 
C57BL/6 MHCII KO mice were challenged with 1E5 B16.mOVA tumor on day 0 and 
treated on day 7 with 500 Rads non-myeloablative whole body irradiation followed by 
adoptive transfer of 2.5E6 OTI cells or PBS.  Mice were sacrificed at weekly intervals 
and spleens, tumor-draining lymph nodes, and tumors harvested.  Single cell suspensions 
were prepared from explanted tissue and subjected to flow cytometric analysis of live 
cells as determined by scatter profiles and live/dead cell stain. Mean +/- Standard 
Deviation for 3-5 mice per group are shown. PBS mice were sacrificed following day 21. 
(A&B) Explanted cells were stained for CD8 and OTI-specific tetramer and total 
numbers of cells per tissue determined.  (C&D) Explanted cells were stained for CD8 and 
then intracellularly stained for Ki67.  Cells with staining above isotype control (C) were 
considered Ki67+ and expressed as a percentage of total CD8+ cells (D).  
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4.3.2 Cell Surface Phenotype of OTI CD8+ 
 Having demonstrated that our OTI cells effectively proliferated and trafficked to 
the site of tumor, we next examined their cell surface phenotype over the course of tumor 
treatment.  To begin with, we examined the expression of the adhesion molecules CD44 
and CD62L. Mice were challenged and treated as before, with sacrificing, tissue 
harvesting, and explant preparation again performed at weekly intervals and analyzed via 
flow cytometry.  As shown in Figure 4.4, OTI CD8+ cells demonstrated CD44 and 
CD62L patterns consistent with naïve (CD44- CD62L+), central memory (CD44+ 
CD62L+), and effector/effector memory (CD44+, CD62L-) populations at varying ratios 
depending on their tissue of origin.  DLN explants demonstrated an abundance of naïve 
cells, very few effector cells, and an intermediate level of central memory cells.  TILs, on 
the other hand, demonstrated a dramatic majority of effector/effector memory cells, while 
spleens showed intermediate quantities of all three populations.  
 With our OTI cells demonstrating what appeared to be appropriate patterns of 
CD44 and CD62L expression, we next turned our attention to examining CD127 and 
KLRG-1, which have been shown to be variably expressed on different CD8+ 
populations.  As shown in Figure 4.5, OTI CD8+ within DLNs and spleens were almost 
entirely CD127+ KLRG-1-.  TILSs demonstrated an overall majority of these same 
CD127+ KLRG-1- negative cells, but showed an increased frequency of double negative 
cells as well.  Interestingly, few KLRG-1+ cells were identified within our OTI CD8+.  
However, evaluation of OTI- host CD8+ cells demonstrated increased numbers of 
CD127- KLRG-1+ cells (~10-30%) relative to OTI+ CD8+ cells (~0-10%) over the 
course of tumor progression (data not shown). 
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Figure 4.4 CD44 vs. CD62L expression by OTI CD8+ in tumor-bearing mice. 
C57BL/6 MHCII KO mice were challenged with 1E5 B16.mOVA tumor on day 0 and 
treated on day 7 with 500 Rads non-myeloablative whole body irradiation followed by 
adoptive transfer of 2.5E6 OTI cells.  Mice were sacrificed at weekly intervals and 
spleens, tumor-draining lymph nodes, and tumors harvested.  Single cell suspensions 
were prepared from explanted tissue and subjected to flow cytometric analysis of live 
cells as determined by scatter profiles and live/dead cell stain.  (A) Tetramer+ (OTI+) 
CD8+ cells were classified as naïve, central memory (CM), or effector/effector memory 
(E/EM) based upon their CD44 and CD62L expression patterns as shown in (B).  Mean 
+/- Standard Deviation for 3-5 mice per group are shown.   
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Figure 4.5 CD127 vs. KLRG-1 expression by OTI CD8+ in tumor-bearing mice. 
C57BL/6 MHCII KO mice were challenged with 1E5 B16.mOVA tumor on day 0 and 
treated on day 7 with 500 Rads non-myeloablative whole body irradiation followed by 
adoptive transfer of 2.5E6 OTI cells.  Mice were sacrificed at weekly intervals and 
spleens, tumor-draining lymph nodes, and tumors harvested.  Single cell suspensions 
were prepared from explanted tissue and subjected to flow cytometric analysis of live 
cells as determined by scatter profiles and live/dead cell stain.  (A) Tetramer+ (OTI) 
CD8+ cells were analyzed for CD127 and KLRG-1 expression patterns as shown in (B).  
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 Finally, having examined markers associated with differing CD8+ populations, 
we next examined the negative costimulatory molecules PD-1, LAG-3, and TIM-3.  
These molecules are thought to be involved in T-cell exhaustion and have been further 
implicated to play roles in Treg function.  As shown in Figure 4.6, OTI CD8+ cells from 
spleens and LNs were primarily negative for all three markers, whereas TILs 
demonstrated strikingly high percentages of cells expressing these markers, suggesting a 
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Figure 4.6 Expression of PD-1, LAG-3, and TIM-3 by OTI CD8+ in tumor-bearing 
mice. 
C57BL/6 MHCII KO mice were challenged with 1E5 B16.mOVA tumor on day 0 and 
treated on day 7 with 500 Rads non-myeloablative whole body irradiation followed by 
adoptive transfer of 2.5E6 OTI cells.  Mice were sacrificed at weekly intervals and 
spleens, tumor-draining lymph nodes, and tumors harvested.  Single cell suspensions 
were prepared from explanted tissue and subjected to flow cytometric analysis of live 
cells as determined by scatter profiles and live/dead cell stain.  Mean +/- Standard 
Deviation for 3-5 mice per group are shown.  Of note, day 28 samples were unavailable 
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4.3.3 OTI CD8 Develop a Functional Tc1 Phenotype 
 Having examined the proliferation, trafficking, tumor accumulation, and cell 
surface phenotype of our OTI+ cells, we turned our attention to their effector capabilities, 
beginning with the evaluation of their antigen-specific cytokine expression profiles. Mice 
were challenged and treated as before, with sacrificing, tissue harvesting, and explant 
preparation again performed at weekly intervals.  Cells were then seeded into in vitro 
stimulation with OVAI peptide with subsequent intracellular flow cytometric analysis of 
the cytokines IFNγ, TNFα, IL-2, and IL-17.  As shown in Figure 4.7, CD8+ explants 
from all three tissues of tumor-bearing mice demonstrated high levels of IFNγ and TNFα 
expression.  IL-2 and IL-17 expression, on the other hand, were found only sparingly and 
at very low levels (each at ~2%) (data not shown).    
 We next investigated the ability of our OTI cells to effectively kill antigen-loaded 
targets in vivo.  Tumor-bearing mice were given adoptive transfer of a 1:1 mix of 
CFSEhigh OVAI peptide-loaded and CFSElow non peptide-loaded target splenocytes and 
evaluated for killing effect 16 hours later by assessing for target populations in recipient 
spleens and tumor-draining lymph nodes.  Unfortunately, TIL samples yielded inadequate 
numbers of target events for evaluation.  As shown in Figure 4.8, tumor-bearing mice 
treated with OTI+ CD8+ cells effectively lysed nearly 100% of peptide-loaded targets 
with no effect on antigen-free targets.  Mice treated only with PBS demonstrated only 
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Figure 4.7 OVAI-specific CD8+ develop Tc1 effector cytokine profiles in tumor-
bearing mice. 
C57BL/6 MHCII KO mice were challenged with 1E5 B16.mOVA tumor on day 0 and 
treated on day 7 with 500 Rads non-myeloablative whole body irradiation followed by 
adoptive transfer of 2.5E6 OTI cells or PBS.  Mice were sacrificed at weekly intervals 
and spleens, tumor-draining lymph nodes, and tumors harvested.  Single cell suspensions 
were prepared from explanted tissue and subjected to in vitro stimulation with OVAI 
peptide followed by intracellular flow cytometric analysis of live cells as determined by 
scatter profiles and live/dead cell stain. Representative FACS profiles of IFNγ (A) and 
TNFα (C) staining are shown with corresponding Mean +/- Standard Deviation for 3-5 
mice per group in (B) and (D), respectively. Of note, all untreated PBS mice were 
sacrificed following day 21, and day 21 TIL samples were not of adequate numbers to 
evaluate.     
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Figure 4.8 OTI CD8+ effectively lyse OVAI peptide-loaded targets in vivo. 
C57BL/6 MHCII KO mice were challenged with 1E5 B16.mOVA tumor on day 0 and 
treated on day 7 with 500 Rads non-myeloablative whole body irradiation followed by 
adoptive transfer of 2.5E6 OTI cells or PBS.  Mice were given adoptive transfer of a 1:1 
mix of CFSEhigh OVAI peptide-loaded and CFSElow non peptide-loaded target 
splenocytes and evaluated for killing effect 16 hours later by assessing for target 
populations in recipient spleens and tumor-draining lymph nodes (inadequate numbers 
were obtained from tumor).  % Lysis was defined as being equal to (1-(target/non-
target))x100.  FACS target gating is shown in (A), with representative plots from PBS- 
(B) and OTI-treated (C) mice along with corresponding Mean +/- Standard Deviation for 
3-5 mice per group in (D).  Of note, all untreated PBS mice were sacrificed following day 
21, and day 28 target labeling failed and thus no data was available for this time point.   
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4.4 Discussion 
 
 In this second study we sought to characterize our adoptively transferred OTI Tc0 
cells throughout the course of tumor treatment, with a particular emphasis upon 
understanding their effector function as a means for later assessing the implications of 
Treg suppression upon CD8+ cells.  In order for an antigen-specific naïve CD8+ cell to 
enact killing of an appropriate antigen-bearing target tumor cell, the CD8+ cell must 
proliferate, differentiate, traffic, and enact effector cytolytic function using a number of 
potential mechanisms.  Previous studies utilizing naïve CD8+ cells for this function had 
been able to demonstrate these very steps taking place (Chen et al., 2005), and we 
therefore hoped to recapitulate some of the same findings.   
 To begin with, we examined the expansion, trafficking, and accumulation of our 
cells.  By making use of luciferase-expressing transgenic mice, we were able to utilize in 
vivo bioluminescent imaging to repeatedly monitor these events in tumor-bearing mice.  
These studies demonstrated that OTI CD8+ cells quickly trafficked to and accumulated 
within the tumor tissue.  As early as 3 days following transfer, cells could be detected 
within regions consistent with tumor draining lymph nodes, and were further localized 
within tumor tissue as early as 5 days post transfer.  While the accuracy of the timing 
seen here is certainly dependent upon the detection threshold of our system, 3-5 days 
from transfer to visible trafficking and accumulation within the tumor mass is reasonable 
and consistent with previous work.  Studies by Rabinovich and colleagues (Rabinovich et 
al., 2008) comparing tracking of OTI cells using the firefly luciferase used here against 
an enhanced vector demonstrated OTI cells within the site of OVA vaccination at 5 days 
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post transfer using the traditional luciferase.  They further demonstrated that the 
minimum number of cells needed for detection using the traditional luciferase was on the 
order of 10E5, suggesting a reference range for the minimum number of trafficked cells 
demonstrated in our studies.   
 Besides the timing of initial trafficking, our BLI studies also gave some insight 
into the kinetics and durability of CD8+ accumulation within the tumor.  Following their 
initial detection between days 10 and 12 (3-5 days post transfer), cells accumulated 
rapidly through the 14-16 day time point, but then showed a deceleration in this 
accumulation.  This result may indicate a true slowing of accumulation, but may also 
reflect technical limitations associated with our BLI platform, as well as changes in the 
tumors themselves.  Subcutaneously growing B16 tumors are well known to develop 
necrotic and ulcerative cores as they progress (Overwijk & Restifo, 2001), and this was 
consistently observed within our studies.  These necrotic sites would represent a potential 
dead space for OTI accumulation, and in fact upon close examination of individual 
mouse images (Figure 4.1), such dead spaces can be demonstrated as early as day 16.  
Also of note in our BLI studies, while there was a definite early focus of signal within the 
tumor, as time progressed signal could be detected throughout the body of the mouse, 
particularly in areas of exposed, non-hairy skin, likely due to decreased light absorbance 
by the black hair of the mouse.  This widespread signal distribution likely represented the 
systemic expansion of OTI cells in these mice, at least in part due to homeostatic 
proliferation induced by the whole-body irradiation used in this study. 
 To further corroborate and expand upon our BLI data, we also performed 
histologic evaluation of our tumors to confirm that our OTI cells were in fact penetrating 
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with the tumor and not merely colocalizing in two dimensional space.  These studies 
clearly demonstrated that OTI cells could be found in high volume surrounding the tumor 
mass, but also could be found deep within the tumor mass itself.  Previous studies have 
indicated that the penetration of adoptively transferred cells into melanoma lesions is 
very low, on the order of <0.005% per gram of tumor (Pockaj et al., 1994; Goedegebuure 
et al., 1995), thus making histologic quantification difficult.  Our studies also confirmed 
this finding, showing wide variability in overall TIL prevalence, which was also observed 
in the aforementioned studies by Rabinovich and colleagues (Rabinovich et al., 2008).  
Interestingly, however, we anecdotally found a high degree of correlation between the 
incidence of OTI cells and MHCII staining within our tumor samples.  Areas with a high 
volume of OTI cells demonstrated strong MHCII staining, whereas areas devoid of OTI 
cells demonstrated low to negative MHCII signal.  This finding was consistent with our 
hypothesis of inflammation-induced upregulation of MHCII by tumor cells, and suggests 
that our OTI cells were actively producing inflammatory cytokines within the tumor.   
 As a final means of assessing the proliferation of OTI cells within our model, we 
performed flow cytometric analysis of explanted spleens, tumor-draining lymph nodes, 
and tumors to assess for total host OTI- and OTI+ CD8+ cell numbers during tumor 
progression in conjunction with the use of Ki67 staining.  Ki67 is a protein of uncertain 
function, which has been well documented to be expressed within the nuclei of actively 
replicating cells (Starborg et al., 1996).  Analysis of spleens and tumor draining lymph 
nodes revealed that the vast majority of CD8+ cells during the first two weeks (day 14 
and 21) following irradiation and adoptive transfer were OTI+ cells.  Ki67 expression 
during this time frame was very high within CD8+ cells from both OTI-treated and PBS 
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mice, suggesting a high degree of proliferation in all CD8+ populations which would be 
consistent with a picture of lymphopenia-induced homeostatic proliferation caused by our 
non-myeloablative irradiation.  Between the second and third weeks post transfer, both 
OTI+ and total CD8+ numbers increased dramatically, with the increase in total CD8+ 
being beyond that accounted for by OTI+ CD8+, suggesting a recovery of host-derived 
CD8+ cells.  Ki67 expression during this interval was decreased relative to earlier time 
points, suggesting a slowing of overall proliferation.  Finally, between the third and 
fourth week post-transfer, OTI+ CD8+ numbers plateaued while total CD8+ numbers 
continued to rise, suggesting continued host CD8+ expansion.  
 Analysis of accurate TIL numbers via flow cytometry proved to be exceedingly 
challenging, with the low cell yields and large volume of necrotic debris making accurate 
cell enumeration impossible.  However, Ki67 analysis was able to be performed upon 
TIL samples.  While overall lower than the percentages seen early on with spleen and 
tumor samples, a consistent low-level (10-20%) Ki67 expression level was observed 
throughout the course of treatment.  This consistent low-level proliferation likely 
represents a continuous antigen-driven proliferative response within the tumor, as 
opposed to the likely larger influence of homeostatic proliferation seen within the spleen, 
and to a lesser extent DLN cells. 
 Having established the effective proliferation and trafficking of our OTI CD8+ 
cells, we next turned our attention to characterizing their surface phenotype.  A number 
of cell surface molecules have been utilized to classify the various subpopulations of 
CD8+ cells.  One such pairing of molecules are the cell adhesion molecules CD44 and 
CD62L.  Naïve cells are classically thought of as being CD44- and CD62L+, while 
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antigen-experienced cells become CD44+, being either CD44+ CD62L+ for central 
memory cells, and CD44+ CD62L- for effector/effector memory cells.  These variable 
expression patterns have functional consequences.  Expression of CD62L allows 
residence within secondary lymphatic tissues, whereas its loss allows migration into 
peripheral tissues (Butcher & Pickler, 1996).  Upon analyzing our explant cells for these 
two markers, we were able to demonstrate that all three major populations of CD8+ cells 
were in fact present.  Most strikingly within this analysis was the extremely high 
predominance of CD44+ CD62L- effector/effector memory cells within TIL populations, 
which was to be expected given their peripheral tissue location and had been previously 
demonstrated in other models (Chen et al., 2005).  Also noteworthy was the large volume 
of CD44- CD62L+ naïve cells that persisted throughout the course of tumor progression 
in spleens and DLNs.  Despite the tumor burden of these mice, the majority of OTI CD8+ 
cells remained antigen inexperienced based upon CD44/CD62L staining.  Finally, it is 
important to note that a significant number of CD44+ CD62L+ central memory cells 
were identified, particularly in spleens and DLNs.  As previously mentioned, growing 
evidence suggests that these cells are critical for the development of a long-lasting, 
durable immune response (Wherry et al., 2003; Berger et al., 2008).  The fact that all 
three CD8+ populations were found in our model suggests that a failure of CD8+ 
differentiation from our naïve OTI CD8+ cells was not the cause of the long-term 
treatment failure seen in this model.  
   Having established that all three major CD8+ subpopulations were present, we 
next evaluated two other cell surface molecules: CD127 and KLRG-1.  CD127, also 
known IL7 receptor alpha, is expressed on naïve cells, downregulates in the setting of 
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active antigen stimulation, and is again found upregulated on central memory cells as 
well as effector cells destined for future memory development (Bengsch et al., 2007; 
Boettler et al., 2006; Wherry and Ahmed, 2004).  Killer cell lectin-like receptor G1 
(KLRG-1) expression classically defines antigen-experienced CD8+ cells capable of 
enacting effector function but otherwise impaired in long-term proliferative capacity 
(Voehringer et al., 2002).  The combination of these two markers has recently been used 
to assess CD8+ populations over the course of viral infection, with chronic viral infection 
demonstrating a majority of CD127- KLRG-1+ CD8+ cells, whereas resolved infections 
demonstrate primarily CD127+ KLRG-1- CD8+ memory cells (Ibegbu et al., 2005; 
Thimme et al., 2005).   
 In analyzing these populations within our own study, we found that the majority 
of OTI CD8+ cells in all tissues analyzed demonstrated a CD127+ KLRG-1- phenotype, 
which would be consistent with either naïve cells or central memory cells.  Given that the 
majority of our spleen and DLN OTI CD8+ demonstrated a CD44- CD62L+ naïve 
phenotype, CD127+ KLRG-1- cells within those tissues also likely represent naïve cells.  
In TIL samples, however, the largest proportion of cells were shown to be primarily 
CD44+ CD62L- effector/effector memory cells.  This combination suggests that the 
CD127+ KLRG-1- cells within tumors are not naïve cells, but rather likely effector cells 
that are either destined for memory cell production, or perhaps more likely have not yet 
altered CD127/KLRG-1 expression.  Perhaps in support of the latter, unlike spleens and 
DLNs, tumor samples also contained a high fraction of CD127- KLRG-1- OTI CD8+ 
cells.  This expression pattern suggests an active antigen stimulation state without 
compromise of future proliferative potential seen with KLRG-1 expression.  Such a 
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population has recently been demonstrated on intrahepatic Hepatitis C virus-specific 
CD8+ cells (Bengsch et al., 2007).  Interestingly, as previously mentioned, evaluation of 
OTI- host CD8+ cells demonstrated increased numbers of CD127- KLRG-1+ cells (~10-
30%) relative to OTI+ CD8+ cells (~0-10%) over the course of tumor progression (data 
not shown).  The significance of this finding is unknown at this time, although it at the 
least validates the technical staining accuracy of our KLRG-1 and CD127 markers.   
 A third set of cell surface molecules examined were the negative costimulatory 
ligands PD-1, LAG-3, and TIM-3, which were previously discussed in detail (Chapter 
2.7).  PD-1 expression is considered a marker of immune exhaustion, and T-cells 
expressing this molecule are typically dysfunctional in their proliferative and effector 
capacities (Blackburn et al., 2009; Wherry et al., 2007; Day et al., 2006).  LAG-3 is a 
negative regulator of activated T-cells with close relationship to the CD4 molecule 
(Huard et al., 1994; Hannier et al., 1998) and has previously been shown to regulate 
activated T-cell expansion (Workman et al., 2004). Binding of TIM-3 to its ligand, 
galectin-9, results in Th1 cell death (Zhu et al., 2005).  All three of these molecules have 
been implicated in the function of Tregs (Workman & Vignali 2005; Zhou et al., 2010; 
Sakuishi et al., 2013), and antibody blockade of each of these molecules alone or in 
combination has shown improvement in tumor clearance in a number of models (Woo et 
al., 2012; Ngiow et al., 2011; Duraiswamy et al., 2013).  We were able to demonstrate 
that our OTI CD8+ cells demonstrated minimal expression of these markers in spleens 
and DLNs, but in contrast TILs expressed high levels of all three molecules in excess of 
50% of cells in many cases.  Similar high frequency expression of these molecules has 
been described for TILs from a number of models (Woo et al., 2012; Curran et al., 2010; 
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Fourcade et al., 2012).  This predominance of negative costimulatory molecule 
expression within or OTI cells may serve as an explanation as to the lack of long-term 
protective immunity seen in our tumor model.   
 Finally, having examined the proliferative, homing, and cell surface phenotype of 
our cells, we turned our attention to examining their effector phenotype.  Our initial 
analysis here focused upon the ability of our CD8+ cells to secrete effector cytokines and 
to display CTL activity by lysing antigen-loaded targets.  Given limitations of the 
experimental setup used, we could not distinguish in this analysis between adoptively 
transferred OTI+ CD8+ cells and host-derived CD8+ cells which were also specific for 
OVAI peptide.  Given the large quantity of OTI cells given it is likely that the large 
majority of effect seen was from these cells.  In either case, since our goal was to assess 
the OVA-specific effector cell activity in our tumor bearing model, a contribution by the 
host CD8+ T-cells to this pool would not alter the relevance of our findings.   
 Analysis of cytokine secretion in our model indicated that a large percentage of 
CD8+ cells were capable of secreting both IFNγ and TNFα in response to OVAI 
stimulation in vitro.  The overall frequency of cells secreting these cytokine within total 
CD8+ cells did decreased over time, particularly later in the course of tumor treatment.  
Given the late increase of host-derived CD8+ cells demonstrated previously, this 
decreased frequency of cytokine secretion in response to OVAI stimulation likely 
represents in large part a dilution effect rather than a loss of secretory capability.  Despite 
this overall decrease frequency of secretion, TIL samples demonstrated maintained and 
even increased frequency of IFNγ and TNFα secretion in response to OVAI peptide.   
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 Secretion of IFNγ and TNFα is consistent with a Tc1 phenotype as opposed to a 
Tc2 phenotype (Carter & Dutton, 1995; 1996; Cerwenka et al., 1998), the former of 
which as mentioned has been previously shown to show superior anti-tumor effects 
(Dobrzanski et al., 1999).  Due to our initial positive results with IFNγ and TNFα, 
coupled with the inferior technical detection ability of IL-4, IL-5, and IL-10, we did not 
assess for the production of those Tc2 cytokines in this study.  It certainly would be 
possible that some of our cells developed a Tc2 phenotype as well.  Interestingly, besides 
their secretion of IFNγ and TNFα, our cells secreted only negligible levels of IL-2 and 
IL-17.  While lack of IL-17 secretion was not unexpected, the lack of IL-2 secretion was 
somewhat surprising, and may suggest another cause for the lack of long-standing 
immunity seen in our model.  Tc1 cells are classically described to secrete IL-2.  Further, 
the superior ability of central memory cells over effector memory cells to promote long-
term immune protection has been attributed to the ability of central memory cells to 
secrete IL-2 in an autocrine fashion, rendering them somewhat independent of T-helper 
cells (Wherry et al., 2003).  The fact that our OVAI-specific CD8+ cells did not secrete 
significant amounts of IL-2 in any compartment suggests that they may lack this 
necessary component of long-lasting immunity. 
 Finally, as a last assessment of our OTI CD8+ cells, we evaluated their ability to 
lyse OVAI-loaded target cells.  Tumor-bearing mice treated with OTI CD8+ 
demonstrated an impressive ability to lyse OVAI-loaded splenocytes with little non-
specific influence upon OVA-free targets.  Mice not treated with OTI CD8+ 
demonstrated only minimal lysis of these same targets, suggesting that this cytotoxic 
effect was in fact due to our OTI CD8+ cells.  Unfortunately, our analysis of in vivo CTL 
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activity was limited to spleens and tumor draining lymph nodes, as insufficient numbers 
of target cells were isolated from our tumor samples.  Given the phenotypic differences 
seen in our other studies, most notably the high frequency expression of PD-1, LAG-3, 
and TIM-3 within our TIL samples, coupled with the fact that our tumors were not 
permanently treated but rather only suffered a treatment lag, it would not be surprising to 
see a reduction of functional CTL activity within the TIL samples.  The fact that the 
B16.mOVA tumor was not permanently treated despite the presence of OVAI-specific 
CTL would suggest either a loss of OVA antigen from the tumor (which had previously 
been ruled out), or perhaps a state of local functional immune impairment within the 
tumor, which would be supported by our negative costimulatory molecule staining.  
 In conclusion, in this second study we were able to characterize the trafficking, 
proliferation, cell surface phenotype, and effector profile of our adoptively transferred 
naïve OTI Tc0 cells during the course of B16.mOVA tumor progression.  Our cells 
effectively proliferated, trafficked to, and accumulated within tumors.  They further 
developed surface phenotypes consistent with multiple lineages including naïve, central 
memory, and effector/effector memory cells CD8+ T-cells.  These various populations 
showed variable distributions amongst spleen, DLN, and tumor that were consistent with 
current dogma.  Our cells demonstrated CTL activity and cytokine expression consistent 
with a Tc1 effector phenotype.  Finally, TILs from our study demonstrated a high degree 
of exhaustion marker expression consistent with the failure of long-term tumor clearance 
seen.  The characterization of out adoptively transferred naïve OTI Tc0 cells performed 
here will hopefully allow for elucidation of Treg suppressive effects upon CD8+ cells in 
our future studies.  
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Chapter 5 
 




 In our first study, we were able to establish a model of antigen-specific immune-
mediated tumor rejection of B16.mOVA by OTI CD8+ that could subsequently be 
suppressed by OTII Tregs in MHCII KO mice.  In our second study, we characterized the 
expansion, tumor trafficking, cell surface phenotype, and effector function our OTI CD8+ 
in tumor-bearing mice.  In this third study, we set out to further examine the influence of 
tumor MHCII expression upon Treg suppression and to examine the alterations in OTI 
CD8+ phenotype elicited by Tregs in order to better understand the suppressive 
mechanisms involved.     
 It is well established that Tregs can have a negative impact upon anti-tumor 
immune response.  This has been demonstrated both through models where depletion or 
blocking of Treg function improves tumor response and effector T-cell function (Onizuka 
et al., 1999; Shimizu et al., 1999; 2002; Turk et al., 2004; Ko et al., 2005; Leach et al., 
1996), as well as in models where adoptive transfer of Tregs has been demonstrated to 
suppress established tumor antigen-specific cytotoxic CD8+ T-cells (Turk et al., 2004; 
Antony et al., 2005).  Understanding of the phenotypic alterations in CD8+ T-cells 
brought about by Tregs is, however, less understood.  Multiple models have 
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demonstrated that Tregs can impair CD8+ proliferation and IFNγ production in vitro 
(Suvas et al., 2003; Piccirillo & Shevach, 2001; Dittmer et al., 2004; Murakami et al., 
2002), but the alterations that occur in vivo are somewhat mixed and appear to vary 
depending on the model used.   
 Depletion of Tregs prior to HSV infection has been shown to result in improved 
CD8+ proliferation, increased expression of the activation markers CD44 and CCR5, and 
increased cytotoxicity, as well as improved memory responses to recall antigens (Suvas 
et al., 2003).  In a recent study utilizing the B16 melanoma model, Treg depletion was 
associated not only with improved tumor outcome, but specifically with increased 
absolute numbers of CTLs, a doubling of CD8+ TILs, and significantly increased 
frequency of activated CD44+ and granzyme B+ CD8+ cells in spleens, DLNs, and most 
strikingly within the tumor tissue itself (Klages et al., 2010).   
 Models of transplant tolerance have demonstrated that when transplanted into 
tolerized animals, antigen-specific CD8+ cells proliferated and accumulated normally, 
but demonstrated impaired IFNγ secretion and direct cell-mediated cytotoxicity, 
including failed graft rejection (Lin et al., 2002).  In a mouse model of persistent 
retroviral infection, adoptively transferred CD8+ cells proliferated and became activated 
but failed to produce IFNγ or decrease viral loads.  This failure of effector function was 
ameliorated upon Treg depletion using anti-GITR antibodies (Dittmer et al., 2004).  
Studies performed on human melanoma samples have similarly indicated the generation 
of high avidity tumor antigen-specific CD8+ T-cells that display effective expansion and 
tissue homing, but impaired production of IFNγ and decreased perforin-mediated 
cytotoxicity at the site of tumor (Zippelius et al., 2004).  This independent regulation of 
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cytotoxicity versus proliferation and cytokine production has been previously well 
described for CD8+ T-cells (Snyder et al., 2003; Hernandez et al., 2002).  Beyond their 
effects on effector CD8+ function, Tregs have been suggested to alter the CD8+ recall 
responses in a number of models (Suvas et al., 2003; Dittmer et al., 2004; Lin et al., 
2002), and have further been implicated to inhibit division of memory CD8 T-cells in an 
IL-2–dependent fashion (Murakami et al., 2002). 
 Perhaps the most thorough and relevant data to our own study comes from 
experiments by Chen and colleagues (Chen et al., 2005) who evaluated the effects of 
influenza hemagluttinin (HA)-specific Tregs upon HA-specific CD8+ cells in HA-
expressing tumor-bearing mice.  In their study, they demonstrated that the addition of 
Tregs abrogated the rejection of HA-expressing tumors otherwise elicited by adoptive 
transfer of naïve HA-specific CD8+ T-cells.  They further demonstrated that the presence 
of these Tregs did not alter the expansion, homing, differentiation, activation, or cytokine 
secretion by HA-specific CD8+, but did result in a suppression of direct CD8+ T-cell-
mediated cytotoxicity.   
 Thus, in this third study, we sought to evaluate the implications of variable tumor 
MHCII expression upon the suppressive effects of Tregs as previously seen in Chapter 1, 
and further to characterize the phenotypic alterations elicited by Tregs upon the OTI 
CD8+ T-cell phenotype previously characterized in Chapter 2 as a means of better 
understanding the suppressive mechanisms involved.  Unfortunately and to our surprise, 
we found a complete absence of Treg suppression for all three OVA-expressing B16 
variants tested, including the original B16.mOVA, which had previously demonstrated 
what appeared to be suppression in MHCII KO recipients. Upon examining the 
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phenotype of our OTI CD8+ cells in the presence of Tregs, we found no differences in 
the proliferation, homing, cell surface phenotype, cytokine secretion, or cytotoxicity of 
our OTI CD8+.  To evaluate these two negative results, we verified that this lack of 
suppression or alteration in OTI phenotype occurred despite the persistence and 
continued expression of Foxp3 by our OTII Tregs.  When evaluated in vitro it was 
discovered that, although they expressed functional MHCII, our OVA-bearing tumor 
cells failed to directly present endogenously produced OVA to OTII cells.  Subsequent 
investigation into the background of our OVA lines and construct revealed that despite 
the presence of full length OVA within these tumors, through an unknown mechanism 
they fail to present to or activate OTII T-cells (Preynat-Seauve et al., 2007).  Regrettably, 
this finding therefore makes all Treg studies performed herein uninterpretable.  
 
5.2 Materials and Methods 
 
5.2.1 Mice 
 Mice six to eight weeks old were used for all experiments, with matching of 
donor/recipient gender whenever possible.  All mice were housed and bred in the Johns 
Hopkins University Cancer Research Building I mouse facility using standard 
procedures, and all experiments involving the use of mice were performed in accordance 
with protocols approved by the Animal Care and Use Committee of the Johns Hopkins 
University School of Medicine.   
 C57BL/6 WT (C57BL/6NCr) and C57BL/6 45.1+/+ (B6-LY5.2/Cr) mice 
homozygous for the CD45.1/Ly5.2 congenic marker were purchased from the NCI 
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(Frederick, MD).  C57BL/6 Thy1.1+/+ (B6.PL-Thy1a/CyJ) mice homozygous for the 
Thy1.1/CD90.1 congenic marker, C57BL/6 I-Ab-/- (B6.129S2-H2dlAB1-Ea/J) mice bearing 
a homozygous deletion within the MHCII gene locus (Madsen et al., 1999), C57BL/6 
RAG1-/- (B6.129S7-Rag1tm1Mom/J) mice bearing a homozygous deletion of the Rag1 
gene, and C57BL/6 OTII+/+ (B6.Cg-Tg(TcraTcrb)425Cbn/J) mice bearing homozygous 
insertion of the OTII αβ TCR specific for chicken ovalbumin peptide 323-339 (OVAII - 
ISQAVHAAHAEINEAGR) presented by the MHCII molecule I-Ab (Barnden et al., 
1998) were purchased from Jackson Laboratory (Bar Harbor, ME).  C57BL/6 RAG1-/- 
OTI+/+ (B6.129S7-Rag1tm1MomTg(TcraTcrb)1100Mjb) mice bearing homozygous 
knockout of the Rag1 gene along with homozygous insertion of the OTI αβ TCR specific 
for chicken ovalbumin peptide 257-264 (OVAI - SIINFEKL) presented by the MHCI 
molecule H-2Kb (Hogquist et al., 1994) and C57BL/6 RAG1-/- OTII+/+ (B6.129S7-
Rag1tm1MomTg(TcraTcrb)425Cbn) mice bearing homozygous knockout of the Rag1 gene 
along with homozygous insertion of the OTII αβ TCR specific for OVAII were 
purchased from Taconic (Germantown, NY).  C57BL/6 Foxp3-GFP+/+ and +/y mice 
were a generous gift from Dr. Alexander Rudensky (Fontenot et al., 2005b).  C57BL/6 
Luci+/+ mice expressing firefly luciferase under the control of the β-actin promoter (Cao 
et al., 2004) were a generous gift from Dr. Leo Luznik.  
 C57BL/6 OTII+/+ Thy1.1+/+ mice were created by crossing C57BL/6 OTII+/+ 
with C57BL/6 Thy1.1+/+ to create OTII+/- Thy1.1+/- F1 progeny.  These F1 progeny 
were then intercrossed and F2 progeny typed according to the presence of Thy1.1, 
absence of Thy1.2, and increase in CD4:CD8 ratio as seen in CD4 transgenic mice to 
suggest OTII+/? Thy1.1+/+ status.  Since this CD4:CD8 skewing cannot differentiate 
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between OTII+/- and OTII+/+, F2 offspring were then testcrossed to C57BL/6 WT mice 
and progeny again typed for CD4, CD8, Thy1.1, and Thy1.2.  F2 parents were considered 
to be OTII+/+ only if all pups showed CD4:CD8 skewing with a minimum of 8 pups 
typed.  Once successfully generated, male and female OTII+/+ Thy.1.1+/+ mice were 
maintained as an independent colony.   
 C57BL/6 OTII+/- Thy1.1+/- Foxp3+/y mice were generated by crossing C57BL/6 
OTII+/+ Thy1.1+/+ male mice with a C57BL/6 Foxp3-GFP+/+ female.  Resultant female 
progeny were OTII+/- Thy1.1+/- Foxp3-GFP+/- and were not utilized due to decreased 
frequency of Foxp3 expression resulting from random X-inactivation in Foxp3-GFP 
heterozygotes.  Male progeny on the other hand were Foxp3-GFP hemizygotes (+/y) and 
thus all Foxp3+ cells expressed the transgenic Foxp3-GFP and were subsequently used as 
Treg donors.   
 C57BL/6 RAG1+/- OTI+/- CD45.1+/- and RAG1+/- OTI+/- Luci+/- mice were 
generated by crossing C57BL/6 RAG1-/- OTI+/+ mice with C57BL/6 45.1+/+ and 
C57BL/6 Luci+/+, respectively, to create heterozygote F1 progeny which were used as 
donors in experiments. 
 
5.2.2 Tumor Cell Lines and Culture 
 All tumor cell lines were grown in ‘CTL’ media comprised of RPMI 1640 
supplemented with 10% fetal bovine serum (FBS), penicillin-streptomycin (100 IU/ml & 
100 ug/ml), L-glutamine (2 mM), HEPES buffer (5 mM), and 2-mercaptoethanol (100 
uM) at 37°C in a humidified 5% CO2 incubator.  Addition of G418 (1000 ug/ml) was 
used for selection/maintenance of mOVA expression, and hygromycin (200 ug/ml) was 
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used for selection/maintenance of C2TA expression.  For in vitro induction of MHCI & 
MHCII, cells were cultured in 100 U/ml IFNγ (Peprotech, Rocky Hill, NJ) for three days.   
 The B16-F10 cell line is a melanoma derived from the C57BL/6 background.  It 
has virtually undetectable baseline MHCI and MHCII expression, both of which can be 
induced by exposure to IFNγ.  The B16-F10-D cell line is a variant of this same B16-F10 
tumor that similarly has undetectable baseline MHCI and MHCII, but through unknown 
mechanisms has lost the ability up-regulate MHCII in the presence of IFNγ.  Both of 
these tumor lines were contained within longstanding laboratory stocks.  B16.mOVA is a 
derivative of the B16-F10 line, which has been engineered to express a membrane-bound 
version of chicken ovalbumin (OVA) via stable transfection with pcDNA3.1(+)/mOVA 
under neomycin/G418 selection as previously described (Preynat-Seauve et al., 2007) and 
was a gift from Dr. Bertrand Huard.  B16-F10-D.mOVA and B16.mOVA.CIITA are 
OVA-expressing derivates of the above B16 lines with non-inducible and constitutive 
MHCII expression, respectively, that were created in house as previously described in 
Chapter 3.   
   
5.2.3 OTI Tc0 Isolation 
 C57BL/6 OTI+ splenocytes were harvested into single cell suspension by 
crushing through a 100 um cell strainer (BD Biosciences; San Jose, CA) followed by 
subsequent red blood cell (RBC) lysis using ammonium-chloride-potassium lysis buffer 
(ACK) (Gibco; Carlsbad, CA).  RBC-free splenocytes were then enumerated and washed 
with ice-cold PBS.  CD8+ cells were then purified using negative selection with MACS 
CD8a+ T-cell Isolation Kit I or II according to manufacturer instruction using MACS LS 
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separation columns (Miltenyi; Auburn, CA).  Following purification, cells were stored at 
4°C in CTL media until ready for use.  Cell purity was analyzed by FACS analysis for 
CD8, CD4, and Thy1.2 and was consistently greater than 95% CD8+ Thy1.2+ CD4-. 
Prior to adoptive transfer, cells were washed 3 times in ice-cold PBS, counted, and 
diluted as needed. 
 
5.2.4 Regulatory T-Cell Culture & Retroviral Transduction 
 Regulatory T-cells were generated using two different culture methods which 
each produced equivalent in vitro suppressive ability (data not shown).  In the first 
method, C57BL/6 RAG-/- OTII+/+ splenocytes were harvested into single cell 
suspension by crushing through a 100 um cell strainer (BD Biosciences; San Jose, CA) 
followed by subsequent red blood cell (RBC) lysis using ammonium-chloride-potassium 
lysis buffer (ACK) (Gibco; Carlsbad, CA).  RBC-free splenocytes were then enumerated 
and washed with ice-cold PBS.  CD4+ cells were then purified using positive selection 
with MACS CD4 (L3T4) Microbeads according to manufacturer instruction using MACS 
LS separation columns (Miltenyi; Auburn, CA). Following purification, cells were stored 
at 4°C in CTL media in preparation for culture and cell purity was analyzed by FACS 
analysis for CD4 and Thy1.2 and was typically around 75% CD4+ Thy1.2+.  10 cm 
tissue culture plates (Corning; Tewksbury, MA) were coated for 2 hours at room 
temperature with 10 ml PBS containing 2 ug/ml of non-azide, low-endotoxin anti-CD28 
(clone 37.51) and anti-CD3 (clone 145-2C11) antibodies (BD Biosciences; San Jose, CA) 
and subsequently washed twice with 10 ml PBS.  Purified CD4+ cells were then seeded 
into antibody-coated plates at 1E6 CD4+ cells/ml in 10 ml ‘Treg media’ consisting of 
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CTL containing 5 ng/ml hTGFβ (R&D Systems; Minneapolis, MN), 500 U/ml hIL-2 
(NCI Clinical Repository; Rockville, MD), and 100 nM Retinoic Acid (Sigma; St. Louis, 
MO).  Cells were then cultured for 2 days in a humidified 37°C 5% CO2 incubator.   
 For retroviral transduction, a retroviral construct Retro.Luci.Thy1.1 containing the 
congenic marker Thy1.1 and a codon-optimized firefly luciferase gene (Rabinovich et al., 
2008) was utilized.  Virus was added at a Multiplicity of Infection (MOI) of 5 directly to 
day 2 cultured Treg cells in the presence of 0.2 ul/ml polybrene (Sigma; St. Louis, MO) 
and 2 ul/ml Lipofectamine 2000 (Invitrogen; Carlsbad, CA) and mixed thoroughly by 
gently swirling plates.  Cells were then incubated with virus for a total of 3 hours in a 
humidified 37°C 5% CO2 incubator with gentle swirling of plates every 30 minutes.  
 Following transduction (or for cultures not transduced), 30 ml additional pre-
warmed Treg media was added and the culture continued for a total of 6 or 7 days.  Cells 
were harvested, washed in ice-cold PBS, counted, and stored at 4°C in CTL media until 
ready for use.  Cells were analyzed for purity using FACS analysis for Foxp3, CD4, and 
CD25. Purity usually exceeded 75% Foxp3+ CD4+ CD25+. For transduced cultures, 
cells were also analyzed for Thy1.1 expression to determine transduction efficiency, 
which was typically 5-10%.  Prior to adoptive transfer, cells were washed 3 times in ice-
cold PBS, counted, and diluted as needed.   
 In the second method of Treg culture, C57BL/6 OTII+/- Thy1.1+/- Foxp3-
GFP+/y splenocytes were harvested into single cell suspension and subjected to RBC 
lysis as above.  RBC-free splenocytes were then enumerated and seeded at 1E6 
splenocytes/ml in 50 ml Treg media into at T162 flask (Corning; Tewksbury, MA).  2 
ug/ml OVAII peptide (Genscript; Piscataway, NJ) was added to each flask and the cells 
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cultured upright for 4 days.  On day 4, an additional 50 ml of pre-warmed Treg media 
was added and the flasks were laid down for an additional day of culture.  On day 5, an 
additional 20 ml of pre-warmed CTL media containing 500 U/ml hIL-2 was added and 
the cells cultured a final day.  On day 6 cells were harvested, washed with ice-cold PBS, 
and FACS sorted for CD4+ Foxp3-GFP+ on a BD FACSAria (BD Biosciences; San 
Jose, CA) to a final purity of >98%.  Following sorting, cells were stored in CTL at 4°C 
until ready for use.  Prior to adoptive transfer, cells were washed 3 times in ice-cold PBS, 
counted, and diluted as needed. 
 
5.2.5 Tumor Challenge and Treatment 
 A fresh vial of tumor cells was thawed for each challenge experiment and grown 
for approximately 7 days with harvest at approximately 70% confluency to ensure 
exponential growth.  For challenge, cells were harvested from adherent culture flasks 
using 0.25% trypsin-EDTA (Gibco; Carlsbad, CA) and washed in ice-cold CTL media.  
Cells were washed 3 times in ice-cold PBS, counted, and diluted to 1E6 cells/ml in ice-
cold PBS.  Mice were then challenged subcutaneously with 1E5 tumor cells in the 
previously shaved right flank on day 0.  On day 6, mice were transferred to fresh clean 
caging and provided with water containing trimethoprim/sulfamethoxazole (Sulfatrim; 
dosed for 95 mg/kg/24hr; obtained from the Johns Hopkins Hospital pharmacy) in 
preparation for irradiation. On day 7, mice were irradiated at 500 Rads whole body 
irradiation and then adoptively transferred via tail vein injection with OTI Tc0 and/or 
OTII Tregs.  Tumor size was then determined with cross-sectional caliper measurement 
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once or twice weekly.  Mice were sacrificed at the first sign of suffering or for timed 
explant sampling as indicated. 
 
5.2.6 In Vivo Bioluminescent Imaging 
 D-Luciferin (Perkin-Elmer; Waltham, MA) was prepared fresh at 15 mg/ml in 
PBS, sterile filtered using a 0.22 um syringe filter, and stored on ice in the dark prior to 
injection.  Mice were given 200 ul intraperitoneal (i.p.) injection of D-Luciferin to 
provide an approximate dose of 150 mg/kg.  They were then anesthetized using 
isoflurane in preparation for imaging.  Imaging was performed 10 minutes after injection 
of D-Luciferin in order to optimize light signal per the manufacturer’s protocol.  Mice 
were imaged using the IVIS Spectrum (Perkin-Elmer; Waltham, MA) in vivo imaging 
system under real-time isoflurane anesthesia.   
 To ensure signal accuracy, the longest exposure without pixel saturation was 
utilized.  No more than 5 mice were imaged at a single time to minimize signal bleed.  To 
maximize signal sensitivity, the smallest imaging field that could fit all samples was 
utilized.  For groups demonstrating wide mouse-to-mouse variability, mice bearing large 
signal intensity were imaged and removed to allow reimaging and uncovering of lower-
intensity signals. Image data was acquired and analyzed using Living Image software 
(Perkin-Elmer; Waltham, MA).  Regions of Interest (ROIs) were generated based upon a 
2% maximum pixel signal threshold within each image, and data expressed as Radiance 
(photons/s/cm^2) in order to control for variability in exposure times used.  Mice were 
imaged once or twice weekly, and never more than every other day to avoid anesthesia-
induced failure to thrive. 
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5.2.7 In Vivo CTL Kill Assay 
 C57BL/6 CD45.1+/+ donor mice were sacrificed and spleens harvested for use as 
target cells.  RBC-free, single cell suspensions were then prepared as described 
previously.  Splenocytes were counted, seeded at 10E6 cells/ml in warmed CTL media 
with or without 1 ug/ml OVAI peptide (Genscript; Piscataway, NJ) into culture flasks, 
and incubated 2 hours at 37°C in a humidified 5% CO2 incubator for peptide loading.  
Cells were transferred to 50 ml conical tubes and washed with warmed PBS.  Cell pellets 
were then thoroughly resuspended in 1 uM (OVAI targets) or 0.1 uM (unlabeled targets) 
Carboxyfluorescein Succinimidyl Ester (CFSE)(Invitrogen; Carlsbad, CA) and incubated 
for 20 minutes in a light-protected 37°C water bath.  CFSE labeling was then quenched 
with ice-fold FBS for 5 minutes on ice and cells washed twice with ice-cold PBS and 
counted.  Peptide loaded (CFSE high) and non-loaded (CFSE low) cells were then mixed 
1:1 for a total cell count of 50E6 cells/ml and stored on ice in the dark prior to injection.  
Recipient mice were i.v. injected with 200 ul target mix via tail vein.  Extra cells were 
stored overnight at 4°C in CTL for use as FACS controls.  Recipients were sacrificed and 
harvested approximately 18 hours later for analysis of target cell killing via flow 
cytometry.  % Lysis was defined as being equal to (1-(target/non-target))x100. 
 
5.2.8 Ex Vivo Lymphocyte Isolation and Stimulation 
 Tumor-bearing mice were sacrificed and spleens, lymph nodes, and tumors 
harvested into ice-cold CTL media.  RBC-free, single cell suspensions of spleens and 
LNs were prepared as outlined previously.  Given the large volume of necrotic debris, 
tumor tissue samples required more elaborate processing.  Single cell tumor suspensions 
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were prepared by crushing tissue through a 100 um cell strainer (BD Biosciences; San 
Jose, CA).  Cells were then washed with ice-cold RPMI and spun at 1000 RPM, leaving 
smaller dead cell fragments in the supernatant.  This step was repeated until the 
supernatant was grossly clear of pigmented debris.   RBC lysis was then performed using 
ACK lysis (Gibco; Carlsbad, CA).  Dead cell removal was then further performed using 
one or two rounds of ficoll-paque (GE Life Sciences; Piscataway, NJ) separation.  Cells 
were counted and stored in ice-cold CTL media until ready for FACS staining or in vitro 
stimulation. 
 For in vitro stimulation, 1E6 explant cells were seeded in 1 ml CTL media in a 
24-well flat bottom plate (Corning; Tewksbury, MA).  2 ug/ml OVAI peptide (Genscript; 
Piscataway, NJ) was then seeded into test wells along with 1 ul/ml GolgiPlug 
(brefeldin A) (BD Biosciences; San Jose, CA).  Negative controls received GolgiPlug 
without OVAI peptide, and positive controls were treated with 2 ul/ml Leukocyte 
Activation Cocktail containing PMA/ionomycin and GolgiPlug (BD Biosciences; San 
Jose, CA).  Cells were then incubated overnight (~16 hours) at 37°C in a humidified 5% 
CO2 incubator.  The following morning, cells were harvested and analyzed via flow 
cytometry.  
 
5.2.9 Antibodies and Flow Cytometry 
 I-Ab-FITC (clone AF6-120.1), I-Ek-FITC (clone 14-4-4S), H-2Kb-FITC (clone 
AF6-88.5), H-2Dd-FITC (clone 34-2-12), CD25-PE (clone PC61), CD4-APC (clone 
RM4-5), CD8-PE and CD8-A700 (clone 53-6.7), Thy1.1-PerCP (clone OX-7), Thy1.2-
FITC (clone 30-H12), TNF-APC (clone MP6-XT22), CD44-V500 (clone IM7), Ki67-
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PerCP-Cy5.5 (clone B56), and IFNγ-PE (clone XMG1.2) were purchased from BD 
Biosciences (San Jose, CA).  PD-L1-BrilliantViolet421 (clone 10F.9G2), Galectin-9-
PE (clone 108A2), CD127-APC (clone A7R34), PD-1-BrilliantViolet421 (clone 
29F.1A12), IL-17a-PacificBlue (clone TC11-18H10.1), and TIM-3-PE (clone RMT3-
23) were purchased from BioLegend (San Diego, CA).  Thy1.1-APC-eFluor780 (clone 
HIS51), CD62L-PerCP-Cy5.5 (clone MEL-14), KLRG-1-PE-Cy7 (clone 2F1), IL-2-PE-
Cy7 (clone JES6-SH4), Foxp3-FITC (clone FJK-16s), and LAG-3-PE (clone C9B7W) 
were purchased from eBioscience (San Diego, CA). CD4-PE-TexasRed (clone RM4-5) 
was purchased from Invitrogen (Camarillo, CA).  All antibodies were titrated for optimal 
staining intensity vs. background signal for 1E6 cells/reaction.  All isotype control 
antibodies were from the same manufacturer and used at the same concentration as their 
associated test antibody.     
 Qdot625-“tetramer” specific for OTI CD8 cells was prepared in house.  
Monomer of H-2Kb coupled with the chicken ovalbumin peptide 257-264 SIINFEKL 
were prepared by the NIH Tetramer Core Facility (Atlanta, GA) and stored at -80°C until 
ready for tetramerization.  For tetramerization, a 25 ul aliquot of approximately 2 ug/ml 
monomer stock was thawed on ice and diluted to a total volume of 100 ul with sterile 1X 
PBS.  20 ul of Qdot625-Streptavidin (Invitrogen; Camarillo, CA) was then added to the 
monomer, mixed thoroughly, and allowed to incubate on ice in the dark for 20 minutes.  
This step was repeated a total of 4 times to yield a final solution of 200 ul tetramer at 
0.225 ug/ml concentration.  Formed tetramer was titrated using RAG-/- OTI+/+ 
splenocytes and stored at 4°C until use.  All formed tetramers were used within one 
month of preparation.  It should be noted that this is in fact not a true tetramer, as each 
	   143	  
Qdot has between 5 and 10 streptavidin molecules bound to it, each of which can bind 
up to 4 monomers.  Thus, the end molecule is a large multimer and not a true tetramer. 
 For all extracellular antibody staining, 1E6 cells were washed with FACS buffer 
containing 1X Hanks Balanced Salt Solution (HBSS), 10 mM HEPES buffer, 2% FBS, 
and 0.1% sodium azide and stained with appropriate antibody for 15 minutes at room 
temperature in the dark followed by two washings with FACS buffer.  No more than 5 
antibodies were stained at a single time.  Cells were similarly washed for tetramer 
staining but were incubated for 30 minutes.  Viability staining using LIVE/DEAD 
Yellow and Aqua Fixable Dead Cell Stain Kit (Invitrogen; Camarillo, CA) was 
performed according to the manufacturer’s instructions at a 1:2000 dilution with a 30 
minute room temperature incubation and washing steps using PBS.  Cellular 
fixation/permeabilization was performed using the Foxp3 Staining Buffer Set 
(eBioscience; San Diego, CA) according to manufacturer instructions with fixation 
performed for 45 minutes at 4°C in the dark.   Subsequent intracellular staining was 
performed for 30 minutes at 4°C in the dark with washes using the staining buffer set.  
For multi-step staining sequences, the following sequence was always followed:  
Tetramer, extracellular antibody, Live/Dead stain, fixation/permeabiliation, intracellular 
stain.  Following staining, cells were stored in FACS buffer at 4°C in the dark and were 
analyzed within 24 hours of staining.   
 Flow cytometry was performed on the BD FACSCaliber, FACSAria, or 
LSRII with data acquisition using CellQuest Pro or FACSDiva (BD Biosciences; 
San Jose, CA).  Data analysis was further performed with FACSDiva as well as FlowJo 
(Tree Star Inc.; Ashland, OR). 
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5.2.10 Histology 
 Mice were sacrificed and tumors, spleens, and lymph nodes (LN) harvested into 
ice-cold CTL media.  Tissues were then blotted to remove excess CTL and transferred to 
Intermediate Tissue-Tek CryoMolds (Sakura Finetek; Torrance, CA) containing a small 
layer of Optimal Cutting Temperature (OCT) media (Sakura Finetek; Torrance, CA) and 
subsequently covered with OCT media.  Tissue chambers were then flash-frozen in a 
beaker of liquid nitrogen-cooled isopentane (Sigma; St. Louis, MO).  Once fully frozen, 
samples were transferred on dry ice to a -80°C freezer for storage prior to cryosectioning.  
Tissue was subsequently cryosectioned at 5 um sections onto “Plus” slides, fixed in ice-
cold acetone for 10 minutes, and air dried for 30 minutes by the Johns Hopkins Histology 
Core.  Following sectioning and fixation, slides were stored in a -80°C freezer until 
stained.   
 Primary antibodies used for staining included:  I-Ab-biotin (clone AF6-120.1; Ms 
IgG2a), CD45.1-FITC (clone A20; Ms IgG2a), and Thy1.1-APC (clone OX-7; Ms IgG1) 
(BD Biosciences; San Jose, CA).  All isotype controls were used at the same 
concentration and were from the same supplier as the test antibody.  Fluorescein/Oregon 
Green Rabbit IgG Antibody (Invitrogen; Camarillo, CA) was used as a secondary 
antibody to increase primary antibody-FITC signal. Goat anti-Rabbit AlexaFluor488 
(Invitrogen; Camarillo, CA) and Stretavidin-Cy3 (Sigma; St. Louis, MO) were used for 
tertiary staining.      
 For staining, slides were allowed to warm to room temperature for 5 minutes in a 
laminar flow hood and then tissue demarcated with an ImmunEdge Pen (Vector Labs; 
Burlingame, CA) prior to rehydration with PBS for 10 minutes at room temperature.  All 
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subsequent staining and blocking steps were performed in a light-protected, humidified 
chamber with three PBS washes between steps.   Samples were first treated with 1-2 
drops Molecular Probes Endogenous Biotin Blocking Kit (Invitrogen; Camarillo, CA) 
solutions A and B for 30 minutes each at room temperature.  They were then covered 
with 100 ul isotype-control blocking antibodies at 10 ug/ml in Blocking Buffer (2% IgG-
free BSA and 5% normal mouse serum (Jackson Immunoresearch; West Grove, PA) in 
PBS) for 1 hour at room temperature.  This blocking solution was then shaken off without 
PBS wash and replaced with primary antibodies at 10 ug/ml in Blocking Buffer and 
incubated overnight at 4°C.  Slides were then incubated with 100 ul of 2 ug/ml secondary 
antibody in PBS/2%BSA for 1 hour at room temperature, washed, and incubated with 
100 ul of tertiary antibodies diluted 1:100 in PBS/2%BSA for 1 hour at room 
temperature.  Nuclei were then counterstained with Hoechst 33342 (Invitrogen; 
Camarillo, CA) diluted 1:50,000 in PBS for 15 minutes at room temperature.  Following 
PBS wash, slides were fixed and mounted using a single drop of Aqua Poly/Mount 
(Polysciences; Warrington, PA) and cover slips placed and immobilized with nail polish.  
Slides were then stored face-up in light-protected slide boxes at 4°C until imaging.   
Imaging was performed using a Nikon E800 fluorescent microscope using 
standard DAPI, FITC, Cy3, and Cy5 filter sets.  Image acquisition and analysis was 
performed using Nikon Elements Software (Nikon Metrology; Brighton, MI). 
 
5.2.11 OTII Th1 T-Cell Culture 
 C57BL/6 OTII+/- Thy1.1+/- Foxp3-GFP+/y splenocytes were harvested into 
single cell suspension and subjected to RBC lysis as above.  RBC-free splenocytes were 
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then enumerated and seeded at 1E6 splenocytes/ml in 40 ml ‘Th1 media’ (CTL 
containing 10 ng/ml IL-12, 10 ng/ml IFNγ (Peprotech; Rocky Hill, NJ), 2 U/ml hIL-2, 
and 2 ug/ml anti-IL-4 (NCI Clinical Repository; Rockville, MD)) into a T162 flask 
(Corning; Tewksbury, MA).  2 ug/ml OVAII peptide (Genscript; Piscataway, NJ) was 
added to each flask and the cells cultured upright for 4 days.  On day 4, an additional 40 
ml of pre-warmed Th1 media was added and the flasks were laid down for an additional 
day of culture.  On day 5, an additional 20 ml of pre-warmed CTL media containing 2 
U/ml hIL-2 was added and the cells cultured a final day.  On day 6 cells were harvested, 
washed with ice-cold PBS, and FACS sorted for CD4+ Foxp3-GFP- on a BD 
FACSAria (BD Biosciences; San Jose, CA) to a final purity of >98%.  Following 
sorting, cells were stored in CTL at 4°C until ready for use.  
 
5.2.12 In Vitro Direct Tumor Recognition 
 B16 tumor variants were grown for three days in the presence or absence of 100 
U/ml IFNγ (Peprotech; Rocky Hill, NJ) and 5E5 cells seeded in 500 ul CTL media into 
24-well flat-bottom plates (Corning; Tewksbury, MA).  1E6 in vitro polarized, sorted 
OTII Th1 cells were added to each well for a total volume of 1 ml CTL.  2 ug/ml OVAII 
peptide (Genscript; Piscataway, NJ) was added to tumor-containing wells as an antigen 
positive control, as well as to wells containing only Th1 cells to verify absence of MHCII 
in our sorted Th1 cells.  1 ul/ml GolgiPlug was added to all tumor-stimulated wells, 
and 2 ul/ml Leukocyte Activation Cocktail containing PMA/ionomycin and GolgiPlug 
(BD Biosciences; San Jose, CA) was used as a positive control for Th1 cytokine staining.  
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Cells were incubated for 6 hours at 37°C in a humidified 5% CO2 incubator, harvested, 




5.3.1 Failed Tumor Suppression with B16 Variants 
 In our first series of studies, we developed a model in which OTII Tregs were 
capable of suppressing treatment of the MHCII-inducible B16.mOVA tumor line by OTI 
CD8+ in MHCII KO mice (Figure 3.5).  Based upon those findings, we had hypothesized 
that by altering the expression pattern of MHCII within the tumor, we would also alter 
the suppressive pattern demonstrated by our Tregs.  To accomplish this goal, we had set 
out to create B16.mOVA variants that demonstrated constitutive and non-inducible 
MHCII expression, which were successfully created in the form of the MHCII-
constitutive line B16.mOVA.CIITA and the MHCII-non-inducible B16-F10-D.mOVA as 
previously described and characterized in Chapter 3.  With those tools now in hand and 
validated, and with a better understanding of out OTI treatment system, we set out to 
examine the implications of variable MHCII expression upon the ability of OTII Tregs to 
suppress the treatment effect of OTI CD8+.  As modeled in Figure 5.1, we hypothesized 
that the constitutive expression of MHCII in our B16.mOVA.CIITA line would result in 
improved Treg suppression (orange curve) relative to our inducible variant B16.mOVA 
(blue curve), whereas non-inducible MHCII expression by our B16-F10-D.mOVA line 
would result in little to no detectable suppression (yellow curve).      
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Figure 5.1 Hypothesized effect of variable MHCII expression upon suppression of 
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 Thus, recipient C57BL/6 MHCII KO mice were challenged subcutaneously with 
1E5 B16.mOVA, B16.mOVA.CIITA, or B16-F10-D.mOVA tumor on day 0 and treated 
on day 7 with 500 Rads non-myeloablative whole body irradiation followed by adoptive 
transfer of 2.5E6 OTI Tc0 cells with or without co-administration of 7.5E6 OTII Tregs. 
Tumors were then measured at weekly intervals using cross-sectional caliper 
measurements.  As shown in Figure 5.2, OTII Tregs failed to demonstrate suppression in 
any of the three tumor systems.  This failure within the B16.mOVA system was in 
contrast to results previously obtained.  Complicating this result further was the 
observation that the treatment effect of OTI CD8+ within each of the tumor lines was 
quite different.  While these lines had previously been grown and treated in vivo as part 
of their creation and validation, they had not previously been done so in the same 
experiment to allow for direct comparison.  Also evident within this figure is the wide 
range of tumor sizes in some groups as evidenced by the large standard deviation bars 
shown, further complicating the evaluation of this data.     
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Figure 5.2 OTII Tregs fail to suppress treatment of B16.mOVA variants by OTI 
CD8+ in MHCII KO mice. 
C57BL/6 MHCII KO mice were challenged with 1E5 B16.mOVA, B16.mOVA.CIITA, 
or B16-F10-D.mOVA tumor on day 0 and treated on day 7 with 500 Rads non-
myeloablative whole body irradiation followed by adoptive transfer of 2.5E6 OTI cells 
with or without co-administration of 7.5E6 OTII Tregs.  Tumors were then measured at 
weekly intervals using cross-sectional caliper measurements.  Mean +/- Standard 
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5.3.2 Lack of Treg Accumulation within the Tumor 
 Having failed to demonstrate any suppression with our B16.mOVA variants, we 
next sought to examine the activity of our Tregs in vivo.  We first examined the 
trafficking of our Tregs in a manner similar to that done previously for our OTI CD8+.  
Recipient MHCII KO mice were challenged with 1E5 B16.mOVA, B16.mOVA.CIITA, 
B16-F10D.mOVA, or parental non-OVA-expressing B16-F10 on day 0 and treated on 
day 7 with 500 Rads non-myeloablative whole body irradiation followed by adoptive 
transfer of 7.5E6 OTII Tregs bearing the luciferase enzyme via in vitro transduction with 
a retroviral luciferase construct with or without co-administration of 2.5E6 OTI cells.  
Bioluminescent imaging (BLI) was then performed twice weekly to detect the location of 
OTII Tregs via activity of the luciferase enzyme.  As shown in Figure 5.3, OTII Tregs 
were detected in the area surrounding the tumor as early as the first day post transfer (day 
8), but unlike the accumulation seen for OTI cells, the OTII Tregs demonstrated a steady 
decline of signal in the area of the tumor.  Also unlike the OTI cells, the OTII cells 
appeared to never perfectly co-localize with the tumor, but rather were persistently found 
in the tissue immediately surrounding the tumor mass.  This accumulation by Tregs 
within the tumor surroundings appeared to be antigen non-specific and independent of 
MHCII expression, as OTII cells were found with equal intensity in OTI-treated or 
untreated tumors as well as in non OVA-bearing B16-F10 tumors. 
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Figure 5.3 OTII Tregs demonstrate an MHCII-independent, antigen non-specific 
and fading accumulation around, but not within B16 tumor variants. 
C57BL/6 MHCII KO mice were challenged with 1E5 B16.mOVA, B16.mOVA.CIITA, 
B16-F10D.mOVA, or parental non-OVA-expressing B16-F10 on day 0 and treated on 
day 7 with 500 Rads non-myeloablative whole body irradiation followed by adoptive 
transfer of 7.5E6 OTII Luci+ Tregs with or without co-administration of 2.5E6 OTI cells.  
Mice were imaged twice weekly to detect the location of OTII cells.  Mean +/- Standard 
Deviation for groups of 3 mice are shown.  (A) BLI of mice over the course of tumor 
progression.  (B) Representative BLI images of a single mouse over time with experiment 
day indicated in the upper left corner for each image. 
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 To verify the results from our BLI data, we next sought to examine the tumors 
histologically for the presence of OTII Tregs.  MHCII KO recipients were challenged 
with B16.mOVA and treated as before with OTI CD8+ and OTII+/- Thy1.1+/- Foxp3-
GFP+/y mice as Treg donors.  Mice were sacrificed one week after treatment and tumor 
masses harvested and processed for histologic evaluation of MHCII and the congenic 
marker Thy1.1 expressed only by OTII Tregs.  These slides demonstrated a complete 
absence of Tregs within the tumor mass, even in areas with high MHCII expression (data 
not shown), validating the findings from our BLI data suggesting that Tregs were in fact 
not migrating into and accumulating within the actual tumor mass.   
 With our BLI and histologic data suggesting that our Tregs were not accumulating 
within the tumor mass, we next set out to determine if they were persisting in other 
tissues, namely spleens and tumor-draining lymph nodes (DLN).  MHCII KO recipient 
mice were again challenged with B16mOVA and treated as above using OTI CD8+ and 
OTII+/- Thy1.1+/- Foxp3-GFP+/y Tregs.  Mice were sacrificed and spleens, DLNs, and 
tumors harvested for explant analysis at weekly intervals via flow cytometric analysis.  
As shown in Figure 5.4, OTII Tregs were successfully identified via CD4+ Thy1.1+ 
staining, and the vast majority of these cells maintained Foxp3 expression.  OTII cells 
persisted and maintained Foxp3 expression throughout the course of tumor progression, 
although their total numbers were consistently far lower than those seen for our OTI cells 
in prior studies.  Also, significant numbers of Tregs could not be identified within TIL 
samples (data not shown), further supporting their absence in tumor tissue.   
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Figure 5.4 OTII cells persist and maintain Foxp3 expression within B16.mOVA 
tumor-bearing mice. 
C57BL/6 MHCII KO mice were challenged with 1E5 B16.mOVA tumor on day 0 and 
treated on day 7 with 500 Rads non-myeloablative whole body irradiation followed by 
adoptive transfer of 2.5E6 OTI and 7.5E6 OTII Tregs.  Mice were sacrificed at weekly 
intervals and spleens, tumor-draining lymph nodes, and tumors harvested.  Single cell 
suspensions were prepared from explanted tissue and subjected to flow cytometric 
analysis of live cells as determined by scatter profiles and live/dead cell stain. OTII cells 
were identified by expression of CD4+ and Thy1.1 (A) and total numbers enumerated in 
(B).  Foxp3 expression within OTII cells was verified as in (C) and quantified (D).  Mean 
+/- Standard Deviation for 3-5 mice per group are shown. 
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5.3.3 Tregs Fail to Alter OTI CD8+ Phenotype 
 Having demonstrated persistence of OTII Tregs within spleens and DLNs despite 
their absence in tumors and failed suppression of tumor immune rejection, we next 
examined whether the phenotype of our OTI cells was altered by the presence of OTII 
Tregs.  To perform this analysis, we in essence repeated the studies previously described 
in Chapter 4 with inclusion of OTII Tregs alongside our OTI treatment only groups.  
Recipient MHCII KO mice were challenged and treated as before with or without 
addition of OTII Tregs.  To analyze the trafficking and accumulation of OTI cells within 
the tumor, OTI+/- Luci+/- CD8+ were used along with OTII Tregs with imaging 
performed every other day following adoptive transfer.  These studies, as shown in 
Figure 5.5(A), showed that Tregs failed to significant alter the trafficking to or 
accumulation within B16.mOVA tumors by Luci-expressing OTI CD8+.  Similarly, 
analysis of total OTI CD8+ numbers via flow cytometric analysis of explanted spleen and 
DLN tissues revealed no difference in total OTI CD8+ numbers with administration of 
OTII Tregs as shown in Figure 5.5(B).   
 Assessment of OTI CD8+ effector phenotype was similarly examined with 
inclusion of OTII Tregs along with OTI CD8+.  As shown in Figure 5.5(C), levels of 
IFNγ expression were not altered with addition of OTII Tregs.  TNFα expression levels 
were also unchanged (data not shown).  Similarly, evaluation of OTI CD8+ cell surface 
phenotype was performed and demonstrated no changes in CD44/CD62L, 
CD127/KLRG-1, or PD-1/LAG-3/TIM-3 expression levels upon OTI CD8+ when OTII 
Tregs were included (data not shown).  Finally, evaluation of the in vivo cytotoxicity of 
our OTI CD8+ was examined in the presence of OTII Tregs as performed previously.  As 
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shown in Figure 5.5(D), these data showed no decrease in in vivo CTL activity of our 
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Figure 5.5 OTII Tregs do not alter the phenotype of OTI CD8+ in tumor-bearing 
mice. 
C57BL/6 MHCII KO mice were challenged with 1E5 B16.mOVA tumor on day 0 and 
treated on day 7 with 500 Rads non-myeloablative whole body irradiation followed by 
adoptive transfer of 2.5E6 OTI and 7.5E6 OTII Tregs.  Mean +/- Standard Deviation for 
3-5 mice per group are shown.  (A) BLI was performed every other day to analyze in vivo 
trafficking of OTI+/- Luci+/- CD8+ cells in the presence or absence of OTII Tregs.  (B) 
Weekly explants of spleens and DLNs were assessed for total OTI CD8+ cells via FACS 
analysis using CD8 and OVAI-specific tetramer.  (C) Weekly explants of spleens, DLN, 
and TILs were subjected to in vitro stimulation with OVAI peptide and analyzed for 
expression of IFNγ by CD8+ cells.  (D) Tumor-bearing mice were given adoptive transfer 
of a 1:1 mix of CFSEhigh OVAI peptide-loaded and CFSElow non peptide-loaded target 
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splenocytes and evaluated for killing effect 16 hours later by assessing for target 
populations in recipient spleens and tumor-draining lymph nodes.  % Lysis was defined 
as being equal to (1-(target/non-target))x100.   
 
5.3.4 OTII Th1 Do Not Recognize B16 Variants 
 Given the failure of our OTII Tregs to alter the phenotype of our OTI CD8+ cells 
as well as their inability to suppress OTI CD8-mediated tumor treatment, we decided to 
take a step back and evaluate the interaction between our OTII cells and tumor cells in 
vitro.  Specifically, we sought to assess whether our tumor cells were capable of directly 
presenting OVAII antigen to our OTII cells.  To accomplish this, tumor cells were 
cultured for 72 hours with and without 100 U/ml IFNγ and then cocultured for 6 hours 
with in vitro polarized OTII Th1 cells with or without addition of exogenous OVAII 
peptide.  Th1 cells were then harvested and analyzed via intracellular cytokine staining 
for production of IFNγ, TNFα, and IL-2.  As shown in Figure 5.6, OTII Th1 displayed 
cytokine production only when exogenous OVAII peptide was added to tumors that had 
previously been shown to express MHCII (B16.mOVA and B16.mOVA.CIITA treated 
with IFNγ, and B16.mOVA.CIITA without IFNγ treatment).  Importantly, despite the 
presence of MHCII (previously shown and verified again here; data not shown) none of 
these OVA-containing tumors was able to present endogenously-contained OVA antigen 
to OTII Th1 cells.  
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Figure 5.6 B16.mOVA variants fail to directly present endogenous OVA but can 
present exogenous OVAII peptide to OTII Th1 cells in vitro. 
OVA-containing B16 tumor lines B16-F10-D.mOVA, B16.mOVA, and 
B16.mOVA.CIITA were cultured for 72 hours with or without 100 U/ml IFNγ and then 
cocultured for 6 hours with in vitro polarized, sorted OTII Th1 cells with or without 
addition of 2 ug/ml exogenous OVAII peptide as indicated.  Following coculture, Th1 
cells were harvested and analyzed for cytokine production via intracellular cytokine 
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5.4 Discussion 
 
 In this third study we sought to expand upon the findings from our first two 
studies to explore the implications of variable tumor MHCII expression upon Treg 
suppression along with evaluating the phenotype of suppressed CD8+ cells in our model 
as a means of understanding the potential suppressive mechanisms utilized.  
Unfortunately, despite our results in the first study, which had indicated a suppressive 
effect of OTII Tregs upon OTI CD8+ in MHCII KO mice, we were unable to replicate 
these findings when all three tumor lines were utilized.  The cause for this failure, 
particularly for the B16.mOVA line, left us largely at a loss for explanation given that 
none of our reagents or protocols had changed.   
 Closer assessment of each of the tumor curves revealed that each of our three 
tumor variants grew at comparable rates when untreated, but demonstrated widely 
variable treatment responses even without Treg inclusion.  The B16-F10-D.mOVA line 
demonstrated the least treatment response while the B16.mOVA.CIITA line 
demonstrated the greatest and most durable treatment response.  We had previously 
demonstrated that B16.mOVA.CIITA was the only tumor of the three evaluated that 
expressed baseline MHCII as well as MHCI (Figure 3.6), owing likely to the fact that 
CIITA has been shown to play a minor role in MHCI expression (Holling et al., 2006; 
LeibundGut-Landmann et al., 2004).  This prolonged availability of MHCI expression 
may explain the increased treatment effect seen for the B16.mOVA.CIITA tumor.  As to 
why the B16-F10-D.mOVA line responded less to treatment can only be speculated at, 
but given that this particular B16-F10 line was a different derivative than our other 
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B16.mOVA variants, may represent the previously described variability displayed by 
B16-F10 derivative lines (Overwijk and Restifo, 2001). 
 Given the complexity of our experimental design, including use of multiple tumor 
lines, multiple adoptively transferred TCR-transgenic cell populations, and the use of a 
number of genetically engineered and inbred mice, we considered it entirely possible that 
the failure of suppression of tumor growth reflected not a failure of Treg function, but 
rather perhaps was due to the numerous variables in our system not aligning 
appropriately and making consistent results difficult.  This seemed particularly plausible 
given that we had previously shown suppression in our first studies.  Therefore, while 
suppression of tumor rejection was our main and idealized result, it was not the only 
method we had to determine if our Tregs were in fact suppressing OTI CD8+. 
 To this end, we first chose to evaluate the trafficking and accumulation of our 
OTII Tregs in a manner similar to what had previously been performed for our OTI 
CD8+ cells.  MHCII KO mice were challenged with our three OVA-expressing B16 
variants as well as the parental B16-F10 non-OVA-expressing line and then given 
adoptive transfer of OTII Luci+ Tregs with or without OTI CD8+.  Our results here 
demonstrated an early trafficking of Treg cells to what appeared to be the peri-tumoral 
tissue with lack of penetration into the primary tumor mass.  These results further 
demonstrated a persistent decline of Treg signal over the course of tumor growth, and 
what’s more failed to demonstrate a separation of any of the treatment groups.  This lack 
of separation of groups was of particular concern.  Trafficking to the non-OVA-
expressing B16-F10 group suggested a lack of antigen-dependence.  Further trafficking to 
the Treg only B16.mOVA group as well as to either of the B16-F10-D.mOVA groups 
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suggested that MHCII was not involved, as none of these three groups should have 
expressed MHCII.  The fact that we saw the greatest signal immediately following 
adoptive transfer with subsequent waning also suggested a non-specific response, as we 
had envisioned the upregulation of MHCII during the course of tumor progression would 
allow direct interaction with Tregs that would result in increased signal intensity.  Thus, 
collectively, these studies suggested that Tregs were only transiently trafficking to peri-
tumoral area and were not interacting with tumor cells in an antigen-specific, MHCII-
dependent manner.  Histologic examination of tumor explants confirmed the lack of 
Tregs within the tumor despite the presence of high-level MHCII expression in 
appropriate samples.   
 Having failed to demonstrate appropriate trafficking and accumulation of OTII 
Tregs, we evaluated their persistence within tumor-draining lymph nodes and spleens.  
This analysis revealed that OTII cells were in fact present within these tissues, but at very 
low numbers.  Those OTII cells that were present, however, by and large maintained 
expression of Foxp3, indicating that they had not become ‘ex-Tregs’ (Zhou et al., 2009b) 
capable of potentially providing helper function to our OTI CD8+. 
 With our OTII Tregs persisting and maintaining Foxp3 expression within spleens 
and DLNs, we next evaluated for alterations of OTI phenotype in the presence of Tregs.  
While unable to alter the tumor growth outcome in these studies, it remained a possibility 
that our OTI CD8+ phenotype had been altered by Tregs.  Evaluation of OTI CD8+ 
tumor trafficking and accumulation, proliferation, cell surface phenotype, cytokine 
expression, and in vivo cytotoxicity all failed to demonstrate any differences in the 
presence of OTII Tregs.  This was in stark contrast to studies by others that had 
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demonstrated primarily the ability of Tregs to suppress the cytotoxic function of CD8+ 
effector cells while leaving trafficking, proliferation, maturation, and polarization largely 
unaltered (Lin et al., 2002; Dittmer et al., 2004; Zippelius et al., 2004; Chen et al., 2005).  
 The inability of our Tregs to suppress tumor rejection, alter OTI phenotype, or 
demonstrate antigen- and MHCII-dependent tumor interactions raised serious questions 
about the validity of our OVA-expressing tumor model.  A critical component of our 
hypothesis was that tumor cells could directly present antigen to Tregs via tumor-
expressed MHCII.  While we had previously documented tumor MHCII expression in 
vitro (Figures 3.6) and in vivo (Figure 3.9), as well as OVA expression via MHCI-
dependent in vitro (Figure 3.8) and in vivo (Figure 3.4) T-cell recognition, we had yet to 
directly evaluate the ability of our tumors to directly present antigen to OTII cells.  While 
our results from Figure 3.5(B) suggesting suppression in the MHCII KO mice inferred 
this interaction, they did not prove it, and further had since failed to be replicated.  
 Therefore, to better assess this question we evaluated the ability of OTII Th1 cells 
to directly recognize tumor cells via in vitro coculture experiments.  Tumor variants were 
cultured with or without IFNγ in order to induce MHCII expression and, with or without 
exogenous addition of OVAII peptide, were then cocultured with in vitro polarized, 
sorted OTII Th1 cells, which were subsequently evaluated for intracellular cytokine 
expression.  Tumor MHCII expression and MHCI-dependent OVA recognition were also 
confirmed and were as previously demonstrated (Figures 3.6 and 3.8, respectively; repeat 
data not shown).  Despite their ability to express MHCII and be recognized by OVA-
specific, MHCI-restricted T-cells, none of the B16 variants were able to directly stimulate 
OTII Th1 cells with endogenously expressed OVA antigen.  The fact that cells expressing 
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MHCII could stimulate OTII Th1 in the presence of exogenous OVAII peptide suggested 
that this was not a failure of MHCII:peptide:TCR interaction, but rather a failure of 
endogenous antigen content or perhaps endogenous antigen processing and presentation 
within the tumor cells. 
 With this finding, we referred back to the original work by Preynat-Seauve and 
colleagues (Preynat-Seauve et al., 2007) who had previously generated our B16.mOVA 
cell line and mOVA DNA construct.  In their work, despite demonstrating that B16 cells 
expressed full-length OVA protein derived from a DNA construct containing the OVAII 
peptide 323-339 coding sequence recognized by the OTII TCR (also confirmed in our lab 
upon receipt of the mOVA DNA construct), they failed to demonstrate the recognition of 
tumor-derived OVA by OTII cells in vivo.  This occurred for their B16.mOVA lines as 
well as several other tumor lines also expressing their OVA construct.  They did not 
investigate this finding further, and attributed it to an inefficiency of tumor associated 
OVA antigen cross-presentation within host tumor-draining lymph nodes, citing work by 
Dudziak and colleagues that had demonstrated inefficient MHCII antigen presentation by 
some subsets of DCs (Dudziak et al., 2007).  While our in vitro data would suggest that 
this failure of recognition is not due merely to a shortcoming of antigen cross-
presentation, it is in alignment with their findings.     
 Our results, coupled with the findings of Preynat-Seauve (Preynat-Seauve et al., 
2007) and colleagues, convincingly demonstrate that, despite the presence of full length 
OVA protein, its recognition by OTI cells, and the expression of functional MHCII by 
our tumor cells, the OVA protein expressed by our tumor cells is unable to stimulate 
OTII T-cells.  Whether this is the result of altered protein expression, post-translation 
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modification, insufficient protein quantity, or perhaps altered/inadequate antigen 
processing within our tumor cells is unknown.  It is interesting to note that Preynat-
Seauve and colleagues demonstrated the failure of OVA recognition to occur using a 
several different tumor lines all created from their same DNA construct.  This is in 
contrast to other works utilizing tumor-produced OVA that have been shown to be 
recognized by OTII T-cells (Schreiber et al., 2012), which may suggest something 
specific to the Preynat-Seauve construct used in our studies.  Other groups (Quatromoni 
et al., 2011) have also recently reported data consistent with failed OTII recognition of a 
different OVA-expressing B16 line, however, suggesting that this may in fact be a 
broader reaching issue with variable tumor to tumor relevance.  Regardless of the 
mechanism for this lack of recognition, its result is a complete inability to interpret any 
and all Treg studies performed within our studies, sadly making a large body of this work 
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Chapter 6 
 




 The motivation for this study was derived primarily from two sets of findings.  
The first of these is the growing body of literature suggesting that regulatory T-cells exert 
superior suppressive effects when both Treg and Teffector are specific for antigens within 
the same target cell.  This was further expanded upon by prior work within the lab, which 
demonstrated that Tregs are capable of antigen-specific suppression in the setting of a 
heterogeneous mixed-tumor model.  The second set of observations driving our thesis 
involved the increasing awareness that tumor cells, particularly in the setting of an active 
immune response, are capable of undergoing a number of cellular alterations that allow 
them to interact with and manipulate immune cells, including the upregulation of 
molecules involved in antigen presentation pathways.  The increased ability of tumors to 
present self-antigens could allow not only for the presentation of novel antigens, but also 
the ability of tumors to potentially present antigen directly to T-cells, thus providing a 
mechanism for antigen specificity of tumor suppression.  This study was therefore 
designed to test the hypothesis that the upregulation of MHCII by tumor cells allows for 
direct antigen presentation to regulatory T-cells with resultant suppression of immune-
mediated tumor rejection. 
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 In Chapter 3, we were able to develop a novel subcutaneous B16 tumor challenge 
system in which MHCII-inducible B16.mOVA cells were treated by a combination of 
non-myeloablative whole body irradiation and adoptive transfer of naïve OTI CD8+ cells 
in both WT and MHCII KO recipients.  While this model did not afford a permanent cure 
to our tumor-bearing mice, it provided an adequate treatment effect for the subsequent 
evaluation of Treg suppression.  Addition of OTII Tregs to this model resulted in a 
suppressive effect with MHCII KO recipients that failed to be demonstrated in WT mice.  
Our interpretation of this dichotomy at the time was that the recovery of host 
lymphopoeisis within the WT recipients, but not MHCII KO recipients, would result in 
production of polyclonal Tregs capable of suppressing our treatment effect.  Thus, 
MHCII KO mice demonstrated a prolonged treatment effect that allowed for unmasking 
of suppression by our OTII Tregs that was not afforded by the shortened treatment effect 
seen in WT mice.  Further noteworthy within this study was the fact that the suppression 
within our MHCII KO recipients demonstrated a lag relative to untreated mice.  This lag 
fit nicely into our hypothesis of inflammation-induced MHCII upregulation as a 
requirement for Treg suppression with the MHCII-inducible B16.mOVA tumor line.  To 
exploit and expand upon this finding in future studies, we successfully generated the 
MHCII-constitutive B16.mOVA.CIITA and MHCII-non-inducible B16-F10-D.mOVA 
tumor lines and subsequently validated their in vitro and in vivo MHC and OVA 
expression.  
 In Chapter 4, we stepped away from our Treg studies to further examine the 
phenotype of our OTI CD8+ treatment cells over the course of tumor progression.  We 
were able to successfully demonstrate that, upon adoptive transfer, our naïve OTI CD8+ 
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cells effectively proliferated, trafficked to, and accumulated within the B16.mOVA 
tumor.  These cells developed cell surface marker phenotypes consistent with all major 
lineages of CD8+ T-cells including naïve, central memory, and effector/effector memory 
cells, and these populations demonstrated appropriate distributions within spleens, DLN, 
and tumor.  Tumor infiltrating OTI CD8+ further demonstrated high frequencies of 
exhaustion marker expression, perhaps providing a clue to the lack of long-term 
treatment maintenance in our model.  Analysis of effector cell function demonstrated that 
our OTI CD8+ possessed cytokine expression profiles consistent with a Tc1 phenotype 
and were effective mediators of target cell lysis.  Overall, our OTI CD8+ cells developed 
a phenotype appropriate for the tumor treatment effect seen and further one that we felt 
would be amenable to multiple potential mechanisms of Treg suppression.         
 In Chapter 5, we aimed to bring together the findings from our first two chapters 
to further understand the ability of tumors to directly present antigen to Tregs along with 
the suppressive implications of this interaction upon the phenotype of an otherwise 
productive CD8+ T-cell-mediated immune response.  However, we were unable to 
replicate the suppressive findings from our first study.  Probing of this result revealed that 
our Tregs persisted and maintained Foxp3 expression within recipient mice, but displayed 
antigen non-specific, MHCII-independent tumor trafficking with poor long-term 
accumulation.  Further, our Tregs failed to alter the proliferation, trafficking, cell surface 
phenotype, or effector function of our OTI CD8+ cells.  In vitro analysis revealed that our 
OVA-expressing tumor lines were unable to directly present endogenous OVA to OTII 
cells.  Subsequent review of the original work describing our B16.mOVA tumor line 
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corroborated this finding in vivo, but like us could only speculate as to the mechanism of 
this failure.   
 Collectively, the studies described herein have developed and characterized a 
novel tumor challenge and treatment system along with a series of OVA-expressing B16 
tumors with variable MHCII expression patterns that should provide invaluable to future 
studies aimed at elucidating the ability of tumor cells to directly present class II antigens.  
Unfortunately, given the failure of our tumor cells to directly present endogenous OVA 
antigen to OTII cells, the studies involving the direct presentation by tumors to Tregs are 
sadly uninterpretable and ultimately invalid.  This model and the concepts developed 
herein remain poised for future exploitation using an alternative class II antigen for CD4+ 
T-cell recognition. 
 
6.2 Future Directions 
  
 Our study developed a novel tumor challenge and treatment model along with a 
set of B16 tumors with variable MHCII expression patterns, but due to the inability of our 
tumor cells to present endogenous OVA antigen to OTII cells, ultimately failed to address 
its primary hypothesis.  The model itself, however, remains valid and capable of 
answering this question if an appropriate class II antigen within B16 cells can be 
identified.   
 In fact, such a system has been identified in the form of the endogenous 
melanocyte differentiation antigen tyrosinase-related protein 1 (TRP-1 or gp75).  TRP-1 
is present in normal melanocytes as well as melanoma cells, and has been considered as a 
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potential target for immunotherapy within humans (Overwijk et al., 1999).  Muranski and 
colleagues (Muranski et al., 2008) developed a transgenic mouse expressing a MHCII-
restricted TCR, which recognizes an epitope within the TRP-1 protein, and subsequently 
were able to demonstrate the ability to treat B16 tumors in vivo using in vitro polarized 
Th17 TRP-1 cells.  Two recent studies utilizing this model further support its 
applicability to our system.  In the first of these, Xie and colleague (Xie et al., 2010) were 
able to demonstrate that the combination of non-myeloablative whole body irradiation 
along with adoptive transfer of naïve TRP-1 CD4+ cells resulted in the development of a 
Th1 phenotype within TRP-1 cells and a substantial treatment effect upon established 
B16 tumors.  This treatment resulted in an upregulation of MHCII expression by B16 
tumor cells and importantly was not seen when MHCII KO recipient mice were used.   
 In the second recent study utilizing this model, Quezada and colleagues (Quezada 
et al., 2010) were able to elicit long-standing B16 tumor rejection using adoptive transfer 
of these same naïve TRP-1 CD4+ cells in conjunction with non-myeloablative whole 
body irradiation and CTLA-4 blockade.  They further showed that this treatment effect 
was antigen-specific and resulted in an IFNγ-dependent upregulation of MHCII upon 
tumor cells.  Even more importantly, they demonstrated that the use of in vitro polarized 
TRP-1 Th1 cells could treat tumors in MHCII KO mice, an effect that was abrogated with 
addition of MHCII-blocking antibodies.   
 Collectively, these two studies indicate that TRP-1 CD4+ cells can directly 
recognize B16 tumors in an MHCII-dependent fashion.  Inability of direct tumor 
recognition by our OTII+ T-cells was the key failure in our prior Tregs studies, and thus 
use of TRP-1 CD4+ cells as Treg donors could potentially solve this problem.  Therefore, 
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the immediate next step to follow our studies should be to evaluate the ability of TRP-1 
Tregs to suppress OTI CD8+ cells in our tumor model.   
 A second line of evaluation that should be undertaken to expand upon the findings 
within our model surrounds the phenotype of our OTI CD8+ cells, specifically as it 
pertains to their inability to provide long-lasting tumor immunity within recipient mice.  
Besides making elucidation of Treg effects more difficult in our studies, this failure of 
long-term tumor immunity despite the presence of tumor antigen-specific effector cells is 
one of the hallmarks of tumor progression and one of the major shortcomings of adoptive 
immunotherapy in cancer (Rosenberg, 2001; Zippelius et al., 2004; Dudley & Rosenberg, 
2003).  A large volume of research is currently investigating this issue, with a number of 
observations indicating that molecules involved in T-cell exhaustion and costimulation 
are crucial mediators in this process.  Several such molecules, including PD-1, LAG-3, 
and TIM-3, were shown to be expressed at high frequency by tumor-infiltrating OTI 
CD8+ cells in our own study.  The understanding of the function and importance of these 
molecules in tumor progression is increasing (Blackburn et al., 2009; Workman et al, 
2004; Zhu et al., 2005), and the use of antibody blockade of these molecules, along with 
CTLA-4, (Woo et al., 2012; Ngiow et al., 2011; Duraiswamy et al., 2013; Ott et al., 
2013) has resulted in dramatic tumor responses that are changing the frontier of cancer 
immunotherapy.  Further evaluation of these markers, along with potential incorporation 
of antibody-blocking strategies, may allow for improved treatment responses and 
understanding of OTI phenotype and Treg function within our model.      
 A final set of studies that should prove to be insightful would be to further 
evaluate the failure of our OVAII-OTII system, with particular emphasis upon analyzing 
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the antigen processing and presentation pathways within our B16.mOVA tumor.  As 
previously mentioned, despite the fact that our B16.mOVA cells had been previously 
shown to produce full length OVA protein (Preynat-Seauve et al., 2007) which was 
transcribed from a DNA construct that included the OVAII amino acid sequence, our 
tumor cells failed to present this epitope to OVAII-specific OTII cells.  This same finding 
was also observed by the above authors as well as by other groups utilizing a different 
OVA-expressing B16 line (Quatromoni et al., 2011), and yet other groups (Schreiber et 
al., 2012) have reported the successful recognition of tumor-expressed OVA by OTII 
cells, suggesting that this is not a universal phenomenon with the OVA protein.  These 
results may be explained by the previously-mentioned observations of Tsuji and 
colleagues (Tsuji et al., 2012) who have identified a novel HSP90-dependent antigen 
presentation pathway within tumor cells.  In their model, this observation resulted in the 
ability of melanoma cells to directly present novel antigens to CD4+ cells via tumor-
expressed MHCII.  Ironically, their observation of a novel tumor antigen processing 
pathway, which had previously served as support for the motivation to pursue our own 
experiments, may in fact provide an explanation for their failure.   
 
6.3 Concluding Remarks 
  
 In this study, we hypothesized that the inflammation-induced upregulation of 
MHCII by tumor cells could allow for direct presentation of tumor-derived antigens to 
Tregs with resultant antigen-specific suppression of immune-mediated tumor rejection.  
In the end, we were unsuccessful at answering this question due to the inability of our 
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tumor cells to directly present endogenously expressed OVA antigen to our Treg cells.  
Despite this failure, this work is not without merit, and a number of positives can be 
taken from this study.  The novel treatment model along with the panel of variable 
MHCII-expressing B16 tumor lines developed and characterized herein will serve as 
valuable tools going forth in future experiments.  A framework for this evaluation has 
been laid here, and incorporation of an appropriate Treg source, perhaps from the TRP-1 
mouse, should allow for the efficient evaluation of our original hypothesis.  Although 
unanswered here, the question of direct interaction between tumors and Tregs remains an 
important question in the field of cancer immunology worthy of continued investigation.  
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AWARDS & ACHIEVEMENTS 
  
Robert L Lindsay Meritorious Service Award, 2012 
Cancer Research Institute STaRT Graduate Training Fellowship, 2009-2012 
Cornell University Graduate, Summa cum Laude, 2004 
Cornell University Merrill Presidential Scholar, 2004 
Cornell University Ho-Nun-De-Kah Paul Schreurs Memorial Award, 2004 
Cornell University Ertel-Diament Pre-Medical Award, 2004 
Goldwater Scholarship, 2002-2004 
Cornell University Tradition Fellow, 2000-2004 
Cornell University CALS Charitable Trust Grant for Undergraduate Research, 2002 
Cornell University Hatch Multistate Grant for Undergraduate Research, 2002 
Cornell University Morley Grant for Undergraduate Research, 2002 
NIH Undergraduate Scholarship Program (UGSP), 2000-2002 
 
 
ACTIVITIES & SERVICE 
2007-present 
Maryland Juniors Volleyball Club 
Head and/or assistant volleyball coach for a total of 8 junior girls club volleyball teams 
ages 12-18.  Activities included running practices several times per week (November – 
June), coaching all day tournaments approximately twice monthly, and running day-long 
training clinics.   
 
2007-Present 
Chesapeake Regional Volleyball Association (CHRVA) 
CHRVA is the local governing body for the United States Volleyball Association, which 
oversees adult and juniors volleyball nationwide.  I have been involved with both the 
adult and juniors programs in a number of different roles, including coaching juniors 
(above), organizing adult tournaments, officiating, training juniors officials, and guiding 
regional policy changes.   
 
2009–2010 
Baltimore Board of Women’s Sports (BBOWS) Volleyball Official 
Officiated middle and high school volleyball for local boys and girls teams approximately 
twice weekly between August and November. 
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2007–2010 
JHU School of Medicine Histology Teaching Assistant 
Prepared lectures, assisted with microscope- and computer-based laboratories, and graded 
student presentations and exams during the first year medical/graduate student histology 
course each fall. 
 
2004–2009 
Johns Hopkins Hospital IPC Big Buddy Program 
Served as a mentor to a patient of the JHH Intensive Primary Care (IPC) Clinic, which 
cares for children with HIV, with activities approximately two Sundays per month.  
 
2004–2007 
Chesapeake Habitat for Humanity (HFH) 
General volunteer for construction and demolition projects for the local chapter of HFH 
approximately two Saturdays per month.   
 
2004-2006 
Baltimore Rescue Mission 
Medical volunteer at a local homeless shelter approximately two evenings per month.   
 
2000-2004 
Cornell University Habitat for Humanity (HFH) 
A campus based chapter of HFH, which partnered with affiliates from local New York 
counties to organize and oversee student construction activities, fundraisers, community 
outreach events, and spring break volunteer trips.  My roles included that of President 
(2002-2003), Work Projects’ Chair (2001-2002), Board Member (2000-2001, 2003-
2004), and general volunteer (2000-2004).   
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